TITLE

Invasive lobular carcinoma: Preliminary study of the efficacy of a blood based gene expression test fo
Beta-catenin stability, frizzled and cyclin D1 proteins expression in human breast cancer and its relati
Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease - a met
Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate
Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally rec
"Competition on Clinical Mass Spectrometry Based Proteomic Diagnosis" based on serum protein prof
15-year trends in metastatic breast cancer (MBC) survival in Greece - a meta-analysis of ten Hellenic
A 3arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X
A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the
A breast cancer fingerprint in peripheral blood - a novel method for early diagnosis
A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) w
A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone met
A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab res
A new combined therapy strategy to breast cancer treatment: assay of E gene transfection associated
A novel drug Toll-like receptor 9 (TLR9) agonist synergizes with trastuzumab in different trastuzumab-
A randomised controlled trial of a symptom-orientated home care nursing programme in patients with
A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin a
A retrospective study on the efficacy of elliptinium acetate in metastatic breast cancer patients
A simple method to prepare tumour stem cells from the human breast cancer cell line MDA-MB 231
A survey of joint aches, pains and muscle stiffness comparing women with and without breast cancer
A tool to improve personalized cancer care: measuring the response of circulating epithelial tumour ce
Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients
Adjuvant therapy of very young women with early breast cancer
Allele-specific aberrations and two dimensional disparity of copy number alterations in breast cancer
Analysis of factors predicting response to second-line trastuzumab-based therapy in patients (pts) wit
Anthracycline-rechallenge using pegylated liposomal doxorubicin (PLD) in patients with metastatic bre
Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated
Are expression levels of Src kinase family members in human breast tissue related to clinical outcome
Are lymphogenic micrometastases in breast cancer a prelude to macrometastases?
Assessment of the precursors of heme biosythesis in patients with breast tumour
Association of Her2Neu Ile655Val polymorphism with clinical characteristics, response to neoadjuvant
Biosimilar filgrastim is an effective primary prophylactic therapy for neutropenia in patients (pts) rece
Bisphosphonates do not prevent bone fractures in early breast cancer: a meta-analysis
Brain metastases (BM) in HER2-overexpressing metastatic breast cancer (MBC): what changed in the
Brain metastasis from triple negative breast cancer
Brain metastasis in advanced breast cancer: high risk in HER2 positive but not in triple negative patie
Breast cancer - Clinical early disease Neoadjuvant versus adjuvant chemotherapy for women with ope
Breast cancer brain metastases - significant differences in biological markers in early vs. late relapse
Breast cancer in the elderly: a medical perspective
Breast cancer screening program in Khanty-Mansiysk autonomous Okrug - Yugra
Breast cancer trials - is race an important factor?
Breast MRI and preoperative factors associated with cancers of limited extent in wide-local excision sp
Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patient
Can we use age-dependent changes of enzymes activity in benign disease as poor prognostic factors?
Cancer stem cell spotting: the example of breast cancer
Characterization of primary tumour stromal cells and their potential role in the breast cancer microen
Chest xray as a staging investigation in early operable breast cancer - is it necessary?
Child-bearing in breast cancer survivors
CIBOMA/2004-01: a randomised phase III trial assessing adjuvant capecitabine (X) maintenance thera
Circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after prima
CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as
Clinical and biological metastatic breast cancer (MBC) outcomes after discontinuation of treatment wi
Clinical and pathological aspects of 90 infra-centimetric HER2+ invasive breast cancers: a 3centres jo
Clinical and pathological prognostic characteristic of breast cancer patients with brain metastases
Clinical and patohistological caracteristics of synchronous and metachronous bilateral breast cancer
Clinical outcomes and breast cancer subtypes in patients with brain metastases
Clinical outcomes and patients characteristics of triple negative breast carcinoma
Columnar cell lesions are the early precursors of some forms of invasive breast carcinoma - a new gen
Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classifypatients with p
Comparison and combination of gene-set classifiers for prediction of localized breast cancer survival
CORRECT, a web-based, observational study, showing that darbepoetin alfa is effective in treating che
Correlation of Sodium Iodide Symporter (NIS) and Retinoic Acid Receptor Alpha (RARA) expression in b
Current practice of prophylaxis with granulocyte colony-stimulating factors for preventing chemothera
CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of progression
Demographic clinical and pathologic features of breast cancer in males
Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases:
Detection and characterization of tumour cells in sentinel lymph nodes and bone marrow of patients w
Detection of cytokeratin-19 mRNA-positive cells in peripheral blood and bone marrow of patients with
Difference of set up margin between conventional 2D and CT based 3D planning in Korean patients w
Different effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients w
Disease characterisation of triple negative breast carcinomas using functional MRI
Does self regulation and autonomic regulation have an influence on survival in breast and colon carcin
Dolichol dependent hypersensitivity reactions to chemotherapy in breast cancer: the approach for pre
Dose adjusting capecitabine minimises side effects while maintaining efficacy: retrospective review o
Ductal lavage-a tecnhique for the early diagnosis of breast cancer: our experience during the last thre
Early diagnosis and screening for breast cancer: a population-based study
Effect of neoadjuvant chemotherapy on oestrogen receptor, progesterone receptor and HER 2 recepto
Effects of GCSF on circulating tumour cells (CTC) and CA 27.29 in breast cancer patients
Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitab
Efficacy of specialised nurses for newly diagnosed breast and gynaecological cancer patients: a quasi
Elevated circulating estradiol levels are associated with a less aggressive tumour phenotype in postm
Emerging recommendations for the prevention of cancer treatment-induced bone loss in women with
Epidemiology and prognosis of breast cancer in very young population
European Cooperative Trial in Operable Breast Cancer II (ECTO II): activity of primary chemotherapy in
Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients
Evaluating the satisfaction of the Spanish online breast cancer consulting service
Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HE
Expression of cancer/testis tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO 1 in medullary breast ca
Expression of solute carrier genes related to molecular imaging in breast cancer
Factors associated with delayed presentation in the cohort ELIPPSE40 of young breast cancer women
Factors associated with provider delay in the cohort ELIPPSE 40 of young breast cancer women
False positive sentinel node findings in breast cancer - a review of 473 sentinel node biopsy cases
French cost effectiveness study of the MammaPrint 70-gene signature in early stage breast cancer pa
G-CSF use and neutropenic events in patients with breast and lung tumours: data from routine clinica
Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast canc
Genetic susceptibility to breast cancer - new developments and clinical application
Gonadotropin-Releasing Hormone analogues (Gn-RH) in high risk premenopausal breast cancer patien
Guidelines in breast cancer - are they keeping up with the times?
Half of breast cancer patients starting on tamoxifen complete five years of endocrinetreatment
HER-2 positive locally advanced breast cancer: one or two entities?
High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mous
High resolution microarray copy number analysis (array CGH) suggests that determination of HER2 am
HMPS (2-hydroxy-4-methoxyphenylstilbene), a stilbene derivative of rhapontigenin, induces cell death
Human epidermal growth factor receptor 2 (HER2) testing in operable breast cancer: comparison of im
Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late
Hypofractionation versus conventional fractionation radiotherapy (RT) after breast conservative treatm
ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronat
Identification and localisation of sentinel lymph nodes using microbubble enhanced ultrasound in pre-
Identification of gene variants and gene expression profiles predicting long term adverse side effects
Immunocytochemical analysis of mitochondrial protein UCP4 and its correlation with apoptotic and pre
Immunohistochemical evaluation of PI3K/p-Akt pathways alterations in combination with conventional
Immunohistochemical staining of mammaglobin in breast cancer
Impact of hormonal therapy (HT) on cognitive function in postmenopausal women (PMW) with hormon
Impact of p53 protein overexpression on survival of stage II young breast cancer patients
Impacts of surgical margin status in breast-conserving surgery on local recurrence
Impaired glucose tolerance in non-diabetic women during adjuvant chemotherapy for breast cancer
Implementation of guidelines for adjuvant endocrine therapy in early breast cancer
Importance of breast cancer screening in women aged between 35 and 49 years old
Incidence of distant metastasis (DM) in elderly postmenopausal women with operable breast cancer tr
Increased systemic microRNAs in breast cancer correlate with tumour microRNA profile and clinicopat
Influence of chemotherapy on breast cancer cells in the conditions of 24-hour incubation in vitro
Influence of isolated tumor cells in sentinel nodes on outcome in early pT1N0M0 breast cancer
Information and support for Asian and African Caribbean women affected by breast cancer: role of vol
Interaction between bisphosphonates and taxanes in patients with metastatic bone disease
Intra-operative assessment of sentinel lymph nodes in breast cancer with touch imprint cytology - a c
Intraoperative ultrasound guided occult lesion localization in early stage breast cancer surgery
Invasive breast tumour cells induce up regulation of tumour endothelial marker 8 (TEM8) in monocyte
Ipsilateral breast tumour relapse: local recurrence versus new primary and the effect of whole breast
Is fine needle aspiration cytology useful in male breast lesions?
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Ixabepilone/epiribicin combination as therapy for metastatic breast cancer - a phase Ib study
KDR/Flk-1 expression in the tumor tissue vascular endothelial cells in two groups of breast cancer pat
Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by
Left anterior descending coronary artery (LAD) doses from breast radiotherapy: is prone treatment po
Long-term prognostic effects of fasting insulin in early stage breast cancer (BC) patients
Loss of estrogen receptor in human breast cancer cells is associated with an epithelial to mesenchym
M0 breast cancer patients exhibited a decreasing incidence of metastases but no improvement in pro
Management of breast cancer in limited-resource countries
Mesenchymal Stem Cell (MSC) secretion of TGFß and VEGF stimulates Epithelial to Mesenchymal Tran
Methylation in breast cancer and correlate ER with tumor phenotypes and prognostic factors
Micrometastatic tumor cells in blood and bone marrow of patients with primary breast cancer: extend
Minimal axillary lymph node involvement in breast cancer has different prognostic implications accord
Molecular predictive factors of response to taxanes and anthracyclines in breast cancer: toward a targ
Molecular signatures of disseminated tumour cells in metastatic breast cancer patients
MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochem
Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with loca
Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced
Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelb
Multifactorial CNS relapse susceptibility in HER-2-positive breast cancer patients: first results from a p
Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) fo
Neo-adjuvant anthracycline based chemotherapy in locally advanced breast cancer: assessment of to
Neoadjuvant concomitant radio-endocrine therapy for locally-advanced receptor positive elderly breas
New isolated mediastinal lymph node or pulmonary nodule during surveillance of breast cancer: clinic
Newer cytotoxics in breast cancer - are there any and are they still needed?
Optimal radiation field in pathological N0-N1 patients treated with neoadjuvant chemotherapy followe
Optimising anti-HER2 therapy in early breast cancer
Overall response rate (ORR) and clinical benefit (CB) as clinical indicators for the efficacy of sequentia
Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer: a ra
Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen
Pegylated liposomal doxorubicin and Bevacizumab as first-line therapy for locallyrecurrent or metasta
Persistent pain following breast cancer surgery: a nationwide study of predictors and consequences
Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen
Phase II study of sunitinib in combination with trastuzumab for the treatment of metastatic breast can
Poor response to systemic chemotherapy in metaplastic carcinoma of breast
Predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients by three no
Predictive factors of response to neoadjuvant 3weekly epirubicin (EPI) plus docetaxel (DOC) chemothe
Predictive risk factors for brain metastasis in breast cancer
Predictive role of Her-2 receptors on primary tumour in patients with liver metastases from breast can
Predictive value of circulating angiogenic factors in the neoadjuvant treatment of breast cancer
Preoperative serum CA 15–3 and CEA in women with breast cancer and their relationship with relapse
Prognostic significance of breast cancer subtypes and nodal status
PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer
Radiobiological modelling of hypofractionated accelerated partial breast irradiation (APBI) with 50kV x
Radiotherapy in older patients for early breast cancer
Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 p
Resource-based data availability for erbB2-driven breast cancer in Asian women: experts' opinion
Results of an RCT investigating the cost-effectiveness of four follow-up strategies after breast cancer
Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase II
Risk factors for metachronous contralateral breast cancer suggest two etiologic pathways
Role of lymph-nodes scintigraphy in planning of radiotherapy for patients with breast cancer
Role of maintenance chemotherapy in advanced breast cancer
Role of paclitaxel in neoadjuvant chemotherapy in stage IIA-IIIA breast cancer
Safety and tolerability of fulvestrant high-dose (500mg) in postmenopausal women with hormone rece
Secondary PROphylaxis with GCSF has a major effect on delivered dose intensity: the results of the UK
Sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis as a tool
Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts)
Short-term outcome of prospective trial for Japanese breast cancer patients treated with accelerated p
Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotre
Single nucleotide polymorphisms at 241 codon of XRCC3 gene is associated with acute skin reactions
Spectrum of malignant breast masses in adolescent Indian girls: outcome of management at the brea
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate and breast cancer cells to docet
Strategies to preserve fertility in young breast cancer patients
Surfactant protein D as a serological marker of lung inflammation in breast cancer patients under rad
Surgical resection of the primary tumour is associated with improved survival in patients with distant
Surgical treatment of Paget's disease of the breast
Survival and prognostic factors in patients with early-stage breast cancer after conservation therapy
Survival of breast cancer patients with brain metastases
Targeted intraoperative radiotherapy and sentinel node biopsy enable breast and axillary lymph node
Targeting DNA-repair deficiency in mouse models for BRCA-associated breast cancer
Taste and smell changes in patients receiving chemotheraphy for breast cancer
The cariatide study: evaluation of the impact of educational material on the compliance and persisten
The complex genomic landscape of breast cancer
The development of evidence-based guidelines for a nurse consultation in a breast unit, part 1: the pe
The differences of prognostic factors and pattern of failure between invasive micropapillary carcinoma
The discordance between hormonal receptor status and cerb b2 in primary and metastatic breast can
The effects of ECadherin and bcl-2 on prognosis in patients with breast cancer
The effects of prognostic factors on the first recurrence patterns of breast cancer
The efficacy of Tc-99m MIBI for sentinel node mapping in breast carcinoma: comparison with Tc-99m
The influence of polymorphism in TYMS, MTHFR and GSTP1 genes on toxicity and response in breast c
The patient's anastrozole compliance to therapy programme (PACT): evaluating the influence of a sta
The prognostic importance of various clinical, pathological, and immunohistochemical parameters in t
The prognostic significance of age at diagnosis in patients with breast cancer younger than 35 years
The transcription factor p53 enhances the long-term survival effect of survivin in T4 breast cancer pat
Time-dependence of hazard ratios for prognostic factors in patients with early breast cancer
Treatment of small invasive breast cancer with ultrasound-guided radiofrequency ablation followed by
Treatment planning comparison of tangential coplanar beams versus non-coplanar beams in whole br
Trichostatin A and decitabine reverses resistance to docetaxel in human breast cancer cells
Triple combination of 3weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as
Triple negative breast cancer with "basal-like" phenotype: clinical features and characteristics - a retr
Triple-negative high grade invasive ductal breast carcinomas are biologically heterogeneous: differen
Troponin I and Creactive protein as biomarkers for changes in left ventricular ejection fraction in patie
UK national survey on the use of Adjuvantonline as a decision-making tool in early breast cancer (www
Ultrasound-guided radiofrequency ablation of early breast cancer in a resection specimen
Update of survival and prognostic factors of triple-negative breast cancer in Thailand
Use of local anaesthetics in breast cancer surgery
Value of sentinel lymph node biopsy in ductal carcinoma in situ of the breast
Vascular endothelial growth factor (VEGF) 936 C/T gene polymorphism is a risk factor for invasive duc
Verifying CTV-PTV margins for isocentric breast cancer radiotherapy, using an off-line correction proto
ZORO: Prospective
Breast cancer randomized
receptor status and multicenter-study
ethnicity: The Westto prevent
Londonchemotherapy induced ovarian failure w
Experience
Absence of the PALB2 229delT and 1592delT mutation in Korean
patients with BRCA1/2 mutation negative breast cancers
Breast cancer
Knowledge screening
about breast promotion program
feeding practices among breast cancer
patients in India – A case-control study
Is there a relationship between cadmium and human breast cancer?
Breast cancer mortality
Aggressiveness of breastincancer
Tbilisi (Georgia) in 2002–2004
on radioactive contaminated
territories impact
Economic of Grodno regioncancer
of breast (Belarus)management: a revolutionary
change in ten years
Breast cancer research from Low- and Middle-Income Countries
(LMCs)
women published
with hormone in high impact medical(HR+)
receptor-positive journals
breast cancer (BC) on
aromatase inhibitors
capecitabine (AIs) patients (pts) with early breast cancer
(X) in elderly
(GBG 32)
than screening mammography in older breast cancer women: results
of a prospective observational
Risk factors for breast cancer intrial in 5 Italian
elderly womencenters
– retrospective
analysis
Role of 206 patients
of adjuvant chemotherapy in elderly ( 70 years) women with
high-risk early breast cancer
Management
Adjuvant docetaxelof breast
andcancer in the elderly
cyclofosfamide in breast cancer patients
over 65 years: compliance and toxicity
geriatric assessment (MGA): does the consultation with
Adjuvant!online
cancer treated with change the choice
ibandronate (I) of postoperative
with therapy?
or without capecitabine (X):
results
A surveyof of
the GBG
joint 32 ICE
aches, trial and muscle stiffness comparing
pains
women with and without breast cancer
4Ullevaal University Hospital University AFFILIATION
of Oslo, Department of Radiology, Oslo, Norway
5Akademiska sjukhuset, Uppsala, Sweden
3Izmir Research and Training Hospital, Medical Oncology, Izmir, Turkey
4Dokuz
4PACMeR, Eylul University Medical
Gynecological Oncology,Faculty,
Lamia, Medical
Greece Biology-Genetics, Izmir, Turkey
5Universita' degli
6Genentech Studi diPharmacokinetics
Inc., Clinical Milano, Statistica and Medica e Biometria, Milano,
Pharmacodynamics, SouthItaly
San Francisco, USA
7University
8Centre of California San Francisco,
Georges-François-Leclerc, Oncology,
Medical Oncology, SanDijon,
Francisco,
FranceUSA
9Mount Vernon Cancer Centre, Oncology, Middlesex, United
2Leiden University Medical Center, Medical Statistics, Leiden, The NetherlandsKingdom
3Leiden
U. Dafni1,University
I. Grimani2, Medical Center, A.G.
A. Xyrafas1, Biomolecular MassG.
Eleftheraki2, Spectrometry, Leiden, The
Vourli2, G. Fountzilas2 Netherlands
1University of Athens
2Hellenicde
8Institut Cooperative
RechercheOncology Group,
Pierre Fabre, Data
Pierre Office,
Fabre Athens,Boulogne
Oncology, Greece Billancourt, France
9Medical University
6Clatterbridge Centre of for
Gdansk, Oncology
Oncology, Medical
Oncology, Department,
Wirral, Gdansk, Poland
United Kingdom
7Royal Cornwall Hospital, Oncology, Truro, United Kingdom
4Agricultural University of Norway, Chemistry Biotechnology and Food Science, Ås, Norway
5Ullevål
4Centre duUniversity
Cancer.Hospital,
Clinique Department
Universitaires ofSaint
Radiology, Oslo, Norway
Luc, Medical Oncology, Brussels, Belgium
5Sanofi-Aventis,
7Amgen Oncology,and
Inc., Biostatistics Paris, France
Epidemiology, Thousand Oaks, USA
8Amgen Inc., Hematology/Oncology,
4Netherlands Cancer Institute, Department Thousand Oaks, USA
of Medical Oncology, Amsterdam, The Netherlands
5Netherlands Cancer Institute, Department
2University of Granada, Human Anatomy and Embryology, of Molecular Biology, Amsterdam,
Granada, Spain The Netherlands
3University of Jaén, Health
3Idera, Pharmaceuticals, Sciences, Jaén,
Cambridge, USA Spaini
4Universita
A. di Napoli
Molassiotis1, “Federico
S. Brearley1, M.II”, Department
Saunders2, of Endocrinology
O. Craven2, and Molecular
A. Wardley2, and
C. Farrell2, C. Clinical
Todd1, K.Oncology,
Luker1
2Christie NHS Foundation Trust, Oncology, Manchester, United
7Medical University of Graz, Department of Internal Medicine, Graz, Austria Kingdom
8Medical
2InstituteUniversity of Vienna,
Gustave Roussy, Department
Department of Gynecology,
of Medical Oncology,Vienna, Austria
Villejuif, France
3Institute Gustave Roussy, Unit of Biostatistics and Epidemiology, Villejuif, France
H. Bühler1, O.Hospitals
3Portsmouth Schneider1,NHST.Trust,
Abeln1, B. Stolte1,
Nursing, I.A. Adamietz1
Portsmouth, 1Ruhr-Universität Bochum, Frauenklin
United Kingdom
4Portsmouth Hospitals NHS Trust, Radiology, Portsmouth,
1Friedrich-Schiller-University Jena, Clinic for Int. Med. II, Jena, GermanyUnited Kingdom
2Friedrich-Schiller-University
3U.Z. Gasthuisberg, Cardiology, Jena, Women‘s
Leuven, Hospital, Jena, Germany
Belgium
4U.Z. Gasthuisberg, Medical Oncology, Leuven, Belgium
O. Pagani1 1Oncology Institute of Southern
3Rikshospitalet/Radiumhospitalet-HF- Switzerland,
University of Oslo, Division
Geneticsof– Research,
Faculty of Bellinzona,
Medicine OsloSwitzerland
Universit
4Rikshospitalet/Radiumhospitalet-HF- University of Oslo,
2Medical University of Vienna, Department of Surgery, Vienna, Austria Genetics – Faculty division Akerhus Universit
3Medical University
S. Al-Batran1, of Vienna,
M. Scholz2, Department
C. Pauligk1, of Pathology,
E. Jäger1 Vienna,
1Krankenhaus Austria II. Medizinische Klinik, Frank
Nordwest,
2Trium Online,
3Merck & Co., MerckTriumResearch
Online, Munich, Germany
Laboratories, Upper Gwynedd, USA
4Reagent, Scientific Affairs, New York, USA
1University of Glasgow,
4Diakonessenhuis, Dept.Department
of Pathology, of Utrecht,
Surgery,The Glasgow, United Kingdom
Netherlands
5Diakonessenhuis, Dept. of Nuclear Medicine, Utrecht, The Netherlands
D. Baranauskiene1, L. Strumylaite1, O. Abdrakhmanov1, R. Kregzdyte1 1Kaunas University of Medicin
A. Alma1, C. Arce-Salinas1,
3Nottingham University HospitalO. Arrieta-Rodriguez1,
NHS Trust, Oncology P. Figueroa1,
Department, C. Castro1,
Nottingham,M. Santibañez1,
United Kingdom A. Lopez-
4Hospira,
2PACMeR,Oncology, Leamington
Gynaecological Oncology Spa,and
United Kingdom
Obstetrics and Gynaecology, Lamia, Greece
3Generaldel
1Clinica Hospital
lavoro of Lamia, Medical
Fondazione Oncology,
Salvatore Maugeri,Lamia, Greece
Medical Oncology II, Pavia, Italy
2Clinica del
1Queen's lavoro
Centre Fondazione
for Oncology and Salvatore Maugeri,
Hematology, Rehabilitative
Clinical Oncology, Oncology, Pavia,
Hull, United Italy
Kingdom
2Pathology Queen's Centre for Oncology and Hematology, Clinical Oncology, Hull, United Kingdom
1Aarhus University Hospital,
3Centre Georges-François Department
Leclerc, Medical ofoncology,
Oncology,Dijon,
Aarhus, Denmark
France
4Centre Georges-François
2Institute of Oncology and Leclerc,
Radiology Breast andPathology,
Serbia, Gynecologic Cancer Serbia
Belgrade, Registry of Côte d'Or, Dijon, France
3Institute of Oncology and Radiology Serbia, Radiotherapy, Belgrade, Serbia
H. Wildiers1
5Regional 1U.Z. Hospital,
Clinical Gasthuisberg,
Cancer Department of General Medical
Center, Khanty-Mansisk, Oncology
Russian – Multidisciplinary Breast C
Federation
6Khanty-Mansiysk
1Sunnybrook Odette Medical
Cancer Institute,
Centre, Department
Department of of Oncology and General
Medical Oncology, Surgery,
Toronto, Khanty-Mansisk, R
Canada
2University
6The of Toronto,
Netherlands CancerFaculty of Medicine,
Insitute/Antoni vanToronto, CanadaHospital, Radiotherapy, Amsterdam, The N
Leeuwenhoek
7The Netherlands
6Centre HospitalierCancer
Général,Insitute/Antoni van Leeuwenhoek
Medecine, Chambéry, France Hospital, Surgery, Amsterdam, The Nethe
7Centre Régional Léon Bérard, Unité de Biostatistique, Lyon, France
1Donetsk National Medical University, Biochemistry, Donetsk, Ukraine
O.W. Hartmann1,
M.C. Petersen1 1The R.M.Panum
Dwyer1, Institute, Department
S.M. Potter1, of Cellular
P. Dockery2, M.J. and Molecular
Kerin1 1NationalMedicine, University
University of C
of Ireland G
2National University of Ireland Galway Galway, Department of Anatomy, Galway, Ireland
1Queen Elizabeth Hospital, Breast and General Surgery, Birmingham, United Kingdom
N. Kroman1
9Instituto 1Rigshospitalet,
Nacional del Cáncer, Breast Surgery,
Oncology, Copenhagen,
Santiago de Chile, Denmark
Chile
10Instituto
6Charité Valenciano
University de Oncología,
Hospital, Department Oncology, Valencia, Berlin,
of Gynecology, Spain Germany
7Heinrich-Heine-University, Department of
9TRIO, Cancer International Research Group, Paris, FranceGynecology, Duesseldorf, Germany
10Cross
2European Cancer Institute,
Institute Department
of Oncology, of Oncology,
Division Edmonton,
of Epidemiology Canada
and Biostatistics, Milan, Italy
3European
2Institut Institute
Curie, Paris,ofParis,
Oncology,
FranceDivision of Hematology-Oncology, Milan, Italy
3InstitutSklodowska-Curie
2Maria Gustave Roussy, Memorial
Val-de-Marne,Cancer Villejuif,
CenterFrance
and Institute of Oncology, Radiation Oncology, Krak
3Maria Sklodowska-Curie Memorial Cancer
1Institute for Oncology and Radiology of Serbia, Daily Center andHospital
Institutefor
of Chemotherapy,
Oncology, Clinical Oncology,
Belgrade, Gliwice
Serbia
2Institute for Oncology
2Pusan National and Hospital,
University RadiologyInternal
of Serbia, Clinic for
Medicine, Medical
Busan, KoreaOncology, Belgrade, Serbia
3Dong-A University Medical Center, Breast Center, Busan, Korea
1Dr. Abdurrahman
1University Yurtaslan
of Nottingham, Onkoloji EgitimNottingham,
Histopathology, Hastanesi, Medical Oncology, Ankara, Turkey
United Kingdom
2Institute of Cancer Research, The Breakthrough
3European Institute of Oncology, EIO, Milan, Italy Breast Cancer Research Centre, London, United King
4Agendia, BV, Amsterdam,
3Oslo University The Netherlands
Hospital, Cancer Clinic, Oslo, Norway
4Biomedical
5Amgen Research
Germany GmbH,Group, FacultyMunich,
Oncology, of Mathematics
Germanyand Natural Sciences, University of Oslo, Depart
6Onkologische
J. Ryan1, E. Hennessy1, C. Curran1, J.C. Morris2,Frankfurt,
Gemeinschaftspraxis, Oncology, M.J. Kerin1,Germany
R.M. Dwyer1 1Clinical Sciences Institute,
2Division of Endocrinology, Mayo Clinic, Rochester
9Hospital 12 de Octubre, Medical Oncology Department, Madrid, Spain MN, USA
10Hospital Virgen
3University de las
of Genoa, Nieves,
Dissal, Medical
Genova, Oncology Department, Granada, Spain
Italy
4Academic
1Agios SavvasHospital Munich-Bogenhausen,
Anticancer Hospital, Second Department of Pathology,
Medical Oncology, Athens,Munich,
Greece Germany
2Agios Savvas Anticancer Hospital, Pathology, Athens,
7Amgen Inc., Biostatistics and Epidemiology, Thousand Oaks, CA, USA Greece
8Amgen Inc., Hematology/Oncology,
1The Norwegian Radiumhospital, Tumor Thousand
Biology, Oaks,
Oslo,CA, USA
Norway
2Ullevål Hospital,
2University GeneralPathology,
Hospital ofOslo, Norway Department of Medical Oncology, Heraklion, Greece
Heraklion,
3University
S. General
Jo1, M. Chun1, Hospital
H. Jang1, M.ofKim1,
Heraklion,
Y. Oh1, Department
S. Kang1, K. ofChoi2
Pathology,
1AjouHeraklion,
UniversityGreece
Hospital, Radiation On
2Sam Anyang Hospital, Radiation Oncology, Anyang, South
6Leiden University Medical Center, Medical Oncology, Leiden, The Netherlands Korea
7Leiden
4DepartmentUniversity Medical
of Clinical Center, Bristol
Oncology, Surgical Oncology,
Oncology Leiden,
Centre, The Netherlands
Bristol, United Kingdom
5CRUK Clinical
4Institut MR Research
für klinische Group,
Forschung, Royal und
Statistik Marsden Hospital, Sutton,
Methodologie, United Kingdom
Berlin, Germany
5University of Bristol, Academic Unit of Primary Care, Bristol, United Kingdom
I. Kuznecovs1,
2Imperial S. Kuznecovs1,
College Healthcare NHS G. Kuznecova1
Trust, London, 1Preventive Medicine Research Society, Cancer Researc
United Kingdom
3MD Anderson
1Anticancer CancerTheageneio,
Hospital Center, Houston, USA Clinic, Thessaloniki, Greece
3rd Surgical
2Anticancer Universitesi
3Hacettepe Hospital Theageneio, Cytology Department,
Onkoloji Enstitüsü, Medikal Onkoloji,Thessaloniki, Greece
Ankara, Turkey
4Mersin Il Saglik Müdürlügü, Pratisyen Hekim, Mersin,
2Queen Elizabeth Hospital, Pathology, Birmingham, United Kingdom Turkey
3Queen
8CharitéElizabeth Hospital, Breast Surgery,
Campus Virchow-Klinikum, Klinik fürBirmingham,
FrauenheilkundeUnitedundKingdom
Geburtshilfe, Berlin, Germany
9Klinikum der
9Genentech Heinrich-Heine-Universität
Inc., Clinical Science, South San Düsseldorf,
Francisco, Frauenklinik,
USA Düsseldorf, Germany
10Fairfax-Northern Virginia Hematology-Oncology, Department of Medical Oncology, Fairfax, USA
J. O'Shaughnessy,
2Senology Centre of C. Eastern
Osborne,Switzerland,
J. Pippen, M.Oncology,
Yoffe, D. St.
Patt, G. Monaghan,
Gallen, C. Rocha, V. Ossovskaya, B. S
Switzerland
3Universitätsklinik
2Hospital de Parla, für medizinische
Obstetrics Onkologie,
& Gynecology, Inselspital
Parla (Madrid),University
Spain Hospital, Bern, Switzerland
3Universidad
1Hospital Rey Juan
de Santa MariaCarlos, Cienciasofde
– University la Salud
Lisbon, 2, Alcorcón
Oncology, (Madrid),
Lisbon, Spain
Portugal
2University of Virginia, Oncology, Charlottesville, USA
P. Tai1 1University
7Kaiser of Saskatchewan,
Franz Josef-Spital, Department
Medical Oncology, Vienna,of Oncology
Austria Allan Blair Cancer Center, Regina, Cana
8Fondazione
L. Palmeri1, M. Michelangelo,
Vaglica1, A. Operations
Mangiameli2, Office,
L. Di Milano,
Noto1, A. Italy
Bongiovanni1, A. Marchese1, S. Palmeri1 1Un
2CdC
3H. Musumeci,
Clínico Oncologia,
San Carlos, Gravina
Medical di Catania,
Oncologist, Madrid,Italy
Spain
4H. Virgen delUniversity
8Washington Rocio, Medical
School Oncologist,
of Medicine, Sevilla,
SitemanSpainCancer Center, St Louis, USA
9Institut
4University Hospital “Sisters of Mercy”, Pathology, Zagreb,-Sénologie,
Gustave Roussy, Department Oncologie Médicale Croatia Villejuif, France
5University Hospital for Tumors, Medical Oncology, Zagreb, Croatia
4Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Oncologic
5Maria Sklodowska-Curie
2Institut Memorial
Paoli Calmettes, Cancer Cancer
Unit, Center
Marseille, and Institute of Oncology, Department of Tumor Pa
France
3Inserm Umr912, Cancer Unit, Marseille, France
1Ors Pacaand
1HUSLAB – Inserm Umr912,
Helsinki Cancer,
University Marseille,
Central France
Hospital, Department of Pathology, Helsinki, Finland
2Helsinki Gynécologie-Obstétrique,
6Service University Central Hospital, Department
Ap-HM of Surgery,
Hôpital Nord, Helsinki, Finland
Marseille
, FranceGeorgios General Hospital, Oncology Clinic, Chania, Greece
9Ágios
10Ottawa Regional
2Institut Gustave CancerDepartment
Roussy, Centre, Breast Cancer Clinic,
of Laboratory Ottawa,
Medicine, Canada
Villejuif, France
3Institut Gustave Roussy, Breast Cancer Translational Research Unit Breast Cancer Unit Department o
D.F. Easton11University
3Azienda Ospedaliera SSofFilippo
Cambridge, Public
e Nicola, Health Oncologica,
Psicologia and PrimaryAvezzano,
Care, Cambridge,
Italy United Kingdom
4Università degli Studi, Oncologia Chirurgica, L'Aquila, Italy
1Sunnybrook Odette Department
3Catharina Hospital, Cancer Centre, Division Eindhoven,
of Surgery, of Medical Oncology, Toronto, Canada
The Netherlands
4Comprehensive
3KFSH, Radiology,Cancer
Dammam, Centre South,
Saudi Eindhoven Cancer Registry, Eindhoven, The Netherlands
Arabia
4KFSH, Pathology,
1School of MolecularDammam, Saudi Arabia
Medical Sciences and Nottingham University Hospitals Trust University of Notting
2Institute
H.L. of Cancer
McArthur1, Research,
E. Brogi1, The Breakthrough
S. Patil1, M. Wigler2, L.Breast
Norton1,Cancer Research
J. Hicks2, Centre,1Memorial
C.A. Hudis1 London, United King
Sloan-Ket
2Cold Spring Harbor Laboratory, Scientific Laboratory, Cold Spring
4University of Virginia, Endocrinology and Metabolism, Charlottesville, USA Harbor, USA
5Seoul
4DokuzNational University,
Eylul University College
Medical of Pharmacy,
School, Department Seoul, Korea
of Pathology, Izmir, Turkey
5Dokuz Eylul
2Medical University
Phisics, Medical
University School,
Hospital Department
Maggiore of Surgery,
della Carità, Novara,Izmir, Turkey
Italy
3Epidemiology and biostatistics, University Hospital
5Areteion Hospital, Radiology Department, Athens, Greece Maggiore della Carità, Novara, Italy
6Areteion Hospital,
9German Breast Radiotherapy
Group, Statistics,Department,
Neu-Isenburg, Athens,
GermanyGreece
10German Breast Group, Neu-Isenburg, Germany
1Maidstone Hospital, Breast Clinic, Maidstone Kent, United Kingdom
A.L. Børresen-Dale1A.M.
P. Athanassiadou1, 1TheAthanassiadou1,
Norwegian Radium Hospital,
A. Tsipis1, M.Department of Genetics,V.Oslo,
Gonidi2, E. Patsouris1, Norway E. Petra
Kyriakidou1,
2Corfu
3ReginaGeneral Hospital,Cancer
Elena National Cytology Department,
Institute, Corfu, Rome,
Biostatistics, GreeceItaly
4Regina
E.A. Elena
Baker1, L. National Cancer Institute,
Hall2, J. France2, Radiotherapy,
D. Whetter1, P. Bhaskar1Rome, Italy
1University Hospital of North Tees, Professo
2University Hospital
1Academic Hospital of
of the
North Tees, Histopathology
University Charite Berlin,Department,
GynecologicStockton
Oncologyonand Tees, United Kingdom
Obstetrics, Berlin, Ger
2Emory Winship Cancer Institute, Hematology and Medical Oncology,
2Kaunas Medical University Hospital, Pathology Department, Kaunas, Lithuania Atlanta, USA
3Kaunas Medical University, Institute for Biomedical Research, Kaunas, Lithuania
1Seoul National
2Royal BournemouthUniversity Hospital,
Hospital, Department
Endocrinology, of Radiation United
Bournemouth, Oncology, Seoul, South Korea
Kingdom
3Bournemouth University, Statistics, Bournemouth, United Kingdom
1Guy's and St.
2Nizip State Thomas'
Hospital, Hospital,
General Department
Surgery of Medical
Department, Oncology,
Gaziantep, London, United Kingdom
Turkey
3Ankara Oncology
4Belfast City Hospital,
Hospital, General
Northern Surgery
Ireland Cancer Department, Ankara,
Centre, Belfast, Turkey
Ireland
5St. Bartholomew's
H.M. Heneghan1, N.Hospital, Breast
Miller1, M.J. and Endocrine
Kerin1 Unit, London,
1Clinical Sciences United
Institute Kingdom
National University of Ireland Gal

L. Alimkhodjaeva1,
2Helsinki UniversityK.H. Khodjaeva1
Central Hospital,1National
Department Research Center of
of Pathology, Oncology,
Helsinki, Breast cancer, Tashkent,
Finland
3Helsinki
E. Blows1,University Central
J. Hatfield1, Hospital,
K. Scanlon1, A.Department
Richardson2, ofE.
Oncology, Helsinki,
Ream2 1Breast Finland
Cancer Care, Policy & Research
2King's College
2Instituto London,
de Medicina Florence Nightingale
Molecular, SchoolPortugal
Oncology, Lisboa, of Nursing and Midwifery, London, United Kingdo
3Hospital de Santa Maria, Pathology, Lisboa, Portugal
1Warwick Hospital, Breast and General Surgery, Warwick, United Kingdom
2Warwick Hospital, Pathology, Warwick, United Kingdom
1University
F.M. Surgical
Venanzi1, Hospital,
M. Petrini2, Thoracic Surgery
L. Fiammenghi2, Department,
R. Ridolfi2, Split, Croatia
A. Riccobon2, M. Capitani1, A. Concetti1 1Univ
2Istituto Scientifico
2Gloucestershire Romagnolo-Studio
Oncology e Cura deiofTumori,
Centre, Department Oncology,Immunotherapy
Cheltenham, and Somatic
United Cell Therapy U
Kingdom
3Institute of Cancer Research, Clinical Trials and Statistics
1Canisius Wilhelmina Hospital, Pathology, Nijmegen, The NetherlandsUnit (ICR-CTSU) Section of Clinical Trials, Su
2Canisius
2SunnybrookWilhelmina Hospital,
Cancer Center, Surgery, Nijmegen,
Department of ImagingThe Netherlands
Research, Toronto, Canada
3Sunnybrook Cancer
5Bristol-Myers Squibb,Center, Department
Deparment of Medical
of Medical Biophysics,
Oncology, Toronto,
Wallingford, USA Canada
6Braine-l'Alleud, Deparment of Medical Oncology, Brussels, Belgium
I. Nasunova1, A.A. Lushnikova1,
2GlaxoSmithKline, A.A. Parokonnaya1,
Oncology Medicine V.D. Ermilova1
Development Center, 1Cancer
Collegeville, USAResearch Center, Carcino
3University of Leeds, Oncology and Clinical Research, Leeds, United Kingdom
2Institute of Cancer Research, Joint Department of Radiotherapy and Physics, London, United Kingdom
3Institute
4St. of Cancer
Michael's Research, Clinical
Hospital/University Trials and
of Toronto, Statistics
Surgery, Unit,Ontario,
Toronto London,Canada
United Kingdom
5Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Division
2Kuwait University, Department of Pathology Faculty of Medicine, Safat, Kuwait of Clinical Epidemiology, Toron
3Kuwait University,Medical
2Leiden University Department
Center,of Biological Sciences Leiden,
Medical Oncology, Faculty The
of Science, Safat, Kuwait
Netherlands
3Munich Cancer
2Stanford Registry/Munich
University, Comprehensive
Division of Oncology, Cancer
Palo Alto, USACenter, Medical Informatics Biometry and Ep
3Fred Hutchinson
1National Cancer
University Research
of Ireland GalwayCentre, Breast
Galway, HealthGalway,
Surgery, Clinic, Seattle,
Ireland USA
2National
2Centro de Investigaciones Biomédicas, Radiobiology, Granada, SpainInstitute (REMEDI), Galway, Irela
University of Ireland Galway Galway, Regenerative Medical
3Hospital
2Faculty of Virgen de las
Medicine CarlNieves,
Gustav Radiation
Carus atOncology,
UniversityGranada,
of Dresden,Spain
Department of Diagnostic at Klinikum
3Klinikum Chemnitz
6European gGmbH,
Institute of Department
Oncology of Diagnostic,
and University of Milan Chemnitz, Germany Division of Senology, Mila
School of Medicine,
7EuropeanUniversity
1Catholic Institute of
of Oncology,
Sacred Heart,Department of Medicine,
Medical Oncology, Milan,
Roma, Italy
Italy
2Catholic University of Sacred Heart, Institute of Pathology,
6Department of Genetics and Faculty Division, Norwegian Radium HospitalRoma, Italy – Oslo University Hospital,
7Division of Cancer Medicine and Radiotherapy – Department
9German Breast Group, Medicine & Research, Neu-Isenburg, Germany of Oncology, Norwegian Radium Hospita
10German
8Amgen Breast
Inc., Group,Thousand
Oncology, Director, Oaks
Neu-Isenburg,
CA, USA Germany
9Ashford Cancer
8Boehringer Centre,Clinical
Ingelheim, MedicalResearch,
Oncology,Biberach,
Ashford SA, Australia
Germany
9European Organisation for Research and Treatment
8Novartis Pharmaceuticals Corporation, RAD001 Breast of Cancer, Headquarters,
Florham Brussels, Belgium
Park, USA
9Novartis
2INT, Dept. Pharmaceuticals
of Preventive and Corporation,
Predictive Global Oncology
Medicine, Milan, Development,
Italy Florham Park, USA
3RegioneMarsden
10Royal Emilia-Romagna,
Hospital andTumor Registry
Institute of Parma
of Cancer Province,
Research, Parma,
Breast Italy
Unit, London, United Kingdom
3Princess Alexandra Hospital, Cellular Pathology, Harlow, United Kingdom
4St Margarets Hospital, Breast Surgery, Epping, United Kingdom
1Medical
3seoul CollegeUniversity
National Hospital, Hospital,
Radiotherapy, Kolkataof
Department (Calcutta), India South Korea
Surgery, Seoul,
4seoul National University Hospital, Department of Radiation Oncology, Seoul, South Korea
A. Awada1,Medical
2Samsung T. Vora1Center,
1Jules Bordet
Surgery,Institute, Medical Oncology Clinic, Brussels, Belgium
seoul, Korea
3Samsung Medical
2Institute Jules Center,
Bordet – BIGDivision of Haematology-Oncology,
aisbl, Medicine, Brussels, Belgium Department of Medicine, Seoul, Korea
3Institute Jules Bordet, Breast, Brussels, Belgium
1Regina Elena National Cancer Institute, Medical Oncology, Roma, Italy
1Maastricht University
8Athens University Medical
Medical Centre,
School, Department
Breast of Radiation
Unit, Athens, Greece Oncology (MAASTRO), Maastricht, Th
9Leiden University Medical
8SAKK Coordinating Center,Centre,
ClinicalDatacentre, Leiden,Research,
and Translational The Netherlands
Bern, Switzerland
9Clinica Luganese
3Odense UniversityMoncucco, Medical Oncology,
Hospital, Oncology, Odense, Lugano,
DenmarkSwitzerland
4Rigshospitalet,
4EORTC, Brussels,Section
Belgiumfor Surgical Pathophysiology, Copenhagen, Denmark
5Centre Georges-François
7Pfizer Oncology, Development, Leclerc,
LaDijon, France
Jolla, USA
8Regional Cancer University
1National Taiwan Centre, Sunnybrook Health Sciences
Hospital, Oncology Centre,
Department, Toronto,
Taipei City,Canadai
Taiwan
2National of
1Institute Taiwan University
Oncology Hospital,
Ljubljana, Surgeryof
Department Department, Taipei City,
Surgical Oncology, TaiwanSlovenia
Ljubljana,
2University
2Clinica del of Ljubljana,
lavoro Institute
Fondazione of Biomedical
Salvatore Informatics,
Maugeri, Ljubljana,
Rehabilitative Slovenia
Oncology, Pavia, Italy
3Clinica del lavoro Fondazione Salvatore Maugeri, Unit of Pathology, Pavia, Italy
1Baskent
5Jules University,
Bordet Faculty
Institute, Medicalof Oncology,
Medicine, Medical Oncology,
Bruxelles, BelgiumAdana, Turkey
6CHU Charleroi,
3CRLC Medical
Val d'Aurelle, Oncology,
Biostatistics Charleroi,
Unit, Belgium
Montpellier, France
4CRLC Val d'Aurelle, Surgical Oncology Unit, Montpellier,
F. Lumachi1, S.M.M. Basso2, M. Bonamini2, M.B. Marzano2, France
E. Milan2, B.U. Waclaw2, G.B. Chiara2 1Un
2S.M. degli Angeli Hospital, U.O. Chirurgia 1, Pordenone,
1Hospital Clinico San Cecilio, Medical Oncology, Granada, Spain Italy
2Hospital Virgen
2University School deoflas Nieves, Radiation
Medicine, Chair and Oncology,
Department Granada, Spainand Embryology, Wroclaw, Poland
of Histology
3Charité Universitätsmedizin Berlin, Laboratory of Functional Genomics, Berlin, Germany
C. Herskind1, F. Wenz1 1University Medical Center Mannheim University of Heidelberg, Dept. of Radia
I. Kunkler1
6ISRSCT, 1University
Oncology, of Edinburgh,
Meldola (FC), ItalyEdinburgh Cancer Centre, Edinburgh, United Kingdom
7Ospedale
8Sir Ganga diRamCircolo e Fondazione
Hospital, Department Macchi, Division of
of Oncology, Oncology,
New Varese, Italy
Delhi, India
9GlaxoSmithKline,
6Maastricht Oncology
University MedicalR&D, Asia Department
Centre, Pacific, Singapore
of Surgery, Maastricht, The Netherlands
7Maastricht University Medical Centre, Department
9Leiden University Medical Center, Medical Oncology, of Leiden,
Internal The
Medicine, Maastricht, The Netherlands
Netherlands
10US Oncology Research, Inc., Houston, TX, USA
1King's
1N.N. College
Petrov London,
Scientific Division Institute
Research of CancerofStudies,
Oncology,London, United
Radiation Kingdom
Oncology & Nucl. Med., St-Petersburg
2N.N. Petrov Scientific Research Institute of Oncology, Breast Cancer, St-Petersburg, Russian Federati
P. Gascon1 Hospital
3University Clinic
of Medicine andBarcelona,
PharmacyServei d'Oncologia
Craiova, Media,
Radiotherapy, Barcelona,
Craiova, Spain
Romania
4University of Medicine and
7Universitätsfrauenklinik amPharmacy Craiova, Epidemiology,
Klinikum Südstadt, Department ofCraiova, Romania
Gynecology, Rostock, Germany
8Universitätsfrauenklinik
7City Hospital, Oncology, Magdeburg,
Nottingham,Department
United Kingdomof Gynecology, Magdeburg, Germany
8Walsgrave Hospital, Oncology, Coventry, United Kingdom
1Rudjer Boskovic Institute, Molecular Medicine, Zagreb, Croatia
2Rudjer Boskovic
3Santa Maria dellaInstitute, RMDHospital,
Misericordia ltd, Zagreb, Croatia Anatomy and Histology Service, Perugia, Italy
Pathological
4ASL2-Perugia,
1National CancerPalliative Cure Service,
Center Hospital, Perugia,
Radiation Italy Division, Tokyo, Japan
Oncology
2National
2AMRI, Cancer Center
Oncology, Kolkata,Hospital,
India Breast Surgery Division, Tokyo, Japan
3ICON – ARO group, India
4Department of Experimental Pathology and Oncology, University of Florence, Firenze, Italy
5Radiotherapy Unit Clinical
2Eras Medical College Physiopathology
and Hospital, DeparmentDepartment,
of Surgery,University
Lucknow,ofIndia
Florence, Firenze, Italy
3Eras Medical
2Daiichi SankyoCollege and
Co. Ltd, Hospital, Deparment
Therapeutics, of Pathology, Lucknow, India
Tokyo, Japan
3IPBS,
B. Therapeutic
Gerber1, Targets,
H. Mueller2 Toulouse,
1University of France
Rostock, Ob/Gyn, Rostock, Germany
2Fertility-Center Rostock, Ob/Gyn, Rostock,
2“St Savvas” Hospital, 1st Radiotherapy Department,Germany Athens, Greece
3“Ag. Anargiri”
3Maastricht Oncology
University Hospital,
Hosptial, Radiotherapy
Oncology, Department,
Maastricht, Athens, Greece
The Netherlands
4Maastricht
3Helsinki University
University Hosptial,
Central Epidemiology,
Hospital, DepartmentMaastricht, The Netherlands
of Pathology, Helsinki, Finland
4Helsinki University Central Hospital, Department of Oncology,
2Maria Sklodowska – Curie Memorial Cancer, Department of Breast Cancer Helsinki, Finland
and Reconstructive Surger
3Maria Sklodowska – Curie Memorial Cancer, Clinical Trials and Biostatistics Unit, Warsaw, Poland
1Tripoli Medical Center, Haematology and Oncology Department, Tripoli, Libya
1Medical University Hospital of Lublin, Surgical Oncology, Lublin, Poland
J. Jonkers1
1Ankara 1The Netherlands
Oncology Teaching andCancer Institute,
Research Molecular
Hospital, Biology,
Surgery, Amsterdam,
Ankara, Turkey The Netherlands
2Ankara
6St ThomasOncology Teaching
Hospital, and
Institute of Research
Psychiatry,Hospital,
Sussex,Pediaetric Oncology, Ankara, Turkey
United Kingdom
7Hopital St Louis, Citoh, Paris, France
C. Caldas1
2UZ 1Cancer Research
Gent, Oncology UK Cambridge
– Radiotherapy, Research Institute, Department of Oncology, Cambridge,
Gent, Belgium
3University Gent, Nursing Science, Gent, Belgium
1Samsung Medical Center, Radiation Oncology, Seoul, Korea
1Abdurrahman
2Karadeniz Yurtaslan
Technical Onkoloji
University Egitim Faculty,
Medical Hastanesi, Medical Trabzon,
Pathology, Oncology,Turkey
Ankara, Turkey
3Karadeniz Technical
1Cerrahpasa University
Medical Faculty Medical
Istanbul Faculty, Public
University, MedicalHealth, Trabzon,
Oncology, Turkey
Istanbul, Turkey
2Cerrahpasa Medical Faculty Istanbul University,
7Royal Free Hospital, Surgery, London, United Kingdom Pathology, Istanbul, Turkey
8Emam
1Centrum Reza Hospital,
Onkologii Surgery,
– Instytut Mashad,
im. Iran
M.C. Sklodowskiej, Chemotherapy Department, Gliwice, Poland
2Centrum Onkologii
9AstraZeneca, – Instytut
Medical im. M.C.
Department Sklodowskiej,
Oncology, Wedel,Department
Germany of Tumor Biology, Gliwice, Poland
10University Hospital, Gynaecology, Ulm, Germany
1Soroka University Medical
1M. Sklodowska-Curie Center,
Memorial Oncology,
Cancer CenterBeer-Sheva,
and InstituteIsrael
of Oncology, Clinical Oncology, Gliwice, P
2University of Cagliari, Department of Cytomorphology, Cagliari, Italy
3University
2Institute ofof Cagliari,Ljubljana,
Oncology Department of Pubblicof
Department Health and Biostatistics,
Pathology, Cagliari, Italy
Ljubljana, Slovenia
3Medical Faculty of Ljubljana, Institute of Biomedical Informatics,
2Jeroen Bosch Ziekenhuis, Radiology, Hertogenbosch, The Netherlands Ljubljana, Slovenia
3Jeroen Bosch Ziekenhuis,
G. Mazzarella1, Pathology,
A. Bufacchi2, Hertogenbosch,
A. Bonanni1, A. Petrone1,The Netherlands
F. Tortoreto1, C. Guidi1, O. Caspiani1, M. Leon
2Ospedale “S. Giovanni Calibita” Fatebenefratelli Isola Tiberina, U. O. di Fisica Sanitaria, Rome, Italy
1University
1Clinica del of Aberdeen,
lavoro Cancer
Fondazione MedicineMaugeri,
Salvatore Research Program,
Medical Aberdeen,
Oncology United
II, Pavia, Kingdom
Italy
2Clinica del lavoro Fondazione Salvatore Maugeri, Rehabilitative Oncology,
1Alexandra Hospital Athens University Medical School., 1st Department of Obstetrics Pavia, Italyand Gynaecolog
2Alexandra Hospital,Sao
2FMUSP, Pathology, Pathology, Athens, Greece
Paulo, Brazil
3Hospital Sirio Libanes,
4Massachusetts GeneralBreast Center,
Hospital, Sao
Breast Paulo,Medicine,
Cancer Brazil Boston, USA
5Beth Israel Deaconess Medical Center, Breast Cancer Medicine, Boston, USA
1Castle
2Jeroen Hill
BoschHospital, Department
Ziekenhuis, of Medical
Radiology, Oncology,The
Hertogenbosch, Cottingham East Riding of Yorkshire, United Ki
Netherlands
3Jeroen Bosch Ziekenhuis, Pathology, Hertogenbosch, The Netherlands
3lopburi cancer institute, Medicine, Lopburi, Thailand
4Maha Vajiralongkorn Cancer Center, Medicine, Patumthanee, Thailand
1South Manchester University Hospitals Trust, General Surgery, Manchester, United Kingdom
1Kennemer Gasthuis, Department of Surgery, Haarlem, The Netherlands
D. Katalinic1,
2Iridium S. Plestina1GZA,
Kankernetwerk 1Zagreb UniversityWilrijk,
Radiotherapy, Medical Center, University Department of Oncology, Zag
Belgium
3Iridium Kankernetwerk
9German GZA, Nursing,
Breast Group, Statistics, Wilrijk, Belgium
Neu-Isenburg, Germany
10German Breast Group, Medicine & Research, Neu-Isenburg,
Department of Radiotherapy, London, United Kingdom; 2Imperial Germany
College,
School of Medicine, London, United Kingdom
Center Sungkyunkwan University School of Medicine, Department of
Radiation
of Oncology Oncology,
& RadiologySeoul,of South
Serbia,Korea
Department of Epidemiology and
Prevention,
BRAM Belgrade,
Hospital, SerbiaAgartala, India; 2Osmania Medical College,
Physiology,
Community Medicine,
of Medicine, Department Hyderabad, India
of Surgery, Kaunas, Lithuania; 3Kaunas University
of Medicine, Department of Pathological
Control, Epideniology, Tbilisi, Georgia; 3Cancer Anatomy, Kaunas, Center,
Prevention Lithuania
Palliative
State CareUniversity,
Medical Unit, Tbilisi, Georgia
Pharmacology, Grodno, Belarus; 2Grodno
Regional2National
Ireland; Hospital, University
Oncology, of Grodno,
IrelandBelarus
Galway, Department of Economics,
Galway, Ireland
Z. Lwin1, N. Leighl1, M. Krzyzanowska1. 1Princess Margaret Hospital,
Medical
P. Hadji1.Oncology,
1Universit Toronto – Ontario,
¨ at Marburg, Canada Endocrinology, Marburg,
Department
Germany
Neu-Isenburg, Germany; 10German Breast Group, Neu-Isenburg,
Germany
5 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IOR,
Meldola,
ChirurgiaItaly; 6 degli
I, S.M. Istituto Palazzolo,
Angeli Fondazione
Hospital, Pordenone,DonItaly;
Gnocchi, Milano,of
3University Italy
Padova,
S. Department
Monfardini1, of Neurosciences
A. Jirillo1. Biostatistics
1Istituto Oncologico Section,
Veneto, Padova,
Oncologia Italy
Medica
2,Garcia
J. Padova, Italy M. Lomas1, M. Hidalgo1. 112 de Octubre University
Borda1,
Hospital, General Surgery,
J. P´erez1, A. Farriols1, Madrid, Spain
J. Baselga1, S. Di Cosimo1. 1University Hospital
Vall
Scientifico Romagnolo per lo Studio eBarcelona,
d’Hebron, Breast Cancer Center, la Cura deiSpain
Tumori, IOR, Meldola,
Italy
Meinigen, Germany; 8German Breast Group, Statistics, Neu-Isenburg,
Germany;NHS
Hospitals 9UFKTrust,
D¨usseldorf,
Nursing,Frauenklinik,
Portsmouth, Neu-Isenburg,
United Kingdom; Germany
4Portsmouth
Hospitals NHS Trust, Radiology, Portsmouth, United Kingdom
Conclusions: The present study provides SUMMARY an indication that lobular cancers are detected by the blood
The study suggests the test has
Results: β-catenin, Cyclin D1, FRP1 and FRP2 a potential for detecting percentages
expression a form of cancer werewhich53.5±32, is difficult
41.8±33, to detect
25.0±w
Conclusion:
Result: Dataβ-catenin,
eligible forCyclin D1, FRP1
our analyses ve FRP2
could expressions
be retrieved for 13 were not found
studies to influence
evaluating diseaseuse
the adjuvant free
of a
Conclusion:
Efficacy: Current
In Phase available
I (final data),randomized
5 of 15 (33%) evidence do notatsupport
pts treated MTD had the hypothesis
partial responses that after
use ofa bisphos
median
Conclusions:
Results: We showT-DM1 herehasresults
single-agent
for TOT-B activity
(totalinFACT-B
pts with previously-treated,
score) and for TOI-B (trial HER2+ MBC and
outcome is well
index; to
includ
Conclusions: Patients treated with BV in combination with taxanes
Competitions such as these can serve the useful role of providing standards against which new metho as first-line treatment for mBC exp
For a next
Results: step the described
Information is based on procedure
a total ofshould be validated
1365 patients within patientsfollow
a median at riskup forofbreast
3.7 yearscancer andand med i
Conclusions:
Results: 139 ptsThewereresults provide significant
randomised to treatment evidence
(A, 44;ofB,improvement
47; C, 48). Baselinein prognosis of MBC patients
characteristics were as wi
Conclusions:
Results: The combination
915 patients were recruitedarms seem from to offer higher
October 2004-Marchdisease control
2007. Mean rate than
age sequential
= 62.7 years; schedul
ductal h
Conclusions: 28.5 Gy in 5 Fr in 5 weeks of whole breast RT appears
Results: We have identified a gene signature consisting of 689 probes that predict cancer patients as safe in terms of adverse effects
fro
Conclusion: Our results indicate that the blood transcriptome of
DL2 was defined as the RD and the expansion cohort was initiated. PK analysis did not show any drugbreast cancer patients carries biologic
Conclusions: X was safely combined to C. X at 20 mg/m2 D1 + C at 1000 mg/m2 twice a D (D1–14), q
Bonecell
Our metastases (BM) lead toled
culture experiments frequent debilitatingwhether
us to investigate complications
PI3K pathwayin advanced activationcancer, resulting
is able in bon
to predict T
Conclusions: The present work highlights the central importance
Results: Our results showed that the use of doxorrubicin in MCF-7 breast cancer MTS transfected with of PI3K signalling in risk for progress
Conclusions: The transfection
Results: IMO inhibits KPL4 andof genexenografts
JIMT1 E in MCF-7growth MTS isand ablepotentiates
to increasethe theantitumor
chemotherapeutic effect
effect of trastuz
Conclusions:
Results: We demonstrated
Patients in the home care a synergism
arm experienced of IMO plus trastuzumab
significantly lower insymptoms
different trastuzumab-resistan
(composite score of
Conclusions: A nursing symptom management regimen-focused
Results: 512 patients are currently eligible for toxicity and efficacy. In the intention to treat home care programme wasanalysis
able to bth
Conclusions: Neoadjuvant
Results: 306 metastatic EDC cancer
breast in earlypatients
breast cancer
resistantresults in a significantly
to anthracyclines higherelliptinium
received pCR rate than acetateED
Conclusion:
Results: After Elliptinium
16 cycles,acetate is a low cost
the suspension antineoplastic
consisted agent that
of a homogenous provedpopulation
cellular significantpresenting
efficacy in hig me
Conclusion:
In the cancerFocusing
data seton tumorregression
logistic stem cellsanalysis in basic showed
researchpredictors
and cancer of therapy
pain were comes
taxane of age – here w
chemotherap
Conclusions: This research shows that women who have been treated
Results: 497 breast cancer patients were analyzed more than three times during the course of disease for breast cancer may experien
Conclusions:
Results: Adequate CETC measurement
and subpopulation monitoring
of S and SR could provides
be donean ininvaluable
522 out of tool 540for LV prompt
segments. gauging
The meanof sy
Conclusions:
CT, ET, and localSRI allowed
therapies the detection
have of a dose-related
the potential regional
to significantly impact decrease
both the in myocardial
physiologic functionhealth-inclu ear
As many
We appliedunanswered questions
a filter to blood remain,data
(reference) it is not
alsoonly
important
to remove to increase the accrual of
the contaminations young women
(unclear genotype w
Conclusions: These findings provide evidence which genes involve
A significant deterioration of cardiac function was observed in three patients; 40.2% developed brain in breast cancer and studying in tw
Conclusions: Trastuzumab
Results: The studies comprised in multiple
a totallines935 pts,showed considerable
of whom 274 pts had activity.
receivedNonePLD of theaftervariables invest
prior exposur
Conclusion:
Results: Among This832meta-analysis
patients in demonstrates a significant CB
the modified-intent-to-treat from anthracycline
population, 53% had breast rechallengecancer using
and PL 47
Conclusions:
Cohort The benefit
two consisted of 320 of APR triplewith
patients therapymedianhas follow-up
been shown to extend
of 6.3 to non-breast
years. Median age was cancer
58 yearspatient
(IQ
Conclusions: All eight SKFM are expressed in different breast tissues.
Results: In our study population a linear relation between tumour size and the occurrence of regional In invasive breast cancer Src kin
Conclusion:
Results: TheThe mean constant
delta-ALA frequency of smallinmetastases
concentration urine was 16.10 (N0(i+) and Nmi)
μmol/g with increasing
creatinine (95% CI =tumour (14.92–17 size
Conclusion: Our
Results:114 findings
patients withshowLABCthat andheme/porphyrin
107 healthy controls biosynthesis in breast
were included, cancerage
median patients is affected
was 46.4±9, ER
Conclusion: Patients with HER2/neu overexpresion and Ile655Val
Results: 279 pts from 37 centres in 10 countries were randomised: 184 to receive Hospira filgrastim apolymorphism might have more card
Conclusions:
Results: Adjuvant Hospira filgrastim
breast cancerwas equivalent
treatment withto Neupogen for alldid
bisphosphonates parameters
not reducetested. These rate
the fracture included
com
Conclusion:
Results: Our meta-analysis
Overall, 4 patients presented provides substantial
brain evidence
lesions before that bisphosphonates
starting treatment, whilein 42theptsadjuvant
(39%) deve se
Conclusions:
Results: Our results
17 (27.4%) of the confirm
62 patientsthat BM withare a common
brain metastasisevent hadin triple
patients with HER2-overexpressed
negative breast cancer, compa M
Conclusion: Patients with triple negative breast cancer are at a high
Results: All patients have now been followed to death. Eighteen of the 32 HER2 pos patients were dia risk of developing brain metastas
Conclusion: Our study
Results: Patients' shows thatwere
characteristics HER2similar
over-expression
between the increases
two groups, the risk of cerebral
especially metastases
for SBR. All women sign
Conclusion:
Results: This are
Results firstpresented
registry-based in thecase-control
table. study failed to demonstrate improvements in breast-
There
In is highlydisease,
metastatic statistically
quality significant
of life is difference
more important regarding
thanbiological
quantity of markers of primary
life, certainly BC: negative
for older individu
Targeted therapies such as trastuzumab and bevacizumab have
Conclusion: The breast cancer screening programme has been implemented in the majority of munici been shown to be useful in the treatm
However,
Results: 325 it should
RCTs were be noted that atThe
identified. theaverage
moment,mean insufficient
and median detailed ageinformation
reported were has 56.5
beenand collected
55 res
Conclusion:
Results: Of theRacial/ethnic
64 index tumors,information 57 werewasvisible
provided in only a minority
at mammography, 59ofattrials. Also most ofand
ultrasonography these61 trial
at M
Conclusions:
Results: FromRisk of extensive
September 05 tooccult
January disease
08, 431 around MRI-visible
patients lesions decreases
were randomized (217 to Pwith andabsence
214 to C). of wa
Pa
Conclusions: No benefit of homeopathy over standard treatment was
Results: In comparison with healthy group (table), the level of TP activity was reduced at mastopathy. noted in this study. But surprisin
Conclusions: Thus, a similar metabolic displacement during mastopathy and breast cancer may be on
Recently, our understanding of tumor heterogeneity has been expanded through “the hierarchy mode
EvidenceExpression
Results: will be presented
of TGFβ,here which foristhe existence
known to induceof a stem cell hierarchy
epithelial in the normal
to mesenchymal transition breast(EMT),andwa in
Conclusion: Tumour stromal cells have the potential to stimulate
Results: 95% patients (n = 116) had preoperative chest x-ray. Mean age was 61 years (range34–91). angiogenesis and epithelial to mesen
Conclusion:
The literature While
on the there are issues
subject has been withsparse,
cost and and radiation
the majorityin performing routine
of the studies chest and
is small x-raymethodolog
for all ope
Breast cancer
Materials is potential
and Methods: life-threatening
Patients with operable, disease, but many women
node-positive do get cured.
(or node-negative withOntumour
the basis of the
diameter
Results:
In To date, 405 patients
184 postmenopausal HR+ pts from 8 countries
endocrine have been
treatment data randomised.
was analyzed. Baseline
CTCs atcharacteristics
two years were are sh
dete
Conclusions: In the SUCCESS trial we observed persisting circulating
The RR favored PM and PB as compared with P but the differences were not statistically significant (p tumor cells in a relevant number
Conclusion:
We evaluated Thetheadministration
correlation between of M in serumcombinationPDGF-RB, withVe-CAD
weekly and P is feasible
circulating with no unexpected
endothelial cells, meatoxic
Conclusions:
Results: Of 90Though the mechanisms
cases listed, median ageofwas resistance
56 years to(range
bevacizumab24–84).are not well
Median tumourdefinedsize itwasis possible
8 mm (r
Conclusions:
All InfraHER2
patients were treatedtumours may present
with radiotherapy, withunderwent
15% aggressivemetastasectomy,
features including 21% node invasion, high
stereotactic irradia g
Advanced stages, ER-, PR-, HER2+ are related to higher risk of BM.
Results: Out of a total of 49 pts, 51% (25 pts) suffered from synchronous and 49% (24 pts) from meta Major cause of death was brain me
Conclusion:
Results: Twenty Our study
(30.3%) revealed that SBBC
of 66 patients were areluminal,
more frequent
20 (30.3%) in postmenopausal
were HER2+, and women,
26 (39.4%) presentedwere m T
Conclusions:
Results: Patients
In this study, with TN disease
we analyzed 89 were
patients.more likely to
Median age develop distantwas
at diagnosis metastasis
49 years.earlier,
Duringand poor
diagnos
Conclusions:
Results: TN breastthat
We observed cancers
at theare quite distinct
genetic from other
level, lesions from the breast
same cancers,
patientsuch that recurrences
displayed remarkablyfre si
Conclusion: Our results provide strong circumstantial evidence to
Results: A total of 519 pts have been analyzed: 346 with 1–3 positive LN (PN1) and 173 with 4–9 posit suggest that CCLs are the earliest m
Conclusion: Our dataexpression
Results: A Gene-Set show that prognostic
the 70-gene profile
model wasis adeveloped
strong prognostic marker
for individual geneof distant
set from recurrence
the train
Conclusions: The proposed
Difference 7.3±21.5** method can
-7.2±23.4** be used to
5.8±17.4** quantify the potential contribution of a predefined
-6.1±20.7*
*P < 0.01;
Results: NIS**P < 0.0001was
expression (Wilcoxon,
detected paired).
in 74/76 breast cancer tissues analysed (Mean ±SEM, 1.17±0.0
Conclusion: This study is an
Results: The study included 735 pts [99.6%important first stepwomen,to further
median understand the presence,
age 51 y (range: 21–87),regulation
99.1% ECOG and 0– re
Conclusions:
Results: CXCL12Approximately
and CXCR4 one in ten breast
are expressed bycancer
epithelial pts tumor
at highcells or intermediate
and by stromal FN and
risk endothelial
developed gra ce
Conclusions:
Results: CXCL12
Seventeen is awith
men strong,
breast independent
cancer were prognostic
examined, marker. We propose
with median age at that saturation
diagnosis of the (5
65 years re
Conclusion: The study indicates that the male breast cancer cases
Denosumab significantly delayed the time to first on-study SRE compared with ZA (hazard ratio [HR] 0 were all HER-2 negative. All tumou
Denosumab was superior to ZA in delaying or preventing SREs. The incidence of AEs and serious AEs
The sensitivity
Results: CK-19 and accuracy ofCTCs
mRNA-positive methods and DTCs for tumour
could cell detectioninin55.2%
be detected sentinelandlymph
57.6%nodes and bone
of patients pre-m
Conclusions:
Results: The above
Age was medianresults 45 years indicate a strong
old (range: 31–73correlation
years old).between the presence
All patients wore AA oforCTCs
A cup and DTCs
size bra
Conclusions: This study shows that CT based 3-D planning can
Results: At T2, younger and older exemestane users did not perform significantly worse than healthyreduce the radiation field size on each
Conclusions:
Results: 37 pts After
were one year of therapy,
assessable in total tamoxifen has a negative
(16 pts ER-/PR-/Her2-, effect
21 pts on certain cognitive
ER+/PR+/Her2-). 22 ptsfunctions
with oth
Conclusions:
Results: Increased
On average, cellularity
cancer patients andhad scant stromalfor
survived content
10 years of tumours
with the displaying
disease, atthe an triple
actualnegative
KPI: 93%
Conclusions:
Results: Self regulation
The normal amountsmight of Dolbeinan independent
healthy donors prognostic
urine (n = 250) factorarefor6.0–10.0
the survival of breast
mkg/mmol. and
During
Conclusion: There is a reason to suggest that reduced GPT activity,
Results: Dose reductions were required in 41% (n = 131) of patients receiving X monotherapy (to ∼94 lowered N-glycoprotein synthesis
Conclusions:
5 patients with These data
clinical show that
picture the dose had
of carcinoma of X positive
can be reduced,
lavage and either
theywhen used as treatment
had surgical monotherapy as ito
Conclusions:
A breast massAswas ductal lavageinoffers
detected 2838 asubjects
bigger amount
who hadofundergone
cells from athe final examination.
breast duct-lobe unitThe canmean help inag
Conclusion: For screening breast cancer, participation of elderly
Results: After NC, 5 patients had complete pathological response and 2 patients had residual ductal c subjects, subjects living in rural areas
Conclusions:
The analysis of Change
CA27.29 in 1ispatient
based on (4%) the from
dataHER2of 2556 negative
pts. 1252to HER2 positive
pts (49%) lead toat
received change
least one in adjuvan
course
Conclusions:
Key eligibilityNo evidence
criteria: MBCcan be provided
or locally recurrent for adisease,
significant correlation
no prior cytotoxicbetween
treatmentan increase
for MBC, in ECOG
the num PS
1237 pts (Cap
Results: Analyses of the=first615;86T of =a 307; Ant =120
planned 315) were enrolled.
patients showed Addition
that BSI-201of B + improved
G/C hadPFS (Cap: pl
improved C
Conclusions: This preliminary analysis demonstrates that BSI-201
Results: Baseline socio-demographic and medical data were similar between the groups. Evolution of + G/C significantly improves CBR, P
Conclusion:
Results: TheThis onlystudy did notsignificant
statistically provide evidence correlationson the efficacy
found betweenof specialist
circulatingcarehormone
including specialised
levels and al
Conclusion:
Results: Although
In the past, Worldhigher circulating
Health estradiolPMO
Organization levels have been
guidelines andrepeatedly correlated
American Society with anOnco
of Clinical eleva
Conclusions:
The The emerging
German Breast Cancer Study consensus Group is GBSG-2
that BMD alone is
dataset not sufficient
showed to evaluate
similar findings, patient fracture
confirming the poorr
Conclusions: The present analysis confirms the findings of many
Treatment was well tolerated. More frequent delays occurred during the last four cycles of each regim epidemiological and clinical trials tha
Conclusions: All regimens
A significant correlation was werefoundfeasible
between and elevated
achieved bs-HER2a high rate andofnumber
pCR in ER-negative
of M sites (p tumors.< 0.05),Regim as w
Conclusions:
Results: Our 621
In 2008, dataquestionnaires
seem to suggest were that serum HER2
e-mailed to userslevelswho might
gavebe used
their as a “real-time”
permission. 249 users non(40inv
Conclusions:
Results: As ofOur
March online
30th breast
2009,cancer33 ptsconsultation
were enrolled service
(9 stillisongoing):
highly appreciated
6 pts in the byEusers,
5 mg/d particularly
cohort, 17
Conclusions: E in combination with T and H has an acceptable
In the present study monoclonal antibodies “77B”, “57B” and “B9.8.1” (Juretic A et al. The Lancet safety profile and confirms high promis
Onc
The results of our retrospective study suggest that the aforementioned C/T antigens may be used in M
Results: We compared gene expression of all markers according to estrogen receptor and HER2 statu
Conclusions:
Results: Expression
222 women (76%)of glucose
reportedtransporter SLC2A1 discovered
breast symptoms, and iodine transporter
by themselves SLC5A5 in breast
or their cance
partner. Tw
Conclusion: Our results suggest that woman's physical and socio-demographic characteristics
Results: Provider delay was known for 282 women. Provider delay was 1 month or less for 38% of wom and livi
Conclusion:
Methods: WeOur study suggests
reviewed that
all original screen
frozen detected
section – andcancers and cancers
permanent section –detected
slides ofin473
large towns or c
SNB-cases,
Weeconomic
Results: In found 4 false
terms, positive
we now cases
showpossibly
that therepresenting macrophages
cost of MammaPrint with keratin
was offset deposit mate
by the savings, due
Conclusions:
CT In summary,
dose reduction ≥15% inMammaPrint
any cycle 16is(12%)
a gene9 expression
(23%) 4 (18%)profiling test that has proved to be more
*From cycle 1; initiated by day 7 if CT given on Day 1 only
Results: Seventy-three percent of the patients presented a cT1-T2 or by day 11 if CT
tumour. given was
CA15.3 on Day 1+8.
within †Stag
normal
Conclusion: This study
Common cancers suggests
exhibit familialthat Fibronectin
aggregation, 1/CXCL9 with
consistent dosage in serumvariation
substantial could screen a significant
in inherited suscep r
Recent genome-wide
Results: Characteristics association
of patients.association
Mean agestudies
was 42have
yearsidentified thirteen
(range, 26–50 genetic
yrs). 69% ofloci with commo
patients were
Conclusions:
Materials andThese dataPubMed
Methods: show thatandthe administration
conference of a Gn-RH
Web sites analoguetoimproves
were searched lymphocyte num
identify representative tr
Results: Early studies on taxanes as adjuvant therapy were presented in 1998 and 2000,
Patients and Methods: Patients with early stage breast cancer were selected from the Eindhoven Canc but adjuvant
Results: A total
Conclusion: of 1,451
(1) The new of
absence breast cancer patients
progesterone receptorstarted on tamoxifen.
was associated with Of those,
a high 26% had of
probability a treatm
CpR a
Results: MDM4 mRNA expression levels significantly correlated with copy number (Pearson's correlati
Conclusion:
Amplified 10Mdm4
12 is an independent prognostic and predictor of BC and its overexpression could repr
Non-amplified 2 75
Results: Cell viability of breast cancer cells after 24 h exposure to HMPS decreased significantly, and b
Conclusion:
3(+) 11 7 4 4 Our
7 3results
8 demonstrates that proliferation inhibitory effect of HMPS is about 50-fold more
N: No.
Late of pts was observed in 8 patients (10%) in the group treated with hypofractionation with a mea
toxicity
Conclusions:
Materials andInMethods:
our experience,
Betweena 2008 radiation
and hypofractionated
early 2009, 34 patients schedule withdelivering
T1–2N0M0 45breast
Gy in 20 fractions
cancer were
Conclusions: The preliminary results indicate an increase in the incidence
Results: Between 06/2004 and 08/2008 1409 pts were recruited in 172 German centers; 703 pts recei of radiation-induced pneum
Conclusion:
Results: This is findings
Operative the largest adjuvantthat
confirmed study in the elderly
guide-wires werepopulation
successfully and the only
inserted one
into SLNinvolving
of 61 patiea no
Conclusions:
Fatigue is oneByofmeans
the most of this novelcomplaints
frequent technique, among SLN may BCbe readily identified
survivors receiving and RT. Tolocalised
exploreinwhether
the pre-
With
Results: UCP4 positive cytoplasmic expression was detected in 41 (45.5%) of breast cancer smears,lon
the above studies we hope to identify gene variants and gene expression profiles that predict b
Conclusions: Dysregulation
PgR 2.37 (1.03–5.48) 0.043 - - of normal cell death mechanisms plays an important role in the pathogene
UBP 4.24Mammaglobin
Results: (1.73–10.40) 0.002 4.24 to
was found (1.73–10.40)
be absent in 0.002
benign conditions and elevated in both invasive and
Conclusions:
Results: Since positive
The number ER statuson
of publications andthelower
topictumour gradeAIs
was limited. areorassociated
TAM appear withtoaaffect
bettercognitive
prognosis fun f
Conclusions: Compared with HC, HT for BC impacts some aspects of
Results: The prevalence of protein overexpression in the tumor was 20.6% and HER2 overexpression cognition. The effect of ANA and
Conclusions: The results
Results: The median of this
duration ofstudy
follow-updemonstrate
was 72 months a consistent
(range; relationship
8–110 months).between Thep53 protein
5 years localoverre
Conclusions:
Materials andAccording
Methods: to 39this
womenstudy, (agepatients
58.6±12.8with close
years,orBMIpositive marginkg/m2)
27.2 +/-4.9 by carcinoma in situ
participated inhad
this es
There
Results: 75 was an
HR+EBC increase
patients in blood
were glucose
diagnosed in levels
the studywithperiod
later cycles among
(see Table 1).women who received
Post-menopausal hight
Conclusions: The management of adjuvant endocrine therapy in HR+EBC
Of the 27 malign lesions, 12 were in situ tumors (44.4%) while 10 others (37.0%) were early stage inv patients was appropriate in
This studyWe
Methods: shows, evenaincohort
stratified 35–49of year
3614 oldwomen
women, although
treated withtheir
TAMbreast
followingis denser
surgery than
for the
early older ageca
breast g
Conclusions:
Results: WholeElderly
bloodpts with breast
samples cancer are to
were preferable frequently
serum and undertreated for theirdetection
plasma for greater disease, despite bein
and relative
Conclusion: This study is the first to demonstrate that miRNAs are detectable
Results: In the 1 series the rise of a number of mitosis till 1.3% and insignificant induction of apoptosi and in the circulation of
Conclusion: The results
Results: Patients with pN0i+received
diseasein the 5 series
were treated of the
more experiment
often withopen quiteadjuvant
systemic new prospects
therapyinthanbreast th
Conclusions:
Results: The findings
Participants suggest
had unmet that presence
information of isolated
and support tumor
needs, cells in the
particularly sentinel
relating tonodes
skin andis an adv
hair c
Conclusions:
Results: AfterBoth the statutory
received both drugs and voluntary
median timesectors need to make
to progression in bone services
was 5.4 more inclusive,
months; 34.6% by(nraisin
= 9)
Conclusions: Our results suggest a positive clinical impact of BP and taxanes
In our cohort of 232patients, 52 (22%) were positive for metastatic carcinoma to the SLN. Out of these combination therapy in m
Conclusions: TICpatients
Results: All the has accuracy
had theirratenon-palpable
of 90% and positive predictive
breast lesion value
detected andof surgically
100%. Patient should
removed be co
under l
Conclusions:
Results: MOs'Intraoperative
phenotype and ultrasound
functions guidedwere not breast surgery allows
substantially modified detecting of occultof
by the addition early
serumbreast
in cu c
Conclusions:
Results: At a We speculate
median follow-upthatof TEM8 is invlved
10 years, thereinwere cellular
150mechanisms
documentedthat casesfoster both118
of IBTR: leukocytes-de
(79%) wer
Conclusions: Despite uncertainty in some cases in classifying IBTR as
Our results confirm the outcomes of the studies on male breast lesions in the recent literature. LR or NP on clinical criteria, the
Conclusions:
Age-adjustedFNA oddson benign
ratio for abreast
1-unitlesions
increase yielded
in PD many unsatisfactory
was 1.00 (±0.01, p =cases.0.83).However,
Results were due similar
to the go w
Conclusions:
Objective Increased
responses were mammographic
observed at all breast
dose density
levels inis18/32
not associated
(56%) ptswith withhigher breastdisease;
measurable cancer inci 2/1
Conclusions:
Results: Ixa/epi
Images combination
obtained by Nicon is digital
an active first line were
microscope MBC regimen
studied for with a manageable
quantifying safety(KDR)
of VEGFR2 profile. e
Conclusion: The data obtained suggest that VEGFR2 (KDR) expression
Methods: TTP is based on independently reviewed data as of 03 April 2006, when enrollment was halt in breast tumor vascular endoth
Results: Table 1 presents results. Pts with <3 prior regimens on L+C had a 63% reduction in the risk o
Methods & materials: Twenty-two patients with left breast cancer had titanium clips placed in excision
Conclusions:
Materials andMean
Methods: LAD doses from both
An inception prone
cohort & supine
of 512 women tangential-field
with T1–3, N0–1, WBIM0 areBCsignificant.
diagnosedProne at Univepos
Results: Mean age was 50.5±9.7 years. Tumor characteristics were
Conclusions: Our observations suggest that a change from an epithelial to a more invasive mesenchy as follows: T1 = 287, T2 = 158, T3
Supported
Results: In bytheKuwait
recent University
decade the RA grants PC02/04,
incidence of metastasesGM01/05, among GM01/01.
M0 patients decreased markedly, ho
Discussion
Results: Theand Conclusions:
ability to perform In modified
recent decades, development(MRM)
radical mastectomy of metastases in M0 breast
is the mainstay cancer seem
of locoregional tre
Conclusions:
Results: Thoughtfully
Following indirect applied
co-culture resource allocation
with MSCs, all threefor breast
breastcancercancertreatment can improve
cell lines displayed care d
a downreg
Conclusion:
Results: Ours analyses revealed low or absent methylation ESR1and 14–3-3σ in healthy controls cells,
Mesenchymal stem cells have a distinct paracrine effect on breast cancer epithelial and s
Conclusions: This study identifies the presence of variations in global
Results: Positivity rate of ETC controlled RT-PCR on the basis of CK19, MG1, and EpCAM was 8.6% in 1 levels of methylation promoters
Conclusion:
Results: We have
Sentinel lymph used nodeembedded
biopsy (SLNB) tumor and cellsaxillary
(ETC) as internal
lymph node calibrators
dissectionfor accurate
(ALND) wereprocess
performe co
Conclusion:
Results: OurThe
earlypresence
data suggestof a single micrometastatic
that TopoIIa overexpression lymph (cut-off≥12%)
node is associated with a higher
and MAPtau risk of d
underexpressi
Conclusion: These preliminary data suggest that TopoIIa overexpression
Conclusions: Due to the implementation of a technique called the Single Cell array Comparative Geno and MAPtau underexpression
Acknowledgements:
Results: From July 2005 ThistoworkMarch has2008,
received165 research funding by
pts were recruited inthe
35 Communities
centres. The median Sixth Framework
age was 65 Pr
Conclusion:
Results: This(Arm
33 pts is theA,largest
n = 10;study Arm B, investigating
n = 23) have X with an up-to-date
received ≥1 dose of dosage as 1st-line
motesanib. Median monotherap
age is 51
Conclusions:
Results: Motesanib
76 patients were in included
combination betweenwith P or D appears
07/2007 to be tolerable
and 04/2008. Five patientsand shows
neverevidence
received of ant
study
Conclusions: BI-2536
PD (%) 5 (20) 2 (33) 2 (15) showed limited or no anti-tumour activity based on the Simon optimal design. Th
Time to progression,
Results: We evaluated median
the total (wks) 32 33population
resident 29 (n = 1500) of breast cancer pts diagnosed during
Conclusions:
Materials andThis is the Eligible
Methods: first population-based
pts had HER2-negative registry study LR/mBC analyzing CNS metastases in breast
(or trastuzumab-pretreated HER2-pos canc
Results: Between Sept 2006 and data cut-off for this analysis (March
Of 37 patients, 28 consented for retrospective Topo IIA specimen testing. All those that were 2009), 2041 pts were treated. M
Conclusion: In this small
Results: All patients neoadjuvant
completed treatment. study, Topo response
Tumor IIA tumourwas testing did not
evaluated aspredict for likelihood
per RECIST criteria by of m co
Conclusions:
Results: Judicious
A total 43 patientsintegration of systemic
were enrolled and local
(isolated therapyLN:13
mediastinal is the patients,
key to successisolated in pulmonary
breast cancer no
Conclusions:
Targeted The biologic
therapies are ansubtype,
addition size to theof armamentarium
lesion and maximal SUV ontoPET
of agents fightcould
breasthelp physician
cancer. But towhendiffe
Chemotherapy
Results: Locoregional failure free survival (LRFFS), distant metastasis free survival (DMFS), diseaseafre
is an integral and irreplaceable part of the treatment of breast cancer. But there is n
Conclusions: In patients with pathological N0 or N1 after neoadjuvant chemotherapy followed by surg
Results
The are now available
meta-regression analysisfrom(performed
six trials randomizing
on 14 studies, more with than 13,000
1,098 pts) women
identified withtheHER-2
rate ofpositive
ER+ (pea =
Conclusions:
Results: DataInofabsence
300 patients of a large
were series
analysed,of randomized
20 patientstrials dropped addressing
out for thevariousoptimal hormonal
reasons. seque
The overall
Conclusions: No statistically significant differences in patient satisfaction
Results: Between 2001 and 2006, 9779 patients were randomised. Baseline characteristics and range were found between nurse-le
Conclusions: Despite international
Best overall response rate was 23.3% consensus
(exact 95% guidelines, wide global
c.i. 12–39%), median variations
PFS wasconcerning
7.5 monthslocoregion
(95% c.i.
Conclusions:
Results: 3253The
women combination
returnedofthe 2-weekly PLD and
questionnaire B in advanced
(response breast
rate 87%). cancer1543
Overall, is surprisingly toxic ar
patients (47%)
Conclusions:
Results: Persistent
To date, 25 pts painhaveinbeen the surgical
enrolledarea with after
a median breast age cancer
of 59treatment
(39–83) and remains
a median a significant
PS of 1. Pr cl
Conclusions: These preliminary PK results are consistent with data indicating
Results: A total of 60 pts have been enrolled in this ongoing trial (7 pts on the original protocol and 53 that TAM induces hepati
Conclusions:
Results: 39 MCB Thepatients
combination wereof SU (37.5from
identified mg/d; CDDbreast
7352 schedule)tumor +patients
T (wkly or q3w) showed
undergoing acceptable
biopsy or opera
Conclusion:
Results: TheMCB had poordiffer
nomograms response
in thetoinclusion
systemicofchemotherapy, either in neoadjuvant
the results of intraoperative examination setting for local
of SLNs. In
Conclusions:
Results: Fifty-two pts were treated: median age 46 years (range 29–59); median tumor size was 4.5 th
Three nomograms for predicting the likelihood of non-SLN metastases were created at cm
Conclusions: Our data show that 3-weekly EPI/DOC primary CT is very
In this study we aimed to investigate clinic pathologic factors that's associated with intracranial metas active and well tolerated in pati
Material After
Results: and Method:
median We retrospectively
follow-up of 25.5 monthscollected data's
(range: of breast
5–80) cancer patients
from hepatic surgery,with brain metasta
the median cance
Conclusions:
Results: In selected
79 patients werepatients,
evaluated. resection of breast LM can characteristics
The clinicopathological be done safely.ofHerR on primary were
the population tumour cla
Conclusions: In such a NCT population, the initial kinetic variation
Results: During follow-up (36–60 months) 62 (17.1%) patients developed relapse (DR) of the disease of serum VEGF levels appears to be(
Conclusions:
Results: Median Surprisingly,
follow-up was in the 47subgroup of older patients
months. Actuarial (OS andwith DFS)relapse
at 4 years(DR),werebothluminal
CA 15–3 A and
(99.3%CEAan s
Conclusions:
Results: A simple immunopanel
Immunhistochemistry verified canthedivide breast expression
differential cancers intoofbiologicthe top subtypes
discriminatingwith independen
genes (ABC
Conclusion:
Results: For Our
a 45findings
mm diameter suggest a role of size,
applicator the proteosome
isoeffectivein the development
fraction sizes yielding of anthracycline
the same radius resista
for
Conclusions:
The role of partial breast irradiation (PBI) in older patients remains investigational. Level I evidencetis
All scenarios predicted a sphere of equivalence larger than the 10 mm of tumour bed is
No trial of postmastectomy radiotherapy has been conducted exclusively
Results: 62 patients have been randomized: 20 in arm A, 19 in arm B, and 23 in arm C. Median age is in older patients. The surviv
Conclusions:
erbB2 status The study
in Asian accrual
breast is ongoing.
cancer studiesThe results
in 2000 of the first step Simon's design per treatment a
onwards
Conclusions:
Results: The increased
Nurse-led telephoneavailability
f-up with EGP of accurate erbB2 testing
(f-up strategy 4) was the andcheapest
data would and aid improved
most effectivetreatm
f-up
Conclusion: Nurse-led telephone f-up with an educational group
Results: At 2.75 years of follow-up (N = 9779), 740 DFS events were reported. Compared with tamoxi program is the most cost-effective f-u
Conclusions: Initial adjuvant therapy with exemestane in postmenopausal patients with hormone rece
We observed an increased risk of CBC with younger age [adjusted relative risk (RR) 1.2 (95% confiden
Our
In 36results indicate
patients that a positive
with “external tumours” family18 history
(50%) had and SLNyoung ageAx
in the at region
diagnosis of 3the
only, (8%)first– primary
Ax+IM, 9contr (25
Conclusion: Visualization of SLN help to optimized extent of radiation fields in 75% of patients with ex
Advanced/Metastatic
Results: 124 patients Breast Cancer (MBC)
were randomized is considered
between February an2004
incurable disease.
and March 2006:First
62line chemotherapy
in group A and 62
Conclusions: TheDespite
safetytheprofile
higherofincidence
fulvestrant of neutropenia
HD is comparable in thewith triplethat
association regimen,
of fulvestrant AD andthe anastro
higher
The ongoing
Results: In thephase
controlIII study
groupCONFIRM
(N = 203), will provide
only 45% of further
patients clarification
achievedof85% the or
role of fulvestrant
more of plannedHD RDI,in w p
Conclusions: Secondary prophylaxis with G-CSF is necessary to
Results: We found 21 different polymorphisms of BRCA1 and 36 of BRCA2 gene as normal variants inguarantee the quality of chemotherap
Conclusions: First screening
Results: At median follow upwas performed
of 26.5 monthson elderly women
(3.7–99.6) from the with no of
start personal
T, 42 pts or were
familial history for
evaluable of cO
Conclusions:
Results: In this limited
The median follow-up series
afterof radiotherapy
pts, a worse OS waswas248observed
days (range, in HER2+35–456).MBCThe with HER3+
clinical status
stage dis
Conclusion:
3. Drop in 3D-CRT
CRP andfor APBIatis8feasible
VEGF weeks more for Japanese
than 50% breast
was a cancer patients in short follow up. Addition
good marker
Results: Overall, 8 patients developed severe acute toxicity. We foundisaasignificant
4. Cisplatinum weekly with metronomic Endoxan and methotrexate excellent association
combinationwith for tr v
Conclusions: Our results suggest that XRCC3 (Thr241Met) is associated
Results: Out of 394 pathologically evaluated patients, 387 were benign and 7 were malignant cases. M with increased risk of acute sk
Conclusion:
Results: UsingMalignant
both PCa breast
and BCa masses
cellsin we adolescent
have first Indian
identified population are rare (1.7%).
SphK1-dependent In our set of pop
and -independent com
Conclusions: This work points out to potential ways of increasing the effectiveness of chemotherapy fo
Abstract: Approximately
Results: According to their 10% of all SP-D
median breast andcancers
CRP serumappeared levels, in women
patientsunder were 39 years. Improved
categorized into three trea g
Conclusions: Increased levels of SP-D and CRP prior to radiotherapy,
Results: Median survival of the patients who had surgery of their primary tumor was significantly long in the patients of the third group
Conclusion:
Local Removal
recurrence was of the primary
detected in one tumor
patient in patients
after breastwithconservation.
primary distant One metastatic
patient had disease
axillarywas ass
recur
Conclusions: Paget's disease is frequently associated with peripheral
Results: 7-years disease free survival (DFS) and overall survival (OS) for all patients were 0.86% (0.82 or multicentric cancer. Mastecto
Conclusion:
Median durationThe prognosis
of survivaloffrom patients treated between
first recurrence was 5.8 1999–2002
months. Median compared with 1995–1998
duration of follow upappeare
was 24
Conclusion:
Results: MinorPatients with brain metastases
early postoperative complications are premenopausal
(reddening of the andskin
havewound;large tumor
seroma) size,
didmore node
not prolon
Conclusions:
Women The germline
carrying combination of SNB,inWLE
mutations BRCA1 andor IORTBRCA2is a are
safestrongly
surgicalpredisposed
procedure leading both to basa
to developing brea
BRCA1-deficient mouse mammary tumors become resistant to all
Forty-four patients (65.2%) reported that taste and smell changes were the most severe during chem drugs tested, with one exception: p
Conclusions: Much more
Outcome variables: research israte
(1) Compliance needed to understand
(% number of subjectsthe nature, frequency, severity
being ‘compliant’) and duratio
for the adjuvant AI
Results: Study accrual has been completed on March 2009; preliminary results after one-year follow-u
The first Two
Results: generation molecular
main themes were profiling
identified:studies of breast
patient centered cancerroles have at most analysed
en organisation centered few roles.
hundreds In th
Conclusions: In Belgium, the role of a BCN is not informed or implemented
There was no significant difference in the overall survival after surgery between two groups (p = 0.19 by evidence-based guidelin
Conclusion: Our study
Results: Variation of ershowed that, in aprimary
status between matched and case-control
metastaticstudy, breastIMPC cancer group
waswas associated
determined with
in 12 of
Conclusions:
Results: Bcl-2,c E-cadherin,
erb b2 status andis important
p53 expression in thein management
tumor tissueofspecimens metastaticwere breastfoundcancer.
26.31%,the biologic
35.52%
Conclusions:
Results: The 5Theyearresults of this
survival rates study
were showed
found to thatbeE-cadherin,
94.6% and bcl-2, 26.2%and p53 did with
in patients not have
stageany I andsignific
IV d
Conclusions: The progesteron receptor status has a greater effect
Results: In the Tc-99m-MIBI group 23 patients had lymph nodes on scintigraphy images. Sentinel node than estrogen receptor on the first
Conclusion: We conclude
Results: Overall toxicity grade that 99mTc-MIBI
3–4 was observed is a suitable
in 20%radiopharmaceutical
of patients. There were for sentinel
more TYMS node3R/3R
detectiocar
Conclusions:
Results: FromOur preliminary
October 2006 to results
November show 2008,
that polymorphisms
4924 patients were in TYMS and GSTP1
enrolled. may serve
Demographic dataas and
usefu b
Conclusions: As of today, PACT is the largest prospective investigation
The only statistically-significant prognostic parameters for OS on CPHM were tumor size (p < 0.001), l on compliance with aromatase
Conclusions:
Results: RelapseThisoccurred
retrospective,in 36.6% single-institution
of pts (20.5% experience
distant metastases validates: and a) 16.1%
the prognostic importance
local recurrence onlyo
Conclusions:
Results: In theInentire
women below
group of the agethe
53 pts of 35 years,
5-year and the increase
10-year OSof wasage seems
60.4% to 43.4%
and elevaterespectively.
the risk of dis T
Conclusions:
Results: Tumor In size,
our study
gradeSP ptsestrogen
and had a worse outcome
receptors (ER)compared to SN in terms
were time-dependent of both DFS
prognostic and for
factors OS.br A
Conclusions: Tumor stage and grade are time-dependent unfavorable
Results: Up to now, 8 patients with an average age of 67 years (range 58–72) have been included. Th prognostic factors, being signifi
Conclusions:
Results: ThroughIn vivo ultrasound-guided
visual inspection of the radiofrequency
dose distribution ablation
for allcan CT result
slices,in complete
dose cell death
distribution in theinPTV inv
Conclusions:
Results: A treatment
Decitabine did not technique
alter responseutilizing to two non-coplanar
docetaxel in eitherwedgedcell linebeams offers aglobal
even though bettermethylat
solution
Conclusions:
Results: MedianDecitabine
number altersof cyclesthe permethylation
patient was machinery
9 (rangein4–12); both docetaxel-resistant
median relative dose-intensitycell lines, but was re
Conclusions: The tested schedule appeared to be highly active and
Results: 113 cases were identified as triple negative breast cancers with “basal-like phenotype”. Theswell tolerated as first-line treatme
Conclusions: Triple negative
Results: The results breast cancers
are summarized in tablewith 1. “basal-like phenotype” are often presented as poorly
Table 1: 95
Results: Differences
pts enrolled between
from Apr the 07basal– Aprand 08.non-basal
39/95 (41%) subtypes
withdrew of triple
duenegative breast carcinomas
to PTL toxicities (incl. 3 asym o
Conclusions:
Results: Of theFluctuations
25 responders, in TnI24 and CRP oncologists
(96%) are common in pts
said they withusenormal LVEF receiving
Adjuvantonline ddAC-PTL
in clinical practice and a
Conclusions: There is great variability in the use of Adjuvantonline.
Results: Twenty patients with an average age of 66 years (range 51–78) were included in this study. T Currently, there is no consensus o
Conclusions: Ultrasound-guided radiofrequency ablation can result in complete cell death in small inva
Results: The median follow up time was 47.5 months (range, 24–72 months).116 patients were classif
Conclusion:
Results: EightTriple-negative
RCTs were found: breast cancer
6 were is an aggressive
carried disease patients,
out in mastectomy with relatively poor survival.
1 in patients We fo
undergoing
Conclusion: The use of LA in patients undergoing breast cancer surgery can reduce
On definitive pathological examination, invasive growth was found in 10 patients (23%) (Table 1). Sen pain in the early p
Conclusion: In patients with an initial diagnosis of DCIS on core-needle biopsy, SNLB should be perform
Cancer angiogenesis
Results: Systematic SU development
errors were mediatet
1.9 mm in thru vascular endothelial
anterior-posterior growth
(AP), 2.0 mm factor
in Lat (VEGF)
and 2.3hasmmimpor
in CC
Conclusions:
Results: Analysing
Between Marchmatch
2005 and results, our 2007,
August centre63 specific
pts in SU
16 accuracy
sites werefor breast cancer
enrolled. 60 pts treatment is c
are evaluable
Conclusions: These data in pts with primary breast cancer
Analysis of the data shows a similar receptor profile in both white and asianwho are treated by (neo)adjuvant ChT do n
subgroups.
which has an essential role in BRCA2-mediated DNA double-strand break
repair.
Results from the survey will be used for planning future activities and
planning
the of the population
community screeninga program.
and would promote better quality of living among women
in India.
Conclusion: The data obtained show a possible relationship between
cadmium andfirst
Tbilisi for the breast cancer.
time; Breast cancer appears to be the primary cause of
early contaminated
from female mortality territories require specific treatment what differs from
standard
policy protocols
makers or they providers,
and service do not. Situation
in orderrequires further
to predict investigation.
the impact this
could have for cancer service provision in the future.
require at least enhanced level resources likely not routinely available in
these settings.
the benefit of AI therapy in reducing BC recurrences, particularly DM, as
wellonly
the as the
onehigh costs associated
involving the managing
a non-chemotherapy arm.these recurrences.
So far, there are no safety
concerns. First safety data from the entire population
alone but a full MGA should guide in the decision of proposing will be presented.
screening
mammography to elderly women.
a high-risk population in each geographic area other parameters should be
considered.
are needed to define the role of endocrine receptors, given the low
representation
practices of ER-negative
of mamographic tumorscan
screening, in elderly
justify pts.
this fact.We have observed that conservative surgery
meanwhile
cyclofosfamide is a feasible and well tolerated optionwomen.
radical surgery is more frequent in elder for elderly breast
cancer pts. Un update will be provided.
ADJ should never substitute for full MGA in order to prevent specific organtoxicities
of CT
on elderly breast cancer pts. First QoL results will be presented at the
meeting.
and that there appears to be an association between the use of taxane
chemotherapy, aromatase inhibitors or tamoxifen and pain.
 ion that lobular cancers DISCLOSURES
are detected by the blood based gene expression test with implication that lobular and
ecting a form of cancer
ssion percentages were 53.5±32, which is difficult
41.8±33,to detect with normal
25.0±26.9 mammographic
and 31.6±28.3 procedures.
respectively. When theseAdditional results cases
were ofco
l
pressions
eved for 13 were not found
studies to influence
evaluating diseaseuse
the adjuvant free
of and overall survivals.
bisphosphonates compared with no use. Pooled results show
eeated
do notatsupport
MTD had the hypothesis
partial responses that after
use ofa bisphosphonates
median of 11 doses in adjuvant
T-DM1. This treatment
compares of early
with breast cancer former
the following is like
with
T-B previously-treated,
score) and for TOI-B (trial HER2+ MBC and
outcome is well
index; tolerated
including at theand
physical MTD, with minimal
functional well-beingaccumulation after multiple
generic elements and
on with taxanes as first-line treatment for mBC experienced significantly
le of providing standards against which new methods should be assessed and allow critical reflection by both c better QoL changes at most timepoints
validated
ients with in patientsfollow
a median at riskup forofbreast cancer
3.7 years andand in a population
median survival of screening
1.9 years setting.
(median survival 1.3, 1.7, 2.2 and 2
ce44;ofB,
improvement
47; C, 48). Baseline in prognosis of MBC patients
characteristics were as within the(A/B/C):
follows last 15 years,
mediantaking into account
age (55/56/52 all important
years), visceral diseassigni
higher
2004-March disease control
2007. Mean rate than
age sequential
= 62.7 years; schedule in this population
ductal histology = 71%; tumour of pts.grade
The first1+2line all-oral
= 88%; combination
endocrine therap o
east RT appears as safe in terms of adverse effects (assessed clinically
sting of 689 probes that predict cancer patients from controls with an accuracy of 81% (±7%). Functional enrich and by photograph) as a standard 25-fra
scriptome
ort of breast
was initiated. cancer patients
PK analysis did not showcarries anybiological
drug-drug relevant information
interaction with this about breastoftumor
schedule growth. The
administration. gen
Overa
mg/m2 D1 + C at 1000 mg/m2 twice a D (D1–14), q3w is the RD. Final results for efficacy and safety will be pres
complications
whether PI3K pathway in advanced activationcancer, resulting
is able in bone
to predict destruction
Trastuzumab and skeletal-related
resistance in the clinic.events (SRE).ofThe
In a cohort 55 osteocl
patient
al importance of PI3K signalling in risk for progression after Trastuzumab-based
ubicin in MCF-7 breast cancer MTS transfected with E gene enhanced the chemotherapeutic effect of this drug. therapy, which in turn suggests
TS isand
owth ablepotentiates
to increasethe theantitumor
chemotherapeutic effect of drugs
effect of trastuzumab, andcomplete
with speciallysuppression
is able to enhance of tumor the anticancer
growth, potent effe
e
dplus trastuzumab
significantly lower insymptoms
different trastuzumab-resistant
(composite score of allbreast cancers,
symptoms). duespecifically,
More to both, IMOthe direct
had antitumor
lower oraland anti
mucosit
men-focused
city and efficacy. home care
In the programme
intention wasanalysis
to treat able to better
there was assistnopatients
significantin managing
differencetreatment-related
in the incidence oftoxicities serious
stant to anthracyclines received elliptinium acetate. Median age at diagnosis was 51 years (range 29–78),induce
er results in a significantly higher pCR rate than ED. EDC is a feasible and safe regimen but capecitabine ER w
oplastic
of agent that
a homogenous provedpopulation
cellular significantpresenting
efficacy in high metastatic
CD44 and breast cancer
hardly resistant
detectable to anthracyclines,
CD24 immunoreactivity, and accep
a gen
esearchpredictors
howed and cancer of therapy
pain were comes
taxane of age – here we present
chemotherapy (p = 0.03 a convenient
odds ratio 6.01; protocol to easily prepare
CI 1.21–29.90), aromatase the require
inhib
have been treated for breast cancer may experience significant problems
more than three times during the course of disease, 248 during neoadjuvant/adjuvant chemotherapy, 249 durin due to JAPaMS and that there appear
rovides
be donean ininvaluable
522 out of tool 540for LV prompt
segments. gauging
The meanof systemic
dose totherapy
the LV in left-
earlyand stage solid tumours
right-sided patients as awas toolrespectiv
for ther
lated regional
gnificantly impact decrease
both the in myocardial
physiologic function early after
health-including RT. fertility, premature menopause, and bone health
future
mportant
ly to remove to increase the accrual of
the contaminations young women
(unclear genotypes) withbutearly alsoBCdivide
in clinical
into trials
three focused
regions of on AA,
thisAB important
and BB (arounpatien
h genes involve in breast cancer and studying in two directions helps
observed in three patients; 40.2% developed brain metastases on second-line T or during follow-up after a medi in finding a statistically reliable statement
considerable
whom 274 pts had activity.
receivedNonePLD of the variables
after investigated
prior exposure correlated with
to conventional activity of second-line
anthracyclines. At the time therapy. In orde
of PLD therapy,
nificant
-to-treatCB from anthracycline
population, 53% had breast rechallengecancer using
and PLD47%in pretreated
other cancer MBC.typesThe CBR was
(primarily independent
colorectal, lung,of orresistanc
ovarian)
been
ollow-upshown of 6.3to extend to non-breast
years. Median age was cancer
58 yearspatients
(IQR receiving
24–90). Median non-ACtumourbased MEC,size was including
20 mmthose (IQR receiving
15–30 mm). oxa
ent breast tissues. In invasive breast cancer Src kinase is highest
tween tumour size and the occurrence of regional lymph node metastases was observed: primary tumours ≤1 expressed and seems to have a negative impa
tases
e was 16.10 (N0(i+) and Nmi)
μmol/g with increasing
creatinine (95% CI =tumour size suggests
(14.92–17.27) for cancerthat patients
metastasizingand 14.28is a constant process in(95%
μmol/g creatinine the couCI
nntrols
biosynthesis
were included,in breast cancerage
median patients is affected
was 46.4±9, ER andmorePRthan in benign
positive were tumour
46.5% and patients.
24.6%The mean concentratio
respectively, h2N-OE
andrandomised:
ere Ile655Val polymorphism 184 to receive might havefilgrastim
Hospira more cardiac and 95 toxicity.
to receiveThe Neupogen.
presence ofOne Val allele
pt from maythebe can cause
Hospira mo
filgrast
eupogen for alldid
phosphonates parameters
not reducetested. These rate
the fracture included
comparedshort DSN and low
to placebo orrates
no use of either
FN in pts receiving
in intent cytotoxic
to treat analysis che(
evidence
before that bisphosphonates
starting treatment, whilein 42the
ptsadjuvant setting among
(39%) developed BM duringwomen with breasttherapy,
trastuzumab cancer do for not decrease
an overall the
inciden
mmon event
etastasis hadin triple
patients with HER2-overexpressed
negative breast cancer, compared MBC treated with trastuzumab,
to 104 (16.48%) of the 631even controlif survival
patients after
(p =diagnosis
0.047).
ncer are at a high risk of developing brain metastasis and have a poor
ath. Eighteen of the 32 HER2 pos patients were diagnosed with cerebral metastases (0.56), compared to 12 pat survival. There may be case for screening
ssionthe
een increases
two groups, the risk of cerebral
especially metastases
for SBR. All women significantly
received RT. as compared
No difference to patients
was found without
betweenHER2irradiated
over-expres lym
udy failed to demonstrate improvements in breast-conserving surgery, DFS and OS rates with NAC compared w
garding
ant thanbiological
quantity of markers of primary
life, certainly BC: negative
for older individuals. steroid receptors,
Preference HER2given
is often over-expression,
to chemotherapeutic and tripleagents negative w
cizumab have been shown to be useful in the treatment of breast cancer.
me has been implemented in the majority of municipal districts in Yugra. Compared with a similar program in Mo The risk of side effects increases with
nsufficient
an and median detailed ageinformation
reported were has 56.5
beenand collected on the breast
55 respectively. For cancers
the studies detected within the
that reported age BCSP, in particular
in categories, 65
in only a minority
mammography, 59ofattrials. Also most ofand
ultrasonography these61 trials
at MRI. were led, developed
Thirty-five and conducted
(57%) tumors were limited in the western
breast world.Sig
cancers. T
nd MRI-visible
tients lesions decreases
were randomized (217 to Pwith andabsence
214 to C). of washout kinetics at MRI,
Patient characteristics but well
were increases
balanced withbetween
Her2-positive groups. tumoMe
ard treatment was noted in this study. But surprisingly we observed
the level of TP activity was reduced at mastopathy. Upon T1N0M0 the activity is TP is lower than normal (like mlower rates of nausea and vomiting measur
nt during mastopathy and breast cancer may be one of the endogenous factors of malignancy. The biochemical
 y has been expanded through “the hierarchy model” which predicts that cancers contain a minority population
of
uce a stem cell hierarchy
epithelial in the normal
to mesenchymal breast
transition andwas
(EMT), in breast cancer.in tumour compared to normal stromal cells, w
upregulated
al to stimulate angiogenesis and epithelial to mesenchymal
chest x-ray. Mean age was 61 years (range34–91). 53% of patients transition
werethrough
belowsecretion
60 years of of paracrine
age. Average factors
sizesuc
of
diation in performing routine chest x-ray for all operable breast cancer patients, it
the majority of the studies is small and methodological insufficient. Lately some harder evidence has appeared can also produce false positiv
but many women
e-positive do get cured.
(or node-negative withOntumour
the basis of the present
diameter ≥1 cm), knowledge women believed to
hormone receptor-negative, be cured fromEBC
HER2-negative breas
re
e been
ent data randomised.
was analyzed. Baseline
CTCs atcharacteristics
two years were are shown below.
detected in 6.8%There
of ptshave been only(n
on tamoxifen 7 serious adverse
= 9), while 1.9%events
of pts w
sisting circulating tumor cells in a relevant number of recurrence-free breast cancer patients
the differences were not statistically significant (p = 0.09, adjusting for stratification factors). The distributions after cytostatic, en
n-RB,
withVe-CAD
weekly andP is feasible with
circulating no unexpected
endothelial toxicities. This
cells, measured at PDregimen is efficaciouswith
after bevacizumab, in the
TTPtreatment of pts with
and OS: patients wi
to(range
rs bevacizumab
24–84).are not well
Median defined
tumour size itwas
is possible
8 mm (rangethat resistance
2–10), 18 to bevacizumab
being ≤5 mm (T1a). results in relative
There was no resistance
significant
aggressivemetastasectomy,
nderwent features including 21% node invasion, high
stereotactic grade or
irradiation, LVI, irrespective
in combination withofWBRT
T1a or T1borsubclassification.
15% alone 6%. Median Thetim
gher risk of BM. Major cause of death was brain metastases, therefore further
red from synchronous and 49% (24 pts) from metachronous BBC. Median age at diagnosis was 59.6 in SBBC gro studies are needed for early BM p
e
al,frequent
20 (30.3%) in postmenopausal
were HER2+, and women, presented
26 (39.4%) were more often
TN. Time in stage
interval IV as
from hormon
initial receptor
diagnosis positive
to distant tumors wit
metastases
kely to
dian agedevelop distantwas
at diagnosis metastasis
49 years.earlier,
Duringand poor overall
diagnosis, threesurvival.
patients Triple receptor
had stage status
I, forty one may be used
patients had as a pro
stage II
om
ons other
from thebreast
same cancers,
patientsuch that recurrences
displayed remarkablyfree and patterns
similar overall survivals
of genetic of aberrations
the patients(Spearman's
are shorter than non-T
correlation
6 with 1–3 positive LN (PN1) and 173 with 4–9 positive LN (PN2). Among them, 212 (41%) had the 70-gene gooda
ial evidence to suggest that CCLs are the earliest morphologically identifiable non-obligate precursors of more
wasis adeveloped
strong prognostic marker
for individual geneof distant
set from recurrence
the training and breast
set and aspecific
PI as riskdeath in breast
indicator cancer
for each patients
patient withset
in test pos w
quantify
1±20.7* the potential contribution of a predefined gene set for breast cancer risk prediction and multiple gene
ast cancer tissues analysed (Mean ±SEM, 1.17±0.06 log10 RQ). There was a significant positive correlation betw
further
n, median understand the presence,
age 51 y (range: 21–87),regulation
99.1% ECOG and 0–1,
relevance
34.8%of NIS expression
stage in breast
III-IV]. At least tumour
4 CT cycles tissue
were completed by
er pts tumor
helial at highcells
or intermediate
and by stromal FN and
risk endothelial
developed grade cells. 3–4 CT-induced
Microarray geneneutropenia. Primaryand
expression analysis prophylaxis with G
immunohistoch
nostic marker.
xamined, We propose
with median age at that saturation
diagnosis of the (53–79
65 years receptor through
years old).autocrine
The initialCXCL12 production
presentation was areduces
palpablechemolump
st
n-study SRE compared with ZA (hazard ratio [HR] 0.82; 95% CI: 0.71, 0.95; P = 0.01) in this 34-month study.diff
cancer cases were all HER-2 negative. All tumours were ductal invasive carcinomas and 47% were poorly Th
enting SREs. The incidence of AEs and serious AEs was consistent with what has been previously reported for th
dr cell detectioninin55.2%
be detected sentinel
andlymph
57.6%nodes and bone
of patients pre-marrow from breast
chemotherapy, cancer patients
respectively. is debatable. In
Post-chemotherapy, a large
CTCs andcD
orrelation
3 years old). between the presence
All patients wore AA oforCTCs
A cupand sizeDTCs
braevaluated
and meanby RT-PCR
body massfor CK-19
index mRNA
(BMI) wasin23.6.
patients with earlyfie
The radiation b
lanning can reduce the radiation field size on each directions for early breast
rs did not perform significantly worse than healthy women on any cognitive domain. Tamoxifen users performed cancer patient. Also, it shows less
has a negative
/PR-/Her2-, effect
21 pts on certain cognitive
ER+/PR+/Her2-). 22 ptsfunctions
with other in receptor
postmenopausal
phenotypes BC patients, while exemestane
were excluded, 12 were unable doesto not
un
alfor
content
10 years of tumours
with the displaying
disease, atthe an triple
actualnegative
KPI: 93%. phenotype
Survival was cananalyzed
be depicted usingreliably by the DCE-MRI
Cox proportional hazardparamet
regre
ent
ors prognostic
urine (n = 250)factorare
for6.0–10.0
the survival of breast
mkg/mmol. and colon
During carcinoma
the period patients. Further
of observation 90 (21.9%) prospective
of cancer studies
patientsarewerreq
= 131) of patients receiving X monotherapy (to ∼941 mg/m2) and 65% (n = 163) of patients receiving XT (80%m
ced GPT activity, lowered N-glycoprotein synthesis and elevated urinary Dol detected in this group of patients
an be reduced,
sitive lavage and either
theywhen used as treatment
had surgical monotherapy as itorwas
in combination
planned. One with T,marked
with without atypia
compromising
had openefficacy
biopsy in forter
a
nt ofundergone
had cells from athe final examination.
breast duct-lobe unitThe canmeanhelp inage the ofearly diagnosis
the subjects in of breast
whom cancer
a mass had expecially in patients
been detected was 39wi
ion ofresponse
gical elderly subjects, subjects
and 2 patients hadliving in rural
residual areas
ductal and subjects
carcinoma with
in situ. 25low educational
(78%) patients as had well as lower
residual socio-eco
invasive ma
negative to HER2 positive lead to change in adjuvant treatment who would have
56 pts. 1252 pts (49%) received at least one course of G-CSF. 338 pts (13%) exceeded the threshold for CA27.2 otherwise not received transzu
nificant correlation
ase, no prior between
cytotoxic an increase
treatment for MBC, in ECOG
the number
PS 0–1,ofHER2-negative
CTC and the application
disease, no ofCNSG-CSF overThe
mets. CHT. 1° Neverthe
endpoint
were enrolled.
atients showed Addition of B +
that BSI-201 improved
G/C hadPFS (Cap: pl
improved 5.7 median
CBR, mo, B 8.6 mo,
PFS, andp= 0.0002;
median T+Ant:
OS, comparedpl 8.0with
mo, G/CB 9.2 mo, p
alone.
es that BSI-201 + G/C significantly improves CBR, PFS, and OS, compared with
data were similar between the groups. Evolution of QoL and SCN measures over time did not differ significantly G/C alone. BSI-201 + G/C was we
nsthe efficacy
found of specialist
between carehormone
circulating including specialised
levels and all nurses
tested for newly were
variables diagnosed patients
an inverse onewith breastestradiol
between and gynaec and
Ovels have been
guidelines andrepeatedly correlated
American Society with anOncology
of Clinical elevated incidence of breast
CTIBL guidelines cancer,
relied it appears
on bone mineral that in postmenop
density (BMD) a
alone is
ataset not sufficient
showed to evaluate
similar findings, patient fracture
confirming the poorrisk and direct
prognosis treatment
of very young decisions.
breast cancer Although BMD cutoff poin
patients.
dings
s occurred during the last four cycles of each regimen. Grade 3 neutropenia was more frequentlyisobserved
of many epidemiological and clinical trials that the relationship between age and mortality biphasic.duriCom
eded bs-HER2
a high rateandofnumber
pCR in ER-negative
of M sites (p tumors.
< 0.05),Regimen
as well asA between
was the only
highone ECDmeeting
levels and thevisceral/nodal
threshold to move diseaseto sta
(p
dHER2
to userslevels
who might
gavebe used
their as a “real-time”
permission. 249 users non(40%)
invasive marker,within
answered allowing repeated
2 weeks, most evaluations
of them inof HER2
only 1 tostatus
3 da
edservice
(9 stillisongoing):
highly appreciated
6 pts in the byEusers,
5 mg/d particularly
cohort, 17in interms
the 10ofmg/d,
shortand time10toinresponse
the 30 mg/w.and contents. To monitorw
Pts characteristics
acceptable safety profile and confirms high promising anticancer activity.
“57B” and “B9.8.1” (Juretic A et al. The Lancet Oncol 2003) were used to immunohistochemically determine The phase I part of the study is comp the
the aforementioned C/T antigens may be used in MBC as tumor markers of potential prognostic relevance. Due
ers according to estrogen receptor and HER2 status, we did not find any statistically significant differences. We
2A1 and iodine transporter
ms, discovered by themselves SLC5A5 in breast
or their cancer
partner. are independent,
Twenty-two percent of thus, the combined
the symptomatic use ofdelayed
women both markers
presen
ical
Provider delay was 1 month or less for 38% of women, between 1 and 3 months for 46% and over 3 months foe
and socio-demographic characteristics and living area have an influence on delay to presentation. Health
ed
andcancers and cancers
permanent section –detected
slides ofin473
large towns or consisting
SNB-cases, in rural areas are
of 73 treated
ITC cases more
and ofquickly than self detected
400 SNB-negative cases a,ona
epresenting macrophages
cost of MammaPrint with keratin
was offset deposit material
by the savings, due to a or dendritic
lower numbercells. No benign epithelial
of administered cells, foreign
chemotherapies. Themat
mo
xpression
23%) profiling test that has proved to be more accurate than current risk assessment tools. It helps oncolog
4 (18%)
yented
1 onlyaor by day
cT1-T2 11 if CT
tumour. given was
CA15.3 on Day 1+8.
within †Stage
normal IV (breast
range cancer),
(<30 IU/ml) in IIIb-IV (NSCLC)
114 patients or extensive
(86%). disease (SC
Blood concentratio
CXCL9 with
sistent dosage in serumvariation
substantial could screen a significant
in inherited rate of breast
susceptibility. cancer,
Over the pastincluding
25 years,ER-negative
the underlyingbreast cancer.
genetic basisT
es
42have
yearsidentified thirteen
(range, 26–50 genetic
yrs). 69% ofloci with common
patients were ER+, susceptibility
while 31%alleles. These loci
were estrogen includenegative
receptor several plausible
(ER-). Tota c
onsites
eb of a Gn-RH analoguetoimproves
were searched lymphocyte number,
identify representative trials ofdecreases T-regs advances
3 key adjuvant and VEGF,inand seems
breast to improve
cancer: taxanes, thetr
py were presented in 1998 and 2000, but adjuvant taxanes were not readily adopted
east cancer were selected from the Eindhoven Cancer Registry from 1998 to 2006 and linked to the PHARMO Neinto guidelines. In contras
stor
started on tamoxifen.
was associated with Of those,
a high 26% had of
probability a treatment switch to:
CpR achievement anastrozole
suggesting (n = 203),
2 different exemestane
entities (n =
within the all113)
HER
y correlated with copy number (Pearson's correlation = 0.55, p = 0.0001) and this gene is overexpressed when
d predictor of BC and its overexpression could represent a novel molecular mechanism by which a subset of BC
h exposure to HMPS decreased significantly, and both ER-positive and ER-negative breast cancer cells respond
tion inhibitory effect of HMPS is about 50-fold more potent than those of rhapontigenin and furthermore HMPS
he group treated with hypofractionation with a mean of follow up of 435 days and in 10 patients (15%) in the gr
ctionated
009, schedule
34 patients withdelivering
T1–2N0M0 45breast
Gy in 20 fractions
cancer were offered
randomised a significant
into tworeduction
groups. Group of skinAacute toxicity
(n = 17) received(p = sta
0.0
crease in the incidence
ere recruited in 172 German of radiation-induced
centers; 703 pts pneumonitis
received X+I, for 706
the patients of group-B
pts received I only. (hypofractionated
The median age was RT 71regim
ye
eires
elderly
werepopulation
successfully and the only
inserted one
into SLNinvolving a non-chemotherapy
of 61 patients. In 36 patients,arm. SLNSo far,visualised
were there are as no areas
safetyof concerns.
contrast F
N
ong mayBCbe readily identified
survivors receiving and localised
RT. To exploreinwhether
the pre-operative period. Ultrasonic
biological processes underlying Identification
persistent of SLN would
fatigue enab
can affect
ariants and gene expression profiles that predict long term adverse side effects
detected in 41 (45.5%) of breast cancer smears, bcl2 in 36 (40%) and positive nuclear expression of P53 in 52 of RT in BC patients that will she
echanisms plays an important role in the pathogenesis, progression of breast cancer and in responses of tumors
02
enign conditions and elevated in both invasive and in situ carcinoma. There was a positive correlation between
mour gradeAIs
as limited. areor associated
TAM appear withtoaaffect
bettercognitive
prognosis for breast
function when cancer
women patients,
with BC then
aremammaglobin
compared withAhealthyprotein contexpr
in the tumor was 20.6% and HER2 overexpression was 26.4%. Our results suggest that patients with tumorsTo
some aspects of cognition. The effect of ANA and EXE compared with TAM is less clear and not conclusive. thad
a consistent
months (range; relationship
8–110 months). betweenThep53 protein
5 years localoverexpression,
recurrence-free negative
survivalestrogene receptorwith
(LRFS) in patients status,
closeinadequate
or positiv
close
years,orBMI positive marginkg/m2)
27.2 +/-4.9 by carcinoma in situ
participated inhad
this experienced
study which no wasfailure.
approved And by withtheadjuvant radiotherapy,
local ethics committeeclose and
vels
e studywithperiod
later cycles among
(see Table 1).women who received
Post-menopausal highthe riskhigher dose of Dexamethasone
and pre-menopausal women were in combination with doce
managed according
ne therapy in HR+EBC patients was appropriate in the pre-menopausal
4.4%) while 10 others (37.0%) were early stage inv breast ca (stage1, 2a&2b) (early stage breast ca rateand high risk post menopausal subgrou
was 8
although their breast is denser than the older age group, in nonpalpable lesions
ated with TAM following surgery for early breast cancer by age, identified CT status, and the incidence of DM an the malignity rate was 18.6%, c
quently
erum and undertreated for theirdetection
plasma for greater disease, despite beingquantification
and relative at risk for DM,ofand are good
circulating candidates
miRNAs. Of 7for adjuvant
breast cancer hormo
spe
hat miRNAs are detectable and in the circulation of breast cancer patients, compared
osis till 1.3% and insignificant induction of apoptosis till 0.8% was marked. In the 2 series the quantity of mitosis to controls. The circulating
he experiment
more often withopen quiteadjuvant
systemic new prospects
therapyinthanbreast cancer
those withtreatment.
pN0i-disease (87% vs. 51%; P < 0.0001). There was
isolated
pport tumor
needs, cells in the
particularly sentinel
relating tonodes
skin andis an adverse
hair care, andprognostic
diet, bothfactor
duringin early breast
and after cancer, but
treatment. its prognos
Breast care n
ors need to make
progression in bone services
was 5.4 more inclusive,
months; 34.6% by(nraising
= 9) ofawareness
the patients that breast
didn't havecancer
any affects
record ofallprogression
ethnic groups on and
bon
impact of BP and taxanes combination therapy in metastatic bone disease.
e for metastatic carcinoma to the SLN. Out of these 52 patients, TIC was positive in 28 (54%). Thus 28 patients
itive predictive
ast lesion detectedvalue andof surgically
100%. Patient should
removed be counseled
under about 10%
local or general negative
anesthesia. predictive
Tissue value
specimen where TIC
obtained is ni
using
st surgery allows
bstantially modified detecting of occultof
by the addition early
serumbreast cancermedium.
in culture lesions with high accuracy
A kinetic profile of and TEM8 safety
expression revealed
cellular
ere 150mechanisms
documentedthat casesfoster both118
of IBTR: leukocytes-dependent
(79%) were definiteinflammatory
or likely LR; 27 angiogenesis
(18%) wereand tumor
definite orcell migratio
likely NP; an
classifying IBTR as LR or NP on clinical
male breast lesions in the recent literature. criteria, the absolute numbers of each event type appear to suggest that
many
was 1.00 unsatisfactory
(±0.01, p =cases. 0.83).However,
Results were due similar
to the goodwhencytohistologic
BRCA1 and BRCA2 correlations
mutation andcarriers
favourable
werestatistic
analyzed figures
sepa
sityinis18/32
els not associated
(56%) ptswith withhigher breastdisease;
measurable cancer incidence
2/10 pts with in women with BRCA disease
non-measurable mutations. hadTherefore, breast den
complete response.
ne were
pe MBC regimen
studied for with a manageable
quantifying safety(KDR)
of VEGFR2 profile. The RP2Drevealed
expression is 30 mg/m2 of ixabepilone and 75 mg/m2
by immunohistochemistry. of epir
Preliminary au
2 (KDR) expression in breast tumor vascular endothelium from PABC patients
data as of 03 April 2006, when enrollment was halted with 399 pts. OS was based on data as of 01 October 200 is higher than in sporadic BC tissu
regimens on L+C had a 63% reduction in the risk of progression and a 49% reduction in the risk of death. Pts w
 breast cancer had titanium clips placed in excision cavity walls at breast conservation surgery. Each underwen
upine
women tangential-field
with T1–3, N0–1,WBIM0 areBC
significant.
diagnosedProne positioning
at University is likely hospitals
of Toronto to improve LAD dosimetry
between 1989–1996 onlywas
in women
followed wi
racteristics were as follows: T1 = 287, T2 = 158, T3/TX = 59; N0 = 352, N1 = 152;
ge from an epithelial to a more invasive mesenchymal phenotype (a phenomenon described as EMT) may be co ER positive = 337; PgR posit
, GM01/05,
astases GM01/01.
among M0 patients decreased markedly, however survival after metastases did not improve (HR 1.00 v
velopment
stectomy (MRM) of metastases in M0 breast
is the mainstay cancer seems
of locoregional to have
treatment at been increasingly
the basic prevented,
level of breast probably
health care. Thedue to both
availabili
lon for breast
three breastcancer
cancertreatment can improve
cell lines displayed care delivery inofLMCs.
a downregulation The incremental,
proliferation, step-by-step
with the greatest allocation
decrease seen inof th
r
t paracrine effect on breast cancer epithelial cells, which is mediated at least in part by
hylation ESR1and 14–3-3σ in healthy controls and significant differences between breast cancer patients (pts) aVEGF and TGFb-1. Thes
ariations
the basisin ofglobal
CK19, levels of methylation
MG1, and EpCAM waspromoters genes patients
8.6% in 16/187 in healthy controls
with primary and breast
breast cancer24%
cancer, withfor
different
DTC ana p
ETC)
illaryas internal
lymph nodecalibrators
dissectionfor accurate
(ALND) wereprocess control
performed and normalization
in 2,087 of the immunobead
and 1,071 patients respectively. A quantitative
worse metasta RT-P
tic lymph (cut-off≥12%)
xpression node is associated with a higher
and MAPtau risk of distant
underexpression recurrence
(cut-off <30%)as compared
correlate toobjective
with node negative
responsedisease only
to anthr
opoIIa overexpression and MAPtau underexpression are related to response to anthacyclines
ique called the Single Cell array Comparative Genomic Hybridization (SCaCGH) we are finally able to characteri and taxanes, respe
ch funding by
re recruited inthe
35 Communities Sixth Framework
centres. The median age was 65 Programme
years (range as part of the
37–90). 53%international DISMAL collaboration
of pts had hormone receptor-posit f
Xe with an up-to-date
received ≥1 dose of dosage as 1st-line
motesanib. Medianmonotherapy in MBC
age is 51 (range demonstrating
28–66) an excellent
yrs. 5 dose-limiting safety and
toxicities high efficac
(all grade [gr] 3
07appears to be tolerable
and 04/2008. and shows
Five patients neverevidence
received of antitumor
study activity of
drug because in ineligibility.
pts with advanced breastnumber
The median cancer.of Coadmini
cycles w
mour activity based on the Simon optimal design. These data however do not compromise further exploration of
n (n = 1500) of breast cancer pts diagnosed during the period 2004–2007 in Parma Province. Two-hundred and
stry
tivestudy
LR/mBC analyzing CNS metastases in breast
(or trastuzumab-pretreated cancer inLR/mBC),
HER2-positive relation to tumor
ECOG PSbiological
0–2, no prior features,
CT forsystemic
LR/mBC treatmen
and no e
is analysis (March 2009), 2041 pts were treated. Median age was 54 years (range
tive Topo IIA specimen testing. All those that were Topo IIA amplified were also HER2 amplified. Histological 21–93). Most pts (76%) receiv
com
IA tumour testing did not predict for likelihood of complete histological response
esponse was evaluated as per RECIST criteria by monthly clinical examination. More than 50% tumor shrinkage to anthracycline based chemot
ocal therapyLN:13
mediastinal is the patients,
key to success
isolated in pulmonary
breast cancer management.
nodule: 30 patients).In this single patients
Eighteen institute (42%)study neoadjuvant
were confirmed radit
d maximal
ntarium SUV ontoPET
of agents could
fight breasthelp physician
cancer. But towhendifferentiate metastasis from
used as monotherapy withoutbenign lesion in breast
chemotherapy havecancer
led to pati
mo
of the treatment of breast cancer. But there is a need for agents with better
distant metastasis free survival (DMFS), disease free survival (DFS) and overall survival (OS) at 5 years were 92therapeutic index and agents ove
after neoadjuvant chemotherapy followed by surgery, we might dispense radiotherapy to SCN and give only to
ng more
dies, than
with 13,000
1,098 pts) women
identified withtheHER-2
rate ofpositive
ER+ (pearly breastvisceral
= 0.021), cancerinvolvement
to trastuzumab (p =versus non-trastuzumab
0.00013) and prior TAMba (
mized
tientstrials addressing
dropped out for the optimal
various hormonal
reasons. sequential
The overall approach
patient for TAM-pretreated
satisfaction at 12 months was ABC good:
pts, the
meanchoice of bot
of 75.1 w
in patient satisfaction were found between nurse-led telephone f-up and traditional
ere randomised. Baseline characteristics and ranges by country were: mean age: 64 years (SD 9.0); tumour size outpatient clinic f-up. Henc
elines, wide global
c.i. 12–39%), median variations
PFS wasconcerning
7.5 monthslocoregional treatment
(95% c.i. 4.6–8.1 practices
months). Median of early
overall breast
survival cancer aremonths
is 15.9 observed (95%a
B in advanced
esponse breast
rate 87%). cancer1543
Overall, is surprisingly toxic and
patients (47%) only modestly
reported pain, of whom active13% andreported
should not be further
severe pain, 39%investigat
mode
er breast
median agecancer
of 59treatment
(39–83) and remains
a mediana significant clinical problem
PS of 1. Preliminary PK datain about
for LAP 25–60%
from six of patients
patients.areAlthough
summarized breasti
istent
ongoing trial (7 pts on the original protocol and 53 under the amendment [53 pts evaluable for safety andinfor
with data indicating that TAM induces hepatic CYP3A, the primary route of LAP elimination. This key 51 p
DD schedule) + T (wkly or q3w) showed acceptable tolerability and antitumor
2 breast tumor patients undergoing biopsy or operation at NTUH. Initial bulky disease (T3–4) was found in 23 pa activity in HER2+ MBC pts.
emotherapy,
he either in neoadjuvant
results of intraoperative examination setting for locally
of SLNs. In alladvanced disease orUS
three nomograms inexamination
salvage setting for axilla
of the metastatic
was adisepow
kelihood of non-SLN metastases were created at the Institute of Oncology Ljubljana.
years (range 29–59); median tumor size was 4.5 cm (range 3–9) by clinical examination and 4.2 cm by ultrason They differ in the inclusion
gicprimary
factors CTthat's
is very active and
associated well
with tolerated in
intracranial patients with
metastasis LABC,
at initial also producing
diagnosis or during antheinteresting
course of high percentag
disease
data's
nge: of breast
5–80) cancer patients
from hepatic surgery,with brain metastases
the median cancer specific(n: 1570) whoand
survival admitted
median to disease-free
oncology centre between
survival (DFS)199 wa
st LM can characteristics
hological be done safely.ofHerR on primary were
the population tumour could be
classical of arepresenting
neoadjuvantan unfavourable
setting. 23% of the predictive
patients factor for C
achieved
netic variation of serum VEGF levels appears to be the most discriminating
%) patients developed relapse (DR) of the disease (41 and 20 among Groups 1 and 2, respectively), while 301 predictive angiogenic factor. Its ass(
lpatients
(OS andwith DFS)relapse
at 4 years(DR),were
bothluminal
CA 15–3 A and
(99.3%CEAand serum levels
95.8%), were lower
luminal B (95.6% thanandin the subgroup
80.4%), Her2of disease-free
(89.8% and 8
ast expression
tial cancers intoofbiologic
the top subtypes with independent
discriminating genes (ABCB1, prognostic effects and
TOP2A, TOP2B, MKI67 provides
and PSMB7).additional information
We achieved to n
a silen
eosome in
effective the development
fraction sizes yielding of anthracycline
the same radius resistance.
for 50% risk HighofPSMB7
fibrosis expression
as single-dose is an IORT
unfavorable
were d prognostic
= 1.01 Gy wi m
uivalence larger than the 10 mm of tumour bed tissue defined as the target
atients remains investigational. Level I evidence is needed to validate this approach in this age group. volume in the TARGIT trial. Thus hy
arm A, 19 inexclusively
conducted arm B, andin23 older
in armpatients.
C. MedianThe age
survival
is 49advantage
years (range in the DBCGClinical
27–66). 82c trialstagein patients treated
at diagnosis: IIAwith
in 35 a
0ults of the first step Simon's design per treatment arm will be presented at the Meeting.
onwards
erbB2 testing
rategy 4) was theandcheapest
data would and aid improved
most treatment
effective of erbB2-positive
f-up strategy. Mean annual breast
costscancer
per patientin these
werecountries.
€3003 and thi
ational group program is the most cost-effective f-up strategy out of
DFS events were reported. Compared with tamoxifen, exemestane was associated with improved DFS four different f-up strategies for the(hazard
first ye
ane in postmenopausal patients with hormone receptor-positive breast cancer is more effective than tamoxifen
 r age [adjusted relative risk (RR) 1.2 (95% confidence interval (CI) 0.81–1.9) for diagnosis before 50 years comp
nd SLN
ad young ageAx
in the at region
diagnosis of 3the
only, (8%)first– primary
Ax+IM, 9contribute
(25%) – Ax+SSCL, to the risk6 of CBC.–However,
(17%) Ax+IM+ISSCL. the data suggested
After that t
SLN visualizati
extent of radiation fields in 75% of patients with external and 92% – with internal tumour localization
dered an2004
ebruary incurable disease.
and March 2006:First
62line chemotherapy
in group A and 62 in in patients
group B.with The MBCgroups is associated with a median
were well balanced disease
regarding the frst
openia
comparable in thewithtriplethat
association regimen,
of fulvestrant AD andthe anastrozole.
higher response rate recommends
Fulvestrant HD was well it as neoadjuvant
tolerated chemotherapy
and rates of drug-re
urther
f patientsclarification
achievedof85% the or
role of fulvestrant
more of plannedHD RDI, in whereas
postmenopausal patients with
in the intervention grouprecurrent
(N = 204), and metastatic
75.8% achieved breas
necessary to guarantee the quality of chemotherapy dose intensity
RCA1 and 36 of BRCA2 gene as normal variants in 200 BRCA1 and BRCA2 samples of healthy volunteers. We after a neutropenia-associated delay or febral
erly women with no personal or familial history of cancer, in order to identify
9.6) from the start of T, 42 pts were evaluable for OS and incidence of CNS metastases and 40 for response to T benign high frequency variants of B
Saswas
248observed
days (range, in HER2+
35–456).MBCThe with HER3+
clinical status
stage by IHC. Approaches
distribution was as follows: to target
0 in 7 HER2/HER3
patients, 1signaling
in 33, and may
2 inbe w
20.
e0% breast
was a cancer patients in short follow up. Additional follow-up will be needed to assess the long-term feaibility
good marker
e toxicity. We foundisaasignificant
and methotrexate excellent association
combinationwith for triple
variant negative
XRCC3 disease(Thr241Met) from genotype
efficacy asand well as cost.
moist desquamatio
41Met)
ts, 387 were benign and 7 were malignant cases. Mean age of study group was 15.5 yrs with meancritical
is associated with increased risk of acute skin reactions after radiotherapy. More SNPs and age ofSNPs men
t Indian
identified population are rare (1.7%).
SphK1-dependent In our set of population
and -independent components average time to
of docetaxel diagnosis
induced was 10 where
apoptosis, monthsSphK1and majorinhib
of increasing the effectiveness of chemotherapy for prostate and breast cancer by SphK1 inhibition
appeared
erum levels, in women
patientsunder were 39 years. Improved
categorized into three treatment
groups. of breast cancer
Regarding SP-D, in premenopausal
patients of the firstpatients increasedl
group exhibited
r to radiotherapy,
urgery of their primary in thetumor
patients
wasof the third group,
significantly longer indicate
than forthe thepresence
patientsof who an did
inflammatory
not have surgerycondition (31notvs.asso
14
nts withconservation.
breast primary distant One metastatic
patient had disease
axillarywas associated
recurrence withnegative
after a reduction SNB.ofSixthepatients
mortality hadrisk of around
distant 40%.
metastase
ed
erallwith peripheral
survival (OS) foror multicentric
all patients were cancer. Mastectomy
0.86% (0.82–0.89) is theand best
0.92%treatment
(0.90–0.95)option for the majority
respectively. The Coxof patients.
regressi
een 1999–2002 compared with 1995–1998 appeared
as 5.8 months. Median duration of follow up was 24.5 months. 25% (11/44) are alive. worse in spite of more aggressive systemic management.
menopausal
eddening of the andskin
havewound;
large tumor
seroma) size,
didmore node positive,
not prolong and negative
hospitalization. In 14estrogen
patients receptor status.specimen pa
(10%), surgical
RT is a are
RCA2 safestrongly
surgicalpredisposed
procedure leading both to basal-like
to developing breast andbreast axillary lymph which
cancers, nodes frequently
preservation with improved
contain TP53 mutation patie
resistant to all drugs tested, with one exception:
smell changes were the most severe during chemotheraphy administration. platinum-based chemotherapy drugs. Although tumors cannot
erstand
r of subjects the nature, frequency, severity
being ‘compliant’) and duration
for the adjuvant of taste and
AI medication will smell alterations
be analysed at oneandyeartheir significance
based for the
on the subjec
ch 2009; preliminary results after one-year follow-up are expected early 2010 and the study is expected to finis
breast
centered cancerroles have at most analysed
en organisation centered few roles.
hundreds In the of first
samples each. We
role themes have
such asnow completed
assessing the and
physical analysis of 10
psychoso
formed or implemented by evidence-based guidelines and there isn't
urvival after surgery between two groups (p = 0.192). But, the 5-year recurrence free survival after surgery sho a national education program for these sp
dase-control
metastaticstudy, breastIMPC cancer group
waswas associated
determined with
in 12 of LVI,
the ECE,
38 (31%)and highpatientsnuclear
and,grade.
variationAndofIMPC groupwas
pr status showed
shown m
nagement
umor tissueofspecimens
metastaticwere breastfoundcancer.
26.31%,the biological
35.52%, and behaviour
9.21%. of primary
Mean breast
duration of cancer
follow-up can vary
was in its metasta
93.58±3.40 mo
E-cadherin,
94.6% and bcl-2, 26.2%and p53 did with
in patients not have
stageany I andsignificant
IV disease prognostic
respectively. valueThe for higher
our patients.
TNM stage We needof thestudies
disease, which
ag
alymph
greater effect than estrogen receptor on the first recurrence patterns and
nodes on scintigraphy images. Sentinel node was detected at surgery in all 23. In the Tc-99m-antimony s systemic metastases sites of patien
able radiopharmaceutical
20% of patients. There were for sentinel
more TYMS node3R/3R
detection.
carriers among cases with overall toxicity grade higher than 2 i
ymorphisms
24 patients were in TYMS and GSTP1
enrolled. may serve
Demographic dataas and
useful predictors
baseline of toxicity and
characteristics efficacy
including of chemotherapy
median age, diseaseinparam brea
ective investigation on compliance with aromatase inhibitor therapy.
ters for OS on CPHM were tumor size (p < 0.001), lymph-node-status (p < 0.001), location (p < 0.001), and gra It will provide valuable insights into the re
xperience
istant metastasesvalidates: anda) 16.1%
the prognostic importance
local recurrence only). of 5-year
classic recurrence-free
clinicopathological parameters
survival was 57.2%, including
with the stats o
estimated
the increase
d 10-year OSof wasage seems
60.4% to 43.4%
and elevaterespectively.
the risk of disease The 5-year relapse.andThis10-yearfinding,
OS in contradictory
the S negative to the
(SN)generally
pts was 75% obs
me
(ER)compared to SN in terms
were time-dependent of both DFS
prognostic and for
factors OS.breastAmongcancer the prognostic
relapse. Tumor variablessizeevaluated
>2 vs. ≤2only cm p53 enhances
(HR 1.59; 95%
ndent unfavorable prognostic factors, being significant only in the first
of 67 years (range 58–72) have been included. The mean tumor size was 14 mm (range 8–24). Histopathologic 5 years after surgery. Positive ER chang
ncy
ibutionablation
for allcanCT result
slices,in complete
dose cell death
distribution in theinPTV invasive breast identical
was almost cancer. To foravoid
both skin
plans; burns the distance
the 90% of thed
of prescribed
on-coplanar
axel in eitherwedged cell linebeams offers aglobal
even though bettermethylation,
solution compared DNMT enzymeto standard coplanar
activity and DNMTtreatmentgenefor patients with
expression wered
chinery
9 (rangein4–12);both docetaxel-resistant cell lines, but
median relative dose-intensity was response
98% forto T,docetaxel
88% for VNR couldand not
80% be for
enhanced
CAP. Worst usingtoxicity
this DNA was m
ighly active and well tolerated as first-line treatment for HER2+ MBC,
e breast cancers with “basal-like phenotype”. These women were divided to two age groups, 19.3% <40 years also improving patient compliance by allo
asal-like phenotype” are often presented as poorly differentiated tumors and are reported to appear in the you
5sal subtypes
(41%) withdrewof triple
duenegative breast carcinomas
to PTL toxicities of histological
(incl. 3 asymptomatic LVEF grade
decline3 and 3 CHF). Conclusions:
As of Apr '09 TNBC 37 ofptsthe ba
have
son in pts
said they with
usenormal LVEF receiving
Adjuvantonline ddAC-PTL
in clinical practice and and may correlate
1 (4%) with subtle
oncologist said no,declines in LVEF. subsequent
but answered These abnormal ques
6 years (range 51–78) were included in this study. The mean tumor size was 12 mm (range 7–23). Ex vivo RFAinr
Adjuvantonline. Currently, there is no consensus on its use as a decision-making tool for adjuvant treatment
ation can result in complete cell death in small invasive breast cancer, but a high level of accuracy is required i
hs (range, 24–72 months).116 patients were classified as having triple-negative breast cancer. Among these, 66
ressive disease patients,
in mastectomy with relatively poor survival.
1 in patients We found
undergoing that oneand
lumpectomy who1had vascular
for breast and perineural
biopsies under GA. involvement
Two studiesa
reast cancer surgery can reduce pain in the early postoperative period however the evidence to
owth was found in 10 patients (23%) (Table 1). Sentinel node (SN) positivity was found in 4 patients (9%), support this is w
3 of
DCIS on core-needle biopsy, SNLB should be performed routinely, as a substantial portion of these patients will b
ascular endothelial
rior-posterior growth
(AP), 2.0 mm factor
in Lat (VEGF)
and 2.3hasmmimportant role in Mean
in CC direction. cancerofmetastasing and malignant
systematic errors growth.SU
was 0. Random The a
erro
pecific
pts in SU
16 accuracy
sites werefor breast cancer
enrolled. 60 pts treatment is comparable
are evaluable, but slightly
3 pts withdrew better then
their informed expected
consent. compared
All pts to lit
had a regular
cancer who are treated
e in both white and asian by (neo)adjuvant ChT do not support the use of goserelin to protect ChT induced ovaria
A double-strand break
uture activities and
of living among women
tionship between
e the primary cause of
ment what differs from
es
edictfurther investigation.
the impact this
e.routinely available in
s, particularly DM, as
osefar,recurrences.
there are no safety
on will
f proposingbe presented.
screening
er parameters should be
rs, given the low
s. fact.We have observed that conservative surgery undergoes in a larger rate of young women,
onwomen.
r for elderly breast
prevent specific organtoxicities
e presented at the
en the use of taxane
and pain.
 implication that lobular and ductal cancers elicit a common response in whole blood which is recognised by the
edures. Additional
When these cases
results were ofcorrelated
lobular cancer
with are required
factors to support
including these preliminary
menopausal findings. receptor positivity
status, progesterone
no use. Pooled results showed no statistical significant differences with the use of bisphosphonates in early bre
of
esearly
with breast cancer formerly
the following is likely to alter theinterim
presented natural Phase
courseII of the 33
data: disease. Nonetheless
(43.4%) responses there seems
(partial to be a non
or complete), 29 s(
accumulation
being after multiple
generic elements dosing
and the q3w.
breast A Phase III trial
cancer-specific (EMILIA) Baseline
subscale). is enrolling MBCand
TOT-B pts TOI-B
with prior
scoresHER2-directed
were balanc
changes
critical reflection by both clinicians as well as statistical methodologically on the development and data,
at most timepoints compared with those treated with PL+D. This is consistent with E2100 which
application
n survival 1.3, 1.7, 2.2 and 2.6 years for 1991–1994, 1995–1998, 1999–2002, and 2003–2006, respectively). Sur
account
56/52 all important
years), significant
visceral disease prognosticmedian
(66/91/65%), factors,disease-free
and this improvement could be years),
interval (2.9/2.6/2.8 explained almost fully
measurable by t
disease
st line
+2 all-oral
= 88%; combination
endocrine of NVBo
therapy = 89%. with X induced
Median followacceptable
up was 28.3 clinical toxicity
months. Onlyand allowed prolonging
17 patients the infusi
(5.2%) developed m
ograph) as a standard 25-fraction schedule at this stage in follow up.
1% (±7%). Functional enrichment analysis of the genes in the signature suggests that a defense response is pro
eastoftumor
ule growth. The
administration. genesout
Overall, identified possibly
of the 33 reflect the
pts (170cy), a crosstalk between
main Gr3–4 the growing
toxicities tumorasthenia
(N pts) were and the(5),
immunhan
cacy and safety will be presented.
ed
nic.events (SRE).ofThe
In a cohort 55 osteoclastic component
patients treated of BM isbreast
for metastatic a primary cause
cancer, for the of
activation development of SREs.asInhibition
the PI3K pathway, judged by o
rapy, which in turn suggests combination therapeutic strategies to treat Trastuzumab unresponsive
rapeutic effect of this drug. This inhibition was greater than that obtained using the gene therapy or chemother breast canc
enhance
n of tumor the anticancer
growth, effect
potent of the doxorubicin
enhancement in comparison to the
of trastuzumab-mediated ADCC growth inhibition
and strong obtained
inhibition using the gen
of EGFR/ErbB2-re
,Othe
direct
hadantitumor
lower oraland antiangiogenic
mucositis (P = 0.003),activity and enhancement
diarrhoea of ADCC. Moreover,
(P = 0.008), constipation we provided
(P = 0.008), nausea the(P =first evid
0.003),
treatment-related toxicities and support them during the treatment period than receiving
e in the incidence of serious adverse events (EDC: 26.3% vs. ED: 21.1%, p = 0.16). When capecitabine was add standard care alone.
men
1 years but(range
capecitabine
29–78),induced
ER weretoxicity
positive must be monitored
in 49%, negative in closely.
24% and unknown in 27% of pts. Number of metas
to anthracyclines,
D24 immunoreactivity, and acceptable
a generallytoxicity.
accepted Ongoing
featurestudies
of breastoncancer
gene expression
stem cells.profile willshowed
The cells aim at identifying
an intense past
to easily prepare
.21–29.90), the required
aromatase cells
inhibitors (p for further
= 0.02 oddsexperiments.
ratio 2.75; CI 1.21–6.26), tamoxifen (p = 0.01; odds ratio 2.47;
ant chemotherapy, 249 during trastuzumab and or between
PaMS and that there appears to be an association hormonethe use ofDifferent
therapy. taxane chemotherapy,
pattern of therapyaromatase
response inhibito
wer
id tumours as a tool for therapy guidance and optimal personalized therapies to improve
sided patients was respectively 6.7 and 0.6 Gy. The mean dose to the apical, mid and basal LV segments in left therapy results and sp
enopause, and bone health-and the psychological health of young women as they face a diagnosis of BC. Bette
sed
ons of on AA,
thisABimportant patient population.
and BB (around 0, 0.5 and 1). In second step, same SNP numbers were retrieved from tumor data
atistically reliable statement
uring follow-up after a median 21 m about the behaviour
(95% of these groups of genes.
CI 13.86–28.14).
second-line
At the time therapy. In orderthese
of PLD therapy, to predict
(274)forptsactivity of second-line
were heavily pre-treated T, evaluation
(median linesof other factors known
of previous to confer4
chemotherapy
as independent
colorectal, lung,of orresistance to, setting
ovarian). Overall, or total
more doseexperienced
patients of, or time since previousinconventional
No Vomiting the APR group, anthracycline
regardless of therw
ncluding
as 20 mmthose (IQR receiving
15–30 mm). oxaliplatin- and carboplatin-based
In both cohorts majority of the cancer therapy. In these patients,
specimens the APR regimen
were pathologically gradedprovide
as G2
ems to have a negative impact on disease specific survival. Whereas, high
erved: primary tumours ≤1 cm 18.7%, 1–2 cm 35.8%, 2–3 cm 50.8%, and >3 cm 68.1% (p < 0.001). The relatiomembrane expression of Lck provide
a8constant process in(95%
μmol/g creatinine the course of time. According
CI = 12.25–16.30) for benignto the results
tumour presented
patients (p <in0.05).
this study micrometastases
The figures for delta-ALAD are aw
ents.
24.6%The mean concentration
respectively, h2N-OE 3+ ofor
delta-aminolevulinic
FISH+ was 43.9%. The acidfrequency
in urine ofof cancer patients
Ile655Val is significantly
in controls was of 20.6%higherandthanin
allele may be can cause more aggressive tumors. The following study showed
pt from the Hospira filgrastim group withdrew consent and did not receive study medication. The mean numbe a little perspective to individuali
r pts receiving
in intent cytotoxic
to treat analysischemotherapy.
(12 trials, OR:Hospira filgrastim
0.99, 95% may provide
CI 0.73–1.34, an effective
p = 0.932), alternative toanalysis
in comprehensive Neupogen (all for
14
cancer
erapy, do for not decrease
an overall the number
incidence of fractures
of 43%. In about compared
78% of cases withBM placebo or no treatment.
were multiple, with 18% of patients having at
en if survival
ontrol patients after
(p =diagnosis
0.047). Theof BM this patient
proportion population
of patients whoiswere longer
ERthan historical
negative (48.4% reports. Further
Vs 24.2%; p =investigation
0.001) and
e(0.56),
may be case for screening for brain metastasis and even prophylactic treatment
compared to 12 patients in the ERpos group (0.30) and only 3 in the TN group (0.16). Median time to ce in this subset of patients.
s without
ound between HER2irradiated
over-expression.
lymph node TN patients although
(LN) stations. having
Median poor prognosis,
follow-up were 7 years doesand not 6seam
yearstofor
havethe aNAC
highandriskA
rates with NAC compared with AC for women with localised breast carcinoma. Although, patients with a patholo
pression, and tripleagents
chemotherapeutic negativewithstatus are
'safer' more often
profiles such as in weekly
the early BM relapse
taxane regimens,vs. late
newer BM less
relapse group (panthracy
cardiotoxic < 0.001
with a similar program in Moscow, the Yugra breast cancer detection rate was 1.5 times higher and amountedbe
side effects increases with age however, and certainly for antiangiogenic compounds, the balance between t
within the BCSP, in particular the histological findings (size of primary tumor, involvement
ported age in categories, 65% of the participants were under the age of 60. Only 50 studies (15.4%) reported ra of lymph nodes in dise
cted
e in the
limited western
breast world.Significantly
cancers. This limits the generalizability
associated of the data
with extensive breastfrom current
cancer were breast
presencecancerof research
a Her2+ indexto the
ses withbetween
lanced Her2-positive
groups. tumor types
Median age and
was presence
53 years, of 35%
DCISof inthethepatients
index tumor. Tumors nausea
experienced with theorlatter properties
vomiting. In totam
ausea and vomiting measured by patients and by investigators, than in other studies
s lower than normal (like mastopathy), but TK activity was enhanced that can be responsible for some increase using identical chemothe
alignancy. The biochemical test of determination of TK and TP activity in blood serum of patients with mastopa
ontain a minority population of tumor initiating cells or cancer stem cells (CSC) that resist treatment and give ris
ed to normal stromal cells, while there was no difference in expression of its principle receptor, TGFβRII. This wa
tion of
ears of paracrine factors
age. Average sizesuch as VEGF
of tumour wasA and
27.7TGFβ. Further
mm (range understanding
1.5–120 mm). 78% pathways
(n = 91)involved
had T1 or in T2
stromal
tumour cell(diam
ind
an also
rder produce
evidence hasfalse positive
appeared results (as
indicating thatobserved
pregnancy in 3after
of our patients).
breast cancer This can be associated
treatment with immense
does not worsen prognosis p
eved
tive,to be cured fromEBC
HER2-negative breast cancer
receive 6–8should
cyclesnot be advised
of standard from gettingand/or
anthracycline- pregnant.taxane-containing chemotherapy
ny(n7 serious adverse
= 9), while 1.9%events considered
of pts were positivepossibly/probably related to (n
on anastrozole treatment X (hospitalisation
= 1; p = 0.19). for grade 2–4 diarrhoea in
patients after cytostatic, endocrine and zoledronate treatment. Longer
n factors). The distributions of times to progression or death did not significantly follow-updiffer
will deliver
between insight if these
the three cel
arms.
in the
with TTPtreatment of pts with
and OS: patients with Her2-negative
levels of these MBC.
markers lower than the median value achieved a significantly bet
esults
1a). in relative
There was no resistance
significant to subsequent
difference therapies. Alternatively,
in characteristics between T1a rebound
and T1bincreases
(table). in VEGF on
Invasive discontinuati
ductal carcinom
r T1borsubclassification.
15% alone 6%. Median These
timefinding should stimulate
from diagnosis to BM was further prospective
2.7 years research
(range 0–19), to assess
to distant the value
relapse 2.1 oroflocal
adjuv
es are needed for early BM patients selection.
gnosis was 59.6 in SBBC group. In MBBC group median age at first diagnosis was 52.5 and 60.2 for contralatera
receptor positive
nosis to distant tumors with
metastases of aluminal,
same HP findigsand
HER2+, in bothside
TN were breasts.
30.0, 17.0,MBBCandare17.9more oftenrespectively
months, presented as(pan = IBC.
0.04
status
ty one may be used
patients had as a prognostic
stage II and thirtymarker for the breast
five patients cancer
had stage patientsTwo
III disease. withpatients
brain metastasis
presented with metastat
ients(Spearman's
ions are shorter than non-TN breast
correlations cancer.
0.55–0.89; p < Metastatic diseases
0.00001). All CLLs, lowmostly
gradeappear
DCIS,atLNvisceral sites
and their of the patients
matching invasiv
bligate precursors of more advanced lesions in the LNGBN family and that that loss
41%) had the 70-gene good prognosis-profile and 307 (59%) had the 70-gene poor prognosis-profile (strictlyof 16q and gain 1q are theeq
ast cancer patients with positive LN. Combining nodal status (1–3 nodes vs. 4–9 nodes) and
for each patient in test set was predicted using the gene-set specific model. The patients were then classified i 70-gene profile (go
rediction and multiple gene sets as well as clinical parameters can be integrated in a risk prediction model to im
ant positive correlation between NIS and RARA expression in all breast tissues samples (Pearson correlation coe
ast
CT cyclestumour tissue
were completed by 97.4% of pts (median cycle duration: 21 days). Most pts received docetaxel- (65.2
Primaryand
analysis prophylaxis with G-CSF reduced
immunohistochemistry revealedneutropenia
that CXCL12 incidence
but not compared with SP and,
CXCR4 expression for FLG treated
significantly patients
correlates wit
2 production
ntation was areduces
palpablechemotaxis towards CXCL12
lump in 7 patients, releasing
a retraction of themetastasis
nipple in 3 target
patients,tissues.
nipple discharge in 2 patients
as and 47% were poorly differentiated. Most patients (53%) were
1) in this 34-month study. The median time to first on-study SRE was not reached for denosumab positive for the expression of hormonal recep
and therefore
en previously reported for these two agents. This study continues as an open-label study with denosumab.
nts is debatable. In
t-chemotherapy, a large
CTCs andcollaborative study onin
DTCs were identified samples
44 (52.4%) obtained
and 43 at (51.2%)
time of primary
of the 84 surgery
patients,we respectively.
have examine T
mRNA
I) wasin23.6.patients with earlyfield
The radiation breast
sizecancer. The detection
was smaller of CTCs using
on 3-D planning: meanthis assay isatable
difference to deliver
superior edgeclinically
of 2.48 cm rele
(
r Tamoxifen
patient. Also, it shows less irradiated lung volume compared with conventional
users performed worse than healthy controls on verbal memory (P = 0.006, Cohen's d = 0.40) and 2-D planning. Based on this da
while exemestane
cluded, 12 were unable doesto not negatively
undergo MRI,affect cognition
full receptor in this
status waspopulation.
not available Tamoxifen
in 8 andmight 1 pt'shave
tumour a differential
was not vise
oxblyproportional
by the DCE-MRI hazardparameter
regressionve including
which describes the extravascular
age, gender, diagnosis group,extracellular
with aR space.
and SRFurthermore,
as independent increased
param
r prospective
1.9%) of cancer studies
patientsarewere
required to elucidate
presented the prognostic
with different relevance
skin reactions, and utility
including of selfurticaria,
flushing, regulation. dermatitis, er
dpatients
in this group of patients may evidence of the disorders of DPC and possible susceptibility
receiving XT (80% of these patients required dose reductions of both X and T, to ∼950 mg/m2 and ∼5 to the development
atypia had openefficacy
compromising biopsy in forterms of time area
a dysplastic to progression
behind theornippleoverallin survival.
mammography Together these dataexamination:
(histological support the use nega o
scer had expecially in patients
been detected with Gail
was 39.1 years, Risk >1.7. Itit can
whereas wasalso
36.6help
yearsus for
to avoid
those repeated
with a normal cytologic
breastexaminations
examinationdurin (p <
al as well as lower socio-economic levels should receive special attention.
nts had residual invasive malignancy. Quantitative change in Q scores for ER and PR was seen in 6 patients (24%
dederwise the not received
threshold for transzutumab.
CA27.29 only after ThoughCHT. Q In
scores changed
this group 209inpts24% and
(8%) 40% forG-CSF
received ER and andPR129
respectively
(5%) did not.no ch1
ofCNS G-CSF overThe
mets. CHT. 1° Nevertheless
endpoint wasthe results on CA27.29 PFS.
investigator-assessed showedThe aCaphighly
cohortsignificant
and pooled correlation
T or Antbetween
(T+Ant) the adm
cohort
,+Ant:
comparedpl 8.0with
mo, G/C B 9.2 mo, pThe
alone. < 0.0001).
frequency In and
prespecified
nature ofsubgroups,
adverse events HRs favored
(AEs) did B not
arms of the
differ respective
between arms. chemo
lone. BSI-201 + G/C was well tolerated,
e did not differ significantly between groups. with BSI-201 adding no significant toxicity to G/C. Updated CBR, PFS, an
eents
onewith breastestradiol
between and gynaecological cancer. of
and the expression Anthe
improved model of nursing
apoptosis-associated Baxcare
gene is (p
being developed,
= 0.009), sincean
and again the in
inv
t appears
one mineralthat in postmenopausal
density (BMD) as the primarybreast cancer
indicatorpatients the tumors
of fracture risk andthusneedinduced show aRecently,
for therapy. biologically less aggre
guidelines h
ns.
cancer Although BMD cutoff points vary slightly between guidelines, most recommendations now use overall fractur
patients.
ore frequentlyisobserved
nd mortality biphasic.during
ComparedAC (8%)withthan
olderduring
patients, young
AT (1%) women
and experience
one episode of G3 anthrombocytopenia
abnormally high risk wasofdocude
thevisceral/nodal
nd threshold to move diseaseto stage 2 of the
(p < 0.05). study. Theacombined
Noteworthy, significantanalysis
correlationof pCR
hasrates
beenand feasibility
found between was
theinincrease
line wit
ost evaluations
of them inof HER2
only 1 tostatus during
3 days. Meanthe agewhole
was disease
39.9 (18history, with possible
to 68). 94.4% future therapeutic
of participants were women. implications.
Most of them
semg/w.
0 and contents. To monitorwere:
Pts characteristics everymedian
consultation
age 55and y-o;tovisceral
offer online
diseasediscussion
in 79% of boards or groupNo.
pts; median therapy would
of prior chemo- be
estochemically
I part of the study is completed and E 10 mg daily has been selected as the recommended
determine the expressions of, respectively, MAGE-A1, MAGE-A3/4 and NY-ESO-1 C/T antigens in M dose and schedule
al prognostic relevance. Due to the relative rarity of this type of breast cancer, further tests need to be perform
y significant differences. We noted a significant decrease of glucose transporter in patients operated after neoad
mbined
matic use ofdelayed
women both markers in positron-emission
presentation tomography
4 weeks or more. shall be
In multivariate considered
analysis, womenandwho
further studied.
delayed were more lik
ay to presentation. Health education messages are needed to convince symptomatic women
r 46% and over 3 months for the last 16%. In multivariate analysis provider delay >1 month was associated to present quickly
with
uickly than self detected ones and those detected in
400 SNB-negative cases a, according to the original assessment. medium size towns with dispersed medical services and ca
epithelial
ed cells, foreign
chemotherapies. Thematerial nor nevusmean
model estimates cells were
savingsdetected
to be €in9,043
the 473
per SNB
100 cases.
patientsFive
permicrometastases
year in the base andcas
sment tools. It helps oncologists to identify patients who may forgo unnecessary adjuvant chemotherapy in com
LC) or extensive
s (86%). disease (SCLC).
Blood concentrations ofOvarian cancer
CXCL9 and not shown
Fibronectin (N = higher
1 were 12). in cancer patients as compared to norma
R-negative
he underlyingbreast cancer.
genetic These
basis data
for this suggest thathas
susceptibility analysis
become of differential
increasinglygene expression
understood. is aimportant
Three good approach t
classes
i includenegative
eceptor several plausible
(ER-). Totalcandidate
number genes, including
of positive nodesFGFR2,
was 479,TNRC9,
with aMAP3K1,
mean ofLSP1 and
2.6 for NEK10,
each but also
patient. UICC“gene
stage
nand seems
breast to improve
cancer: taxanes, thetrastuzumab,
expected outcome of Pre-HR-BC
and aromatase patients
inhibitors through
(AIs). immunologic
The inclusion mechanisms.
of these treatments in the
ed into guidelines. In contrast, guidelines were quickly updated (1–2 y) to recommend
nd linked to the PHARMO Network to select drug use during follow-up. Patients starting on tamoxifen adjuvant trastuzumab aft
were inclu
203), exemestane
nt entities (n =
within the all113)
HER-2 or positive
letrozolebreast
(N = 64) with (2)
cancer. a mean duration
This high rateuntil first
of CpR switch
was of 2.0with
obtained (SD a=short
1.3) years.
expos
gene is overexpressed when amplified (Mann-Whitney U test p = 0.0018). Mdm4 was overexpressed in 17% of B
ism by which a subset of BC escapes p53-dependent growth control, providing new avenues for therapeutic int
breast cancer cells responded to HMPS. HMPS induced nucleus fragmentation and G2/M arrest followed by sub
enin and furthermore HMPS also inhibits cell growth of LTED cells which are difficult to treat therapeutic agents.
10 patients (15%) in the group treated with conventional fractionation with a mean follow up of 854 days, resp
foup
skinAacute toxicity
(n = 17) (p = standard
received 0.01) andradiotherapy
not significant difference
with of lateplus
50 Gy/25f/5w effects (p 10
boost = 0.4) compared
Gy/5f/1w to the
to tumor bedconventio
and Gro
(hypofractionated RT regimen) over that for the patients of group-A (conventional fractionation).
The median age was 71 years (range 64–88). 570 pts (80.7%) were HR positive and 133 (19.3%) were HR nega However, this
ere
ualisedare as
no areas
safetyofconcerns.
contrast First safety data
accumulation fromathe
within entireLN
defined population
structure will
seenbeclearly
presented
on grey-scale imaging. In 2
tification of
persistent SLN would
fatigue enable
can affect targeted
gene biopsy
expression ofin the breast
blood clinic and mayexpression
cells, genome-wide reduce theanalyses
numberswere
of patients requ
performed
T in BC patients that will shed light of the different mechanisms involved in order to develop
ear expression of P53 in 52 (57.7%), ER in 19 (21.1%) and ki67 in 59 (65.5%) of cancer breast cases. Increasedpreventive strateg
r and in responses of tumors to therapeutic intervention. Taken together the results of our study suggest that U
positive correlation between ER positive status and mammaglobin A expression (57% correlation, p < 0.05, Chi
mammaglobin
compared withAhealthyprotein controls
expression may
(HC). also be results
However, associated with a better
comparing prognosis.
TAM with However,
AIs are not long-term
consistent follow-u
(Table) due t
ear and not conclusive. To date, no long-term effect of HT on cognition has been investigated
hat patients with tumors that were positive for p53 protein, negative estrogene receptors and treated with inadin patients with B
receptorwith
patients status, inadequate
close or positiveanthracyclines dose and
margin by invasive worse survival
carcinoma was notof young earlylower
significantly stagethan
breast
thatcancer patients
of patients wit
adjuvant radiotherapy,
local ethics committeeclose or positive
and all patientsmargin by invasive
gave informed carcinoma
consent. didreceived
Patients not raiseeither
the risk of localofrecurrence
6 cycles fluorouracils
ne
n werein combination with docetaxel
managed according (cycle 5:with
to guidelines, P < 0.001; cycle 6:ofP 1
the exception =pre-menopausal
0.002 [paired t tests])
patient(Table).
who was Before the first
switched ina
k post menopausal subgroups.
y stage breast ca rate was 81.5%). However in low and moderate risk groups some patients did not switch appropri
,malignity rate was 18.6%,
and the incidence comparable
of DM and calculatedto the
all ages' malignity rate, and2.5-
Kaplan-Meier-estimated alsoand
early stagerecurrence
5-year breast ca diagnosed
rates via
ndidates
NAs. Of 7for adjuvant
breast cancerhormonal
specific therapy. The aromatase
miRNAs investigated, inhibitors
across are superior
130 whole to TAM, (106
blood samples and results from the
preoperative BIG
samp
d to controls. The circulating miRNA expression profile correlates with the tumour miRNA expression
eries the quantity of mitosis considerably decreased to 0.6% and expression of apoptosis increased to 1.5%. Si profile and
1%; P < 0.0001). There was no significant difference between the groups in 5-year recurrence-free survival (90
reast cancer, but
ter treatment. its prognostic
Breast significance
care nurses in association
were considered with the
an important standard
source factors may
of information besupport,
and limited. but were in
affects allprogression
ecord of ethnic groupson and
bonethrough greater
until death. 13 representation
patients (out ofof14
BME
withgroups
basal across staff and
NTx record) had services.
elevated Facilitating
levels of N
28 (54%). Thus 28 patients (54%) avoided a second operation for axillary clearance. There were no false positiv
dictive value
e specimen where TIC
obtained is negative
using but histology
intaroeprative is positive.
hand-held 54%
ultrasound of patients
probe can avoid
was easier a second
to localize operation.asse
and surgically TIC,
and
TEM8 safety
expression revealed that in response to TCS from growing MDA-MB231 cells, by 48 hrs, MOs expressed m
esis and
were tumor
definite orcell migration/invasion
likely NP; and 5 (3%) could processes.
not be classified. There were 71 cases of CLBC. Results of an analys
type appear to suggest that WBRT reduces the rate of ipsilateral NP tumours
dcarriers
favourable
werestatistic
analyzed figures, we can
separately, asconclude that FNA
well as when womencytology is an excellent
who developed DCIS diagnostic tool in were
without invasion the work-up
excludeo
ations.
se hadTherefore, breast density
complete response. should
Median timenot be considered
to response a factor
was 11.6 wks for these5.3–26
(range: women in decision-making
wks). Among 18 pts with regardin
mea
pilone and 75 mg/m2
stochemistry. of epirubicin
Preliminary automated image analysis of the receptor core number (density) in vascular endothe
her than in sporadic BC tissues
n data as of 01 October 2008 and andincludes
it indicates
9 ptson more
who wereintensive growth of process
in the screening the tumors
andand pathological
permitted evalua
to enroll to L
on in the risk of death. Pts with ≥3 prior regimens had a 41% reduction in risk of progression with L+C but no si
 ion surgery. Each underwent standard supine CT-scanning before being repositioned & re-imaged prone on an
dosimetry
en 1989–1996 onlywas
in women
followed with breast volumes
prospectively >1000
to 2007. cm3and
Tumor (≥Dtreatment
cup (UK))variables
and/or supine
were LAD NTDmean
obtained doses of
from clinical r
ER positive = 337; PgR positive = 285; grade 1 = 73, grade 2 = 199, grade 3 = 170. Median
escribed as EMT) may be concurrent with gradual adaptation to loss of the functional capacity of the ER transcr follow-up was 11.9
did not improve (HR 1.00 vs 1.18 vs 1.19, p < 0.001). Furthermore, within 5 years following diagnosis, the actu
ented,
st probably
health care. Thedue to both stage
availability migration
of radiation by screening
therapy allows for and developments
consideration of in systemic
breast therapy.
conserving However,
therapy, if m
post-m
step-by-step
greatest allocation
decrease seen inof the
resources can help
T47D cells. address
Analysis economic
of gene disparities
expression across
revealed populations
a significant and provides
increase am
in express
t by VEGF and TGFb-1. These factors play an important role in the metastatic cascade
reast cancer patients (pts) and healthy controls in relative serum levels of methylated gene promoters ESR1 (p and may represent poten
east cancer24%
st cancer, withfor
different phenotype
DTC analysis in BMclasses
and 61.1%and shows that these
in patients differences
with metastatic have clinical
disease. Duringsignificance. In the
a 12 to 24 months
munobead A
spectively. quantitative RT-PCR technique.
worse metastasis-free survivalThe specificity
(MFS) and detection
was observed rate with
for patients of tumor cells in blooddisease
micrometastatic and bonecom m
oobjective
node negative
responsedisease only for patients
to anthracyclines undergoing
(p 0.004) and toALND
taxanes for staging purposes.
(p 0.007). Treatment
HRs is related recommendations
to probability of responf
acyclines and taxanes, respectively. The presence of HRs favourably affects response to treatment
are finally able to characterize single cells using high density microarrays. This will provide us with information with both drua
onal DISMAL collaboration for research into disseminated epithelial malignancies.
had hormone receptor-positive disease and 93% had HER2-negative disease. One male pt was included. The m
llent
ng safety and
toxicities high efficacy
(all grade profile despite
[gr] 3) occurred theabnormal
in 4 pts: dose of 2000liver mg/m2.
functionThis
test seems
and deep especially attractive(Arm
vein thrombosis for elder
A, 1
ced
e breastnumber
median cancer.of Coadministration
cycles was 2 in all with either
organ P or except
types, D had no formajor effect
a median ofon motesanib
4 in PK.
ovarian cancer. Main drug-relate
omise further exploration of this class of agents with optimal documentation of dose, schedule and adequate tra
Province. Two-hundred and twenty-five pts (15%) were HER-2+ (IHC 3+/FISH amplified). Of these, 100 pts were
features,
prior CT forsystemic
LR/mBC treatment, and clinical
and no evidence of CNSoutcome.
metastases. BasedPtson our results,
received Bev 10HER-2
mg/kgstatus
q2windependently
or 15 mg/kg q3w distingui
comb
1–93). Most pts (76%) received taxane-based therapy with Bev, predominantly paclitaxel
2 amplified. Histological complete response (CR) rates were 9/37 (24%). Of 7/28 patients that were TopoIIA pos or docetaxel monothe
anthracycline
e than 50% tumor based chemotherapy.
shrinkage was noted prior to radiotherapy in 48/156 (31%) patients on Tamoxifen and 28/65
tute (42%)
ents study neoadjuvant
were confirmed radio-hormone
to have benign therapy
lesion proved
(grouptoA)be an 25
and effective,
patientsnon-toxic, well-tolerated,
(58%) confirmed to haveinexpensive
metastasis
lesion in breast
emotherapy havecancerled to patients who present
modest responses andnew isolated
benefits mediastinal
to patients. LN or the
Overall, pulmonary nodule
results of trials during surveilla
with chemother
peutic index and agents overcoming the resistance to existing chemotherapeutic
ival (OS) at 5 years were 92%, 83.2%, 81.4% and 87.7%, respectively. Pathological tumor stage and hormone drugs. Targeted therapies do tp
apy to SCN and give only to chest wall or breast in selected patients according to pathological tumor stage.
b=versus
0.00013)non-trastuzumab
and prior TAMbased adjuvantand
(p = 0.0023), chemotherapy. Aside from
visceral involvement (p the negativeand
= 0.00006) PACS 04 TAM
prior trial (p
(528 HER-2 pos
= 0.014), as
d was
s ABC good:
pts, themean choice of both
of 75.1 withORR
a SDand CB as with
of 19.4, clinical parameters
similar values forto standard
evaluate f-up
the activity of upcoming
and telephone new horm
f-up: 74.9 vs 75
outpatient
years (SD 9.0); tumour size T1: 58% (range 37–76%, p < 0.001); positive nodal status: 47% (range 26–85%,vis
clinic f-up. Hence, nurse-led telephone f-up might be an acceptable alternative for hospital clinic p
reast
survival is 15.9 months (95% c.i. 14.0–21.5 months) at a median follow-up of 14.3 months; the 1-year survival lr
cancer are observed among different countries, requiring further research and efforts to achieve optimal
uld
rtednot be further
severe pain, 39% investigated.
moderate pain and 48% light pain. Pain was located in the breast area (86%), axilla (63%
of patients.are
x patients Although
summarized breast-conserving surgery
in the table below and sentinel
showing nodemedian
geometric dissection(95%have reduced limits)
confidence the number of comp
parameters. T
Pvaluable
elimination. This key information may impact in ongoing adjuvant lapatinib studies.
for safety and 51 pts evaluable for antitumor activity]). As of Oct 2008, 10 pts continue on study and 4
y
e (T3–4) wasMBC
in HER2+ found pts.in 23 patients (56.4%). Expression of estrogen receptor and progesterone receptor were 10
eation
setting
of thefor axilla
metastaticwas adisease.
powerful independent variable. Other variables included (different in different nomogra
. They differ in the inclusion
ation and 4.2 cm by ultrasonography of the results
(range of2.5–8);
intraoperative examination
47 pts had of SLNs5 and
invasive ductal, are thus
invasive lobularapplicable in diffe
carcinoma; ER
n interesting high
g the course of disease percentage of pCR in triple negative tumours.
ncology
sease-free centre between
survival (DFS)1999–2005
was 50 monthsyears.andAge, disease
16.6 months stage, menopausal
respectively. status,
There was hormonal status, histopathol
no postoperative mortality. U
urable
23% predictive
of the patients factor for CSS
achieved a pCR. The following factors were significatively associated with a pCR in univariat
ve angiogenic factor. Its association
2, respectively), while 301 (82.9%) were with disease-free
ER status allows (DF).the development
Group 1: baseline of CA
a predictive
15–3 serum index. The(DF)
levels: validation
25.0±
he subgroup of disease-free patients (DF). We conclude that, although serum
80.4%), Her2 (89.8% and 80.9%) and triple negative (74.6% and 58.7%), p = 0.0001; for N0 (98.8% and 93.9% tumor markers levels should be u
sSMB7).
additional information
We achieved to nodal of
a silencing status.
86% Triple
of PSMB7 negative
usingstatus
an RNAi emerged
oligo atas a strong
the adverse prognostic
548. nucleotide factor.Af
in the 5th exon.
en IORT
unfavorable
were d prognostic
= 1.01 Gy with marker
RBEinestimated
breast cancer.by the L-Q formalism and d = 1.64 Gy if RBE was assumed consta
in the TARGIT
h in this age group. trial. Thus hypofractionated APBI should expand the therapeutic window. However, RBE estimate
al in patients
stage treated
at diagnosis: IIAwith adjuvant
in 35%, IIB inPMRT
49%, and
and tamoxifen only emerged
IIIB 16%. Forty-four after
patients 5 years. Patients
underwent surgery,withand4areor more
evaluabin
ing.
cer in these
patient werecountries.
€3003 and this strategy yielded 0.771 QALYs. Mean annual costs per patient and mean effects fo
up strategies
with improved DFS for the(hazard
first year after
ratio breast
[HR], 0.89;cancer.
95% CI, 0.77–1.03; P = 0.12) and RFS (HR, 0.85%; 95% CI, 0.72–1.0
re effective than tamoxifen and has a favourable safety profile.
gnosis before 50 years compared to 50–70], a positive family history of breast cancer [RR 1.2 (95%CI 0.7–2.0) w
r, the data
+ISSCL. suggested
After that tumour
SLN visualization size and
standard nodal status
radiotherapy are more
portals wereimportant
changed in risk factors
27/36 than
cases family
(75%): in history or a
50% – redu
mour localization
edbalanced
ell with a median disease
regarding the free survival between
stratification criteria. A5–12 months,
significant and a median
difference overall
was found survivalresponse
between (OS) between
rates 24–3
in th
neoadjuvant
lerated chemotherapy
and rates of drug-relatedfor stage IIA-IIIA were
withdrawal breast cancer.
very low in both the neoadjuvant and the first-line setting.
urrent and metastatic
(N = 204), 75.8% achieved breast85%cancer.
or more planned RDI (p < 0.01). Randomization was performed for 42% of pat
of healthy volunteers. We also tested has
nia-associated delay or febrile event the occurred.
application of this approach using 25 coded samples with known muta
high frequency variants of BRCA1 and
ses and 40 for response to T and TTP. Median age BRCA2 in Croatian
of pts waspopulation.
53 yearsIntention
(23–77). ofWethis pilot project
observed 25/40was to introd
responses (
R2/HER3
atients, 1signaling
in 33, and may
2 inbe warranted
20. The median tumor size was 16 mm (range, 5–30 mm). The median age was 58 yea
sess the long-term feaibility and efficacy of APBI using 3D-CRT
ypeasand
cy well as cost.
moist desquamation or interruption of radiotherapy due to toxicity; none of the XRCC1, XPD and GST p
More
5 yrs with meancritical
SNPs and age ofSNPs association
menarche at 13 are under
years. Thereevaluation.
was one pregnant patient and family history of breast canc
s was 10 where
poptosis, monthsSphK1
and majority presented
inhibition is criticalinfor
anincreased
advanceddocetaxel
stage (lump size >5
efficacy. cm) making
Furthermore wethe prognosis
have shown omino
that Sp
SphK1 inhibition
nopausal
of the firstpatients increasedlevels
group exhibited survival rates,
within but the
normal therapy
range comparedmay influence
to healthyfertility and
controls ovarian
(<110 function.
ng/ml) at all Current
time po
ammatory
not have surgery (31 vs. 14 months). The 5-year survival rates were 24.5% and 13.1%, respectively (p <all
condition not associated with radiation treatment. The sustained elevated SP-D expression at time
0.0001
mortality
tients had risk of around
distant 40%. The
metastases, twoassociation was independent
with a concomitant recurrence of age, presence
in the of co-morbidity
subclavicular and other
lymph nodes. poten
Four patien
or the majority of patients. MRI may be helpful when considering breast conservation
spectively. The Cox regression model by stepwise selection showed some parameters such as ductal carcinoma or omitting axillary nodal
e. systemic management. Adjuvant treatment in early breast cancer should be based mostly on histological a
sive
receptor status.specimen pathology revealed positive margin. Re-excision of the margins was performed all in o
(10%), surgical
ervation with improved
ently contain patients'
TP53 mutations. Tosatisfaction
study the roleby excellent
of BRCA1/2 or loss-of-function
good aesthetic effect andoncogenesis,
in breast shortening the wetime
haveofgen
tre
ugs. Although tumors cannot be eradicated with cisplatin or carboplatin, the tumor recurrences invariably remai
andyear
ne their significance
based for the quality
on the subject's of life of(2)
assessment. cancer patients.
Persistence Interventions
rate (% number of to subjects
alter taste and
with a smell changes
‘persistent’ usemaof
he study is expected to finish March 2011.
ompleted
sing physicalthe and
analysis of 1000 breast
psychosocial status cancer genomes
of the patient, using high-resolution
providing SNP arrays,
information, providing gene expression
psychosocial support array
and
cation program for these specific (rather new) nurse roles. By this project the guidelines
ee survival after surgery showed significant differences as 68.1% in study versus 81.2% (p = 0.049) in control. D must provide informat
. AndofIMPC
ation groupwas
pr status showed
shown more
in 18loco-regional
of the 38 (47%) recurrence
patients. compared
6 cerb b2 with IDC group,
negative but breast
primary not for cancer
distantbecame
metastas im
ancer can
ollow-up vary
was in its metastases.
93.58±3.40 months.in these metastases,
Sixty-six a repeat
patients (86.8%) werebiopsy may show
diagnosed the newductal
as invasive features of the tumor
carcinoma, 10 p
ents. We need
NM stage of thestudies
disease, which
age include
under 35 more
(p =patients
0.0001), and long follow-up
estrogen periods
(p = 0.014) and to get a decision.
progesteron receptor negativity
c3.metastases sites of patients with breast cancer.
In the Tc-99m-antimony sulfide colloid group 24 patients had lymph nodes on scintigraphy images. Sentinel
oxicity grade higher than 2 in all group (P = 0.016) and in patients receiving 5-FU-based therapy (P = 0.047). Al
cy of chemotherapy
median age, diseaseinparameters,
breast cancer BMI,patients, however
QoL at study large-scale,
start, prospective
co-morbidities studies aremedication
and concomitant warranted.will be p
ocation (p < 0.001), and grade (p = 0.007), and for PFS were tumor size (p < 0.001), location (pif =
valuable insights into the reasons for non-compliance to adjuvant AI therapy and demonstrate a simple interv
0.01), and lym
meters including the stats of menopause, tumor size and location, lymph-node, grade and
was 57.2%, with estimated median survival time 10.9 yr. In univariate Cox analysis the most notable prognost progesterone-recept
adictory
S negativeto the
(SN)generally observed
pts was 75% poor risk
and 56.3% in patientsThe
respectively. below 35 years
5-year and age-related
and 10-year OS in SP decrease
pts was 38%of risk
andin23.8%
the w
valuated
>2 vs. ≤2only
cm p53 enhances
(HR 1.59; 95% negatively
CI 1.21–2.10)theand
effect of SG2/3
grade on survival.
vs. G1 (HR 2.08; 95% CI 1.39–3.13) were unfavorabl
range
surgery.
8–24). Histopathological examination revealed complete from
Positive ER changes their prognostic role with time, beingin
cell death shortly favorable
all lesions. One to beingsuffered
patient unfavorable
ab
in burns the distance of the tumor to the skin should be more than 1 cm and the placement
ans; the 90% of prescribed dose was delivered to a mean of 91.2% (±5.6) of PTV with the CT and to a mean of of a localization wir
treatment
DNMT genefor patients with
expression weredifficult
changed breast anatomy
following (i.e. large
treatment with breast), in terms
decitabine. Histoneof lung and controlateral
H3 acetylation breast
was increased
e for
enhanced usingtoxicity
CAP. Worst this DNAwasmethylation inhibitor.
haematological, withTrichostatin A did increase
WHO 3–4 neutropenia sensitivity
in 36%-12% ofto docetaxel
pts; no patient butdevelope
only in
g patient compliance by allowing a more convenient once every three weeks hospital
e groups, 19.3% <40 years old and 80.7% >40 years old, respectively. Tumor size was described >2 cm in 53.2 admission.
eported to appear in the younger population. Pathological identification of this specific histology needs training a
Conclusions:
F). TNBC
As of Apr '09 37 of
ptsthe basal
have subtype 18
completed occur in younger
mths F/Up; none patients
of whomandhadshowCHFmore aggressive
or LVEF declinepathological chara
<50%. At baselin
tes in LVEF. subsequent
answered These abnormalities
questionsdo onnot
its persist afterasked
use. When chemotherapy during
the frequency of TL.
use,Updated
10 (40%) results will be said
oncologists presented
they a
ol for adjuvant treatment in early breast cancer. Our survey showed that most of the Oncologists
(range 7–23). Ex vivo RFA resulted in complete cell death in 17/20 lesions. In 2 patients histopathological exam would calculat
vel of accuracy is required in proper positioning of the needle electrode. Furthermore, our results have led to th
ast cancer. Among these, 66 patients (56.9%) had premenopausal status and 50 patients (43.1%) had postmen
nd perineural
psies under GA. involvement
Two studiesassociated
used topicalwith
LAshort
whileterm survival and
the remainder cellinfiltration
used type grading has significant
of either correlation
bupivacaine w
or ropiva
evidence to support this is not overwhelming. There is no difference between giving LA pre-incision
und in 4 patients (9%), 3 of whom demonstrated positivity at intraoperative frozen section examination. All but or pre-clos
ortion of these patients will be upstaged to invasive breast cancer based on definitive histological examination;
nd malignant
rrors growth.SU
was 0. Random The aim were
errors of this1.3
study
mmwas to 1.6
in AP, investigate potential
mm in Lat and 1.3relationship between VEGF
mm in CC direction. gene 936
Per patient and C
in
en expected
onsent. compared
All pts to literature
had a regular and former
menstruation own work. In ourFSH.
and premenopausal opinion, this is due
The median agetowas
strict
35patient
years inpositioning
the G+ gr
o protect ChT induced ovarian failure.

ung women,
 ood which is recognised by the test.
ary findings. receptor positivity, Cerb2 positivity, lymph node involvement and staging no statistical significance
rogesterone
of bisphosphonates in early breast cancer versus non use for the overall number of deaths (summary OR: 0.708
less there
nses seems
(partial to be a non
or complete), 29 significant trend forby
(38.2%) confirmed better outcomes
follow-up (F/U)in patientsamong
imaging, receiving treatment.
76 pts with ≥6 Until further
months F/U
BCand
pts TOI-B
with prior
scoresHER2-directed
were balancedtherapy for randomization
between to tx with
arms. Mean changes T-DM1 orscores
to baseline capecitabine +L
were significantly better in B
sistent with E2100 data, which also demonstrated significantly better scores in
development and application of biostatistical informatics for proteomic spectrometry. the BV+PAC arm compared with
2003–2006, respectively). Survival improved significantly across diagnosis time periods, by 26%, 44% and 52%
be years),
2.8 explained almost fully
measurable by the(91/100/88%).
disease use of new agents in number
Median the management of the disease.
of cycles (range) received were (A/B/C): 6 (1–25
d patients
7 allowed prolonging the infusion-free
(5.2%) developed survival. (12 in 50 Gy, 3 in 30 Gy, 2 in 28.5 Gy) out of 327 with RTOG s
moist desquamation
s that a defense response is provoked in breast cancer patients. Furthermore, genes involved in lipid- and stero
growing tumorasthenia
(N pts) were and the(5),
immune system
hand-foot of the host.
syndrome We believe that
(4), neutropenia (20),this tool neutropenia
febrile can constitute a neutropenic
(1), supplement to ex
infec

velopment of SREs.asInhibition
he PI3K pathway, judged byof the
RANKL, a central
presence mediator PIK3CA
of oncogenic of osteoclast activation
mutations or lowand
PTENdifferentiation, mayassoc
expression, was dela
mab unresponsive breast cancer or
he gene therapy or chemotherapy alone. to prevent emergence of resistance. We are currently analyzing a cohort of
hibition obtained
ong inhibition using the gene therapy
of EGFR/ErbB2-related or chemotherapy
signaling. alone. These
In KPL4 xenografts results
IMO alone indicate with
interferes that ErbB
this combined ther
signal transdu
over, we provided
= 0.008), nausea the
(P =first evidence
0.003), of a (P
vomiting TLR9 and ErbB
= 0.041), interaction
pain at membrane
(P = 0.003), fatigue (P =level as novel
0.018) mechanism
and insomnia (P <of0.0
a
receiving standard care alone.
). When capecitabine was added to ED significantly more patients had documented pCR (EDC: 61/256, 23.8% v
n 27% of pts. Number of metastases sites at administration of Celiptium included one site in 21%, two sites in 3
rofile
The willshowed
cells aim at identifying
an intense patients
staining who are particularly
of vimentin, sensitiveintermediate
a mesenchymal to such drug filament
family protein and no cytoker
fen (p = 0.01; odds ratio 2.47; CI 1.20–5.07) and lymphoedema (p = 0.04 odds ratio 2.03; CI 1.04–3.94).
emotherapy, aromatase
attern of therapy inhibitors
response or tamoxifen
were obtained and pain.
with rapidly responding CETC changes over several logs in response t
improve therapy results and spare unnecessary treatments
d and basal LV segments in left-sided patients was respectively 12.8, 5.4 and 4.5 Gy. The median LV segmental
y face a diagnosis of BC. Better tools and strategies to manage these long-term consequences of the disease a
were retrieved from tumor data for which the analysis performed. The distance between blood heterozygote and

f other
nes factors known
of previous to confer4;trastuzumab-resistance
chemotherapy range 1 to 9; 93.4% of (p95Her2,
pts received PTEN-loss)
PLD afterappears necessary.
≥2 previous chemotherapies). Pr
onventional
he APR group, anthracycline
regardless of therapy.
whether A favorable ECOG performance
they had breast cancer or anotherstatuscancer
was the only
type independent
(differences predictive
of 16.6% and f
ents, the APR regimen
e pathologically gradedprovided
as G2 and better efficacy
G3. 49% over
of the the control
patients wereregimen in the prevention
axillary lymph node positive. of CINV.
High cytoplasmic
rane expression of Lck provides better clinical outcome in those breast cancer
68.1% (p < 0.001). The relation between macrometastases and tumour size was similar (6.4%, 21.6%, patients. Further investigations
31.8%, a
s study
5). micrometastases
The figures for delta-ALAD are awere
prelude
38.89 toU/L
macrometastases and can not
(95% CI = 36.73–41.05), andbe41.01
seen U/L
as a(95%
different phenomenon re
CI =37.72–44.30),
ents is significantly
in controls was of 20.6%higherand
than in that
LABCinofbenign
25.4%tumour
(NS). Thepatients.
patients who had h2N-OE presented the polymorphism
little perspective to individualized treatment
medication. The mean number of injections in cycles 1–6 wason a genomic alteration
similar besides able
in the two to let known
groups: 42.0 forpharmagenomic
Hospira filgras
ve alternative to Neupogen for the primary prophylaxis of neutropenia.
comprehensive analysis (all 14 trials included, OR: 0.84, 95% CI 0.65–1.09 p = 0.197), in postmenopausal patie
atment.
with 18% of patients having at least one cerebellar lesion at the time of CT and/or MNR diagnosis; brain was th
al.4%
reports. Further
Vs 24.2%; p =investigation
0.001) and HER2 of riskpositive
factors (40%
for BMVsmay 14%; help
p =identify
0.001) subgroups of patients
was also higher in thefor whom
study CNS ima
population.
nt in this subset of patients.
group (0.16). Median time to cerebral metastases from inclusion was 0.8 years (range 0.5–2.7) for HER2 pos pat
es
s andnot 6seam
yearstofor
have
the aNAC
highand
riskACof groups,
brain metastases.
respectively. Since
Ratesmore than half of the HER2
of breast-conserving pos patients
surgery (BCS) weredeveloped
57.6% an b
though, patients with a pathological complete response had excellent survival rates at 10 years, new phase III t
te
ewerBM less
relapse group (panthracycline
cardiotoxic < 0.001; p =formulations,
0.032; p &= 0.029)Conclusion: Biologicaland
capecitabine, gemcitabine, markers of primary BC significant
vinorelbine.
ounds, the balance between benefits and risks/costs should be carefully weighed.
5 times higher and amounted to 0.3% of the total number of screening women over 40 years (in Moscow – 0.2%
lvement
50 studies of (15.4%)
lymph nodes in disease).
reported We are
racial data. going
Within theto 50improve
studies,the 90%quality
of theofparticipants
data collection
wereinCaucasians.
order to give Ofan
thea
t breast
ere cancer
presence of research to the tumor
a Her2+ index global (plevel. WithPPV
= 0.04, the= growing
69%, NPV incidence
= 65%), of and
breast cancer worldwide,quantity
moderate/extensive it is import
of D
mors with theorlatter
ced nausea properties
vomiting. In total,may bepatients
403 less suitable
(93.5%)for were
more assessable
localized therapy
for thesuch
primaryas partial breast
endpoint, irradiation
with few naus
udies
responsible for some increase in DNA biosynthesis in case of such pathology. The obtained dates about the pe
using identical chemotherapy regimens. The observation and management of emesis could modify inc
erum of patients with mastopathy, we propose to use in early diagnostic of breast cancer.
 at resist treatment and give rise to the bulk of the more differentiated tumor cells. Thus, a tumor can be consid
ciple receptor, TGFβRII. This was supported by changes in epithelial cell cytoskeleton, with reduced cell-cell adh
=ays91)involved in T2
had T1 or stromal
tumour cell(diameter
induced tumour
of 5 cmsprogression is of
or less). Out essential to inhibit
116 chest x-ray, initiation of the
113 (97.4%) metastatic
showed cascad
no metastas
be associated
ent with immense
does not worsen prognosis. patient
In theanxiety. In our cohort
latest update none from
on material of theDanish
patients had Cancer
Breast lung metastasis. Therefore
Coopertive Group, D
t.
xane-containing chemotherapy in the (neo)adjuvant setting (doxorubicin–cyclophosphamide ×4 allowed for nod
ation
19). for grade 2–4 diarrhoea in 3 patients; grade 2 thoracic pain, grade 2 arrhythmia, coronary vasospasm and
pdiffer
will deliver insight
between if these
the three arms.cells can identify patients with increased risk for recurrence who might benefit from
ue achieved a significantly better TTP and OS with the subsequent treatment.
eases
able). in VEGF on
Invasive discontinuation
ductal of bevacizumab
carcinoma (IDC) was the maincould result in a
histological more aggressive
subtype disease.
(89%). In 86 Much remains
cases (96%), to bo
HER2 was
rch to assess
to distant the value
relapse oflocal
2.1 or adjuvant treatment
relapse for these
1.6. Single BM was tumours.
diagnosed in 22%, and multiple metastases in 26% of
s 52.5 and 60.2 for contralateral BC diagnosis, with the median period from first to second BC diagnosis 86 mon
ore oftenrespectively
months, presented as(pan= IBC. BBCMedian
0.040). is an unusual clinicalfrom
time interval entity and because
distant of its
metastasis to atypical and complex
brain metastasis werepresen
20.6,
rain metastasis
tients presented with metastatic breast cancer (MBC). Seven patients received neoadjuvant, eigthy patients rec
atLNvisceral sites
and their of the patients
matching invasiveinitially
carcinoma harboured gain/amplification of 1q31–32 and loss of 16q12, 16q21 a
oss of 16q and gain 1q are the earliest genetic changes
oor prognosis-profile (strictly equal proportions among the in this
2 LNfamily of lesions
groups). Medianthat lead towas
follow-up the10.3
activation
years:of the
dista
nodes)
patientsand 70-gene
were profile (good
then classified into vs. poor) allows
different stratifying
prognostic groupspatients
based onamong subgroups
the derived for whom
PIs. The tailored
survival treat
probabilitie
in a risk prediction model to improve the prediction performance.
mples (Pearson correlation coefficient = 0.215, p < 0.05). The highest levels of both NIS and RARA expression w
t pts received docetaxel- (65.2%) or paclitaxel-containing (28.4%) regimens. G-CSF prophylaxis was used in 69.
SP and,
sion for FLG treated
significantly patients,
correlates with improved
disease freeCT and
delivery. Patients
overall survivaltreated with less
in estrogen than 7positive
receptor days ofand
FLGnegative
experienceca
ssues.
, nipple discharge in 2 patients, scaling of the skin in 2 patients, sub-nipple lump in 2 and lumbar pain in one pa
d expression
for denosumab of hormonal receptors
and therefore couldwhile a relatively
not be estimated.large
Thepercentage
median time (47%) wason-study
to first triple negative
SRE was 806 days for
el study with denosumab.
mary
the 84 surgery we respectively.
patients, have examined the was
There presence
a 93.9%of tumour cells and
(p = 0.344) by immunobead
72.6% (p = 0.999)selection (IMS) and between
concordance characteriza
blo
eisatable to deliver
superior edgeclinically
of 2.48 cmrelevant
(0–4.5information
cm), at medialthatedge
is notofinferior
1.57 cm to(-1–2.7
the detection
cm), at of DTCsedge
lateral in theofbone
2.46 marrow
cm (0–5
2-D planning. Based on this data, we plan to continue to accrue more patients.
0.006, Cohen's d = 0.40) and executive functioning (P = 0.005, Cohen's d = 0.41) and worse than exemestane
8 andmight
ifen 1 pt'shave a differential
tumour effecton
was not visible onMRI.
cognition in various age
TNBC comprised 19%groups. Our results
of the total underscorewith
study population the aneed to inclu
median ag
r space.
R and SRFurthermore,
as independent increased kep reflecting
parameters. the rapid
Of the latter two, aRreturn of contrast
did not influence into the vasculature
survival (odds ratiosuggests that ca
(OR) = 1.043, n
y of selfurticaria,
ushing, regulation.
dermatitis, erythema, pruritus and acne. From this group of patients 74 (82.6%) have had elev
sceptibility
and T, to ∼950 mg/m2 and ∼55ofmg/m2,
to the development chemotherapy-induced
respectively). Time cutaneous
to diseasereactions. Elevated
progression urinary survival
and overall Dol is one of th
were si
er these data support the use of dose reducing X, including the possibility of starting at
(histological examination: negative for malignancy). The other two had MRI who was negative and the techniqu a lower dose (<1,250 m
d cytologic
normal examinations
breast examinationduring the years
(p < 0.001). in those
While 15.1%patients who have
of the subjects nipple
with excretion
suspicious for a long findings
examination time as the
werem
PR was seen in 6 patients (24%) and 10 patients (40%) respectively. ER status changed from positive to negati
rG-CSF
ER and andPR129
respectively
(5%) did not.no change was
1043 pts observed
with stable with regards to
or decreased hormonal
CA27.29 adjuvant
received treatment.
G-CSF (41%) and A study
1175with
did na
nt correlation
pooled T or Antbetween
(T+Ant) the administration
cohorts of G-CSF and
were independently elevated
powered andCA27.29
analyzedlevels
usingdirectly
2-sidedafter CHT. log-rank
stratified This could
tesb
B arms
d not of the
differ respective
between arms. chemotherapies Conclusions: The overall treatment effect of comb
y to G/C. Updated CBR, PFS, and OS for all 120 patients and exploratory correlative analyses of PARP expressio
es (p
being developed,
= 0.009), sincean
and again the intervention
inverse seemed
correlation not being
between targeted
estradiol enough.
and the expression of c-erb-B2 (p = 0.04). Wh
dherapy.
show aRecently,
biologically less aggressive
guidelines phenotype
have begun to include clinical risk factors as part of fracture risk assessment. For e
dations now use overall fracture risk (clinical risk factors with or without BMD) to determine who requires preve
e
G3 anthrombocytopenia
abnormally high risk wasofdocumented
death. These facts AC.
during are G3
important in thewas
neutropenia discussion of options
more frequent forpaclitaxel
after adjuvant treatmen
and capec
es
en found between the increase or the decrease of ECD values and PD or non-PD respectively (p = 0.0001).that
and feasibility was in line with the findings of the ECTO trial. The study was therefore closed confirming Mort
e therapeutic
nts were women. implications.
Most of them were breast cancer patients (60.2%), followed by relatives or friends (32.5%) an
rds or groupNo.
ts; median therapy would
of prior be welcome.
chemo-lines for metastatic disease 3 (range 0–17); H-resistance in 97% of pts; prior taxa
and NY-ESO-1 C/T antigens in MBC tissues.development.
ommended dose and schedule for further Final results,
MAGE-A1, MAGE-A3/4 PK and biomarker
and NY-ESO-1 antigensdata
werewill be presented.
found to be expr
rther tests need to be performed on additional MBC tumor samples with respect to the expression of these C/T
 n patients operated after neoadjuvant chemotherapy (p < 0.05); the reduction of iodide transporter expression
andwho
men further studied.
delayed were more likely to live in rural areas (OR = 7.9, 95%CI [2.1–29.6]), to have a higher level of e
matic women to present
>1 month was associatedquickly
withtothe
a physician
women self even if they of
detection do the
not cancer
have known
(OR =risk factors
12.5, 95%CI and if they live
= [5–33]), withinthe
rurad
persed medical services and care units. Educational programmes for physicians could help them to reduce diag
ases.
atientsFive
permicrometastases
year in the base and
case64 ITC were
scenario. foundresults
These among the
are 69 true to
sensitive positive cases originally
chemotherapy regarded
price, to relative as ITC.
usage
adjuvant chemotherapy in comparison to Adjuvant!Online or stGallen criteria. As patient's quality of life and rat
patients as compared to normal volunteers. Mean concentration for CXCL9 was 851 pg/ml (range: 121–3941) an
xpression
rstood. Threeis aimportant
good approach toof
classes select candidate
genetic loci havebiomarker to set-up“high-penetrance”
been identified: blood assays cancer screening.
genes, such as BRCA1 a
SP1for
2.6 and NEK10,
each but also
patient. UICC“gene
stage deserts”. For the
was II in 114 mostand
women part,
III the loci
in 66 were not
women. previously
Serum E2 wassuspected
suppressedtoto
bevalues
related
<
munologic
sion of thesemechanisms.
treatments in the following international guidelines was analyzed: American Society of Clinical Onc
mend adjuvant trastuzumab
arting on tamoxifen after data
were included were
in the presented
study cohort.in 2005. Following
Continuous use of initial data treatment
endocrine on adjuvant AIsdetermined
was with the re
switch
as of 2.0with
obtained (SD a=short
1.3) years. Of the
exposure of 9patients
weeks to followed for fiveraising
Trastuzumab years,the
51% discontinued
question of the any endocrine
optimal treatme
duration of an
was overexpressed in 17% of BC and was associated with low grade, ER+ and normal expressions of p53, ATM
ew avenues for therapeutic intervention.
nd G2/M arrest followed by sub-G1 accumulation of apoptotic cells in time- and dose-dependent manner. During
ult to treat therapeutic agents. Therefore, HMPS may be a potential therapeutic candidate to treat the recurrent
ean follow up of 854 days, respectively. The difference in frequency of late toxicity was not statistical significan
0.4) compared
Gy/5f/1w to the
to tumor bedconventional
and Group Bschedule.
(n = 17) The
43.2reduction
Gy/16f/22indacute toxicity
plus boost 8.1inGy/3f/3
patients
d. treated with were
All patients hypofractio
tested
al fractionation). However, this is an ongoing study and for statistically confident conclusions an
and 133 (19.3%) were HR negative. Lymph nodes were positive in 335 (48.2%) pts and negative in 368 (51.8% investigation o
esented
rly on grey-scale imaging. In 23 patients, SLN were identified as areas of contrast accumulation within ill-define
e theanalyses
sion numberswere
of patients requiring
performed primary
on whole bloodorsamples
secondary
fromaxillary surgery.classified
BC survivors This technique mayfatigued
as chronic also be (CF)
applicab
2–6
rcancer
to develop preventive strategies.
breast cases. Increased UCP4 expression was significantly associated with P53, ki67 overexpression, wit
ults of our study suggest that UCP4 as an uncoupling protein of mitochondrial membrane is implicated in the ap
57% correlation, p < 0.05, Chi Squared). There was also a positive correlation between lower tumour grades 1 a
is. However,
re not long-term
consistent follow-up
(Table) is required
due to various trial to determine
designs, this.
differences in population and trial duration, and effect of p
investigated in patients with BC. Most trials are not designed
eceptors and treated with inadequate anthracyclines dose died within shorter to evaluate cognitive
periodfunctioning,
of time after and more stud
diagnosis (lo
lylower
stagethan
breast cancer patients. Our data do not support a significant prognostic role for HER2
that of patients with negative margin (92.0% vs. 95.8%, p = 0.49), but the 5 years ultimate local co overexpression in
se the risk
d either of localofrecurrence
6 cycles significantly,
fluorouracil, but lowered ultimate
epirubicin, cyclophosphamide local
(FEC) control
(18) or 3 rate
cyclescompared with negative
of FEC followed marg
by 3 cycles
ltests])
patient(Table).
who was Before the first
switched cycle of chemotherapy,
inappropriately. none had blood
33% of post-menopausal glucose risk
moderate levels in either
patients who the impaired
should haveglu
s
atients did not switch appropriately. This may reflect the nature of an evolving complex evidence base and high
stagerecurrence
year breast ca diagnosed
rates via IGWLBB was as high as 81.5%. Then,
Results: since patients
Elderly when M were detected
(pts) ≥75 yr were via less
imaging,
likelyra
t
omples
TAM, (106
and results from the
preoperative BIG 1–98
samples fromtrial showcancer
breast that letrozole
patients(LET)
and 24significantly
from healthyreduces recurrences,
age matched femaleregardles
contro
rpoptosis
miRNA expression
increased to profile
1.5%.and with various biopathologic
Simultaneously a toxic damage parameters of breast
of cells observed at cancer. In this,oflies
conservation the stroma.
tumor expecta
ar recurrence-free survival (90.3% vs. 93.2%, respectively; P = 0.32) or overall survival, but patients with pN0i+
ors may
ation besupport,
and limited. but were inconsistent in signposting to services appropriate to the needs of women from the
s staff and
ecord) had services.
elevated Facilitating peer
levels of NTx support
before as well
starting as providing,
taxanes (median and signposting
value: 8839 BCE;to,range:
culturally appropriate
38904–51.9 BCE ser
(no
nce. There were no false positives in our series.
r avoid a second
to localize operation.assessed.
and surgically TIC, in ourInexperience, is a such
the same time simple, cost-effective
tissue and rapid
specimen was much intra-operative
more accurate assessme
to tempo
lls, by 48 hrs, MOs expressed maximal levels of TEM8 mRNA (approx. 70 fold increase over reference MOs). Aro
s of CLBC. Results of an analysis which allows for the reporting of multiple events within an individual will be re

diagnostic tool in were

without invasion the work-up
excludedof from
male the
breast carcinomas.
analysis.
6en in decision-making
wks). Among 18 pts with regarding prophylactic
measurable disease,surgery or chemoprevention.
duration of response was ≥4 mo for 13 pts and ≥6 mo for 11 pt
r (density) in vascular endothelium sections of tumor tissue with comparative histological subtype and grade wa
umors
ess andand pathological
permitted evaluation
to enroll of BC.
to L+C for Much
a total higher
of 408 pts.VEGFR2
TTP anddensity and
OS were vascularity
evaluated in PABC
using tumor
Kaplan tissue
Meier ma
analyse
progression with L+C but no significant improvement in OS. TTP cox model indicated a significant trt effect and
ned & re-imaged prone on an in-house platform with an aperture through which index breast falls. Partial-breas
supine
s were LAD NTDmean
obtained doses of
from clinical ≥12 Gy,
records, and
and shouldwere
women be used with for
followed caution in smaller-breasted
recurrence women
and death. Insulin in measure
was whom th
70. Median follow-up was 11.9 years. Mean insulin level was 44.6±31.1 pmol/L. 193 (37.7%) received
onal capacity of the ER transcriptional pathway, leading to an aggressive estrogen independent cancer. adjuvant
rs following diagnosis, the actuarial rate for time to metastases became shorter in the last decade (35% vs 43%
systemic
east therapy.
conserving However,
therapy, if metastases occur
post-mastectomy chestshortly after diagnosis
wall radiation, and for of
theM0 patients,ofthey
palliation appear
painful sooner, whic
or symptomatic
asssignificant
populations and provides
increase a means
in expression of for better
a panel ofensuring equity in with
genes associated access to care.to
Epithelial The use of checklists
Mesenchymal and alloc
Transition (EM
cade and may represent potential therapeutic targets to inhibit MSC-breast cancer interactions
lated gene promoters ESR1 (p = 0.0112) and 14–3-3s (p = 0.0047). Presence of methylated ESR1 in serum of b
ave
ease. clinical
Duringsignificance. In the future
a 12 to 24 months this of
follow-up panel
114 of genes detected
patients could breast
of the primary be useful as markers
cancer for positivity
group CTC early detectio
was
humor cells in blooddisease
micrometastatic and bone marrowto
compared was significantly
node increasedifby
negative patients, molecular
staged analysis
with ALND of a multi-marker
(log-rank p < 0.0001;gene
HR 3.p
Treatment
elated recommendations
to probability of responsefor to
systemic therapy
both drugs (p <should
0.005),not take
even ininto
the account
subgroups theTopoIIa
presence of a single
negative microm
and MAPtau
onse
ill provide us with information about the properties of DTC important for the understanding of the metastaticpos
to treatment with both drugs; Bcl-2 overexpression is related to response only in the subgroup MAPtau ca
s.e male pt was included. The median number of cycles was 7 (range 1–39) with a medium follow up of 16 month
s especially
deep attractive(Arm
vein thrombosis for elderly
A, 125pts.
mg), fatigue (Arm A, 125 mg), gallbladder enlargement (Arm B, 125 mg+D 75
tesanib PK.
varian cancer. Main drug-related toxicities were febrile neutropenia (gr 3/4: 19.7%), and fatigue (gr 2/3: 31.0%)
ose, schedule and adequate translational research to optimize the development of polo-kinase 1 inhibitors.
plified). Of these, 100 pts were treated with adjuvant trastuzumab-based therapy. At a median follow-up of 36 m
status
kg q2windependently
or 15 mg/kg q3w distinguishes
combined pts withwith a higher
a taxane risk or
(alone of CNS
with metastases.
another CT) orIt is however presumable
non-anthracycline that, in s
CT according
aclitaxel or docetaxel monotherapy. Mean duration of therapy was 7.0±4.7 months for Bev and
patients that were TopoIIA positive, 2 had histological CR (29%). Of 14/28 patients that were Topo IIA negative, 4.7±3.1 months
ients on Tamoxifen and 28/65 (43%) on Letrozole. 2–4 weeks after radiotherapy complete and partial remission
xic, well-tolerated,
) confirmed to haveinexpensive, patient-compliant
metastasis (group treatment
B). The disease option,(median
free interval which, till date remains
duration nearly
from initial untrodden
operation g
of br
monary
results ofnodule
trials during surveillance. in combination with molecular-targeted therapies have been superior than t
with chemotherapy
drugs. Targeted therapies
cal tumor stage and hormone do treatment
play an important role in a subgroup
were statistically offactors
significant patients
forinDMFS,
combination
DFS and with
OS to
onchemothe
multivari
o pathological tumor stage.
eand
PACS 04 TAM
prior trial (p
(528 HER-2 positive
= 0.014), patients
as clinical only),
predictors forthese
ORR studies
and CB demonstrate
improvement, remarkably
respectively. consistent results: th
activity of upcoming
and telephone new hormonal
f-up: 74.9 vs 75.3 (ptreatments seems appropriate.
= 0.904). Furthermore, repeatedAnmeasures
ORR of around 10%
analysis and a CB
showed of 40% sho
no significant
lternative for hospital clinic visits. Besides reducing costs and burden on hospital clinics,
status: 47% (range 26–85%, p < 0.001). A mastectomy was performed in 44% of patients, ranging from 19% in it could be appropriate
and efforts the
3 months; to achieve optimal local
1-year survival rate istreatment
70% (95% forc.i.
each breast cancer patient.
52–82%).
breast area (86%), axilla (63%), arm (57%), or on the side of thorax (56%). Factors associated with increased r
e reduced limits)
onfidence the number of complaints,
parameters. future that
They indicate strategies for further
LAP plasma improvement
concentrations are should include
decreased nerve-sparing
by TAM. ax
Final PK ana
dies.
10 pts continue on study and 43 have discontinued, 9 due to AEs. Pts started a total of 259 cycles of tx with a m
progesterone receptor were 10.2% and 20.5%, respectively. Nine patients (23.1%) underwent neoadjuvant chem
(different in different nomograms) were tumor size, lymphovascular invasion, metastasis size in SLN, number o
and are thus
invasive applicable
lobular in different
carcinoma; institutions.
ER- status in 14 pts;All of them
PgR- in 22 include thenegative:
pts; triple results of7the
pts;preoperative US examinat
HER2/neu overexpression

s, hormonal
as status, histopathological
no postoperative findings
mortality. Univariate andsuggests
analysis serum levels
that of tumor markers werenumber
prechemotherapeutic analyzed. 31 cases
of HM (single(0.19
vs m
ociated with a pCR in univariate analysis: ER positivity, PR positivity, low pretherapeutic TGFa level and the incr
predictive
15–3 serumindex. The(DF)
levels: validation of theses
25.0±11.4 results
(DF) vs. (DR)on an independent
31.4±14.6 U/L (p =population is ongoing.
0.003); baseline CEA serum levels: (DF) 5.
mor
0001; for N0 (98.8% and 93.9%) N1–3 (90.8% and 83.6%) and N > 4 (87.1% and 71.8%), in
markers levels should be useful during follow-up, their baseline levels are not useful p=predicting relapse in
0.0001. Significan
ng adverse prognostic
nucleotide factor.After doxorubicine treatment 30.60%±31.2% of the resistant cell lines survived. Th
in the 5th exon.
Gy if RBE was assumed constant. At these dose levels, the influence of repair of sublethal damage during protra
window. However, RBE estimates are sensitive to assumptions of the model at low doses, and the choice of dose
ears.
wentPatients
surgery,with
and4areor more involved
evaluable axillary nodes
for response: should
67% of be considered
the patients receivedforbreast
PMRT conserving
if they havesurgery.
a life expectanc
A pCR in

er patient and mean effects for hospital f-up (f-up strategy 1) were €3603 and 0.750 QALYs. Mean costs and eff
S (HR, 0.85%; 95% CI, 0.72–1.00; P = 0.056), and significantly better DFS on study drug (HR, 0.83; 95% CI, 0.71
 ncer [RR 1.2 (95%CI 0.7–2.0) with a 1st degree or a 1st and a 2nd degree relative with breast cancer compared
factors than
/36 cases family
(75%): in history or age which
50% – reduced, point
in 25% to a high susceptibility to breast cancer or an impaired host defen
– enlarged.

rall
d survivalresponse
between (OS) between
rates 24–36
in the 2months.
groups:Inpartial
general, it can be
response said,
rates that
were patients
64.51% in who
grouprespond to chemotherapy
B compared to only 51.6
ant and the first-line setting.
was performed for 42% of patients after the first cycle and for 73% within the first 3 cycles. The control data a
oded samples with known mutations.
f this
We pilot project
observed 25/40was to introduce
responses genetic
(CR+PR) to T ±testing into the
CT (62.5%) national
and program ofinearly
CNS metastases 20/42detection of breast
pts (47.6%); andTTP
median ov
m). The median age was 58 year (range, 32–79). 15 patients underwent chemotherapy before entering trial. Adv

e of the XRCC1, XPD and GST polymorphisms evaluated conferred an increased risk of acute skin radiation-induc
nd family history of breast cancer was positive in two patients. Average time from start of the symptoms to diag
m) making
hermore the
we prognosis
have shown ominous.
that SphK1Our experience
inhibition highlightsisthe
by docetaxel need to develop
a two-step educational
process involving an awareness progra
initial loss of enzy

yols
and ovarian
(<110 function.
ng/ml) at all Currently there
time points. is a big
Patients public
within theand individual
second groupinterest of breast
exhibited cancer
increased affected
levels at the women in
end of ra
ted
3.1%, SP-D expression(pat<all
respectively time points
0.0001). suggests thatanalysis,
In a multivariable this molecule mayfor
adjusting beage,
a more sensitive
period marker T-classificati
of diagnosis, of lung infla
ofcular
co-morbidity and other
lymph nodes. potentialdied
Four patients confounders. In order to find a biological explanation for the improvement in
in breast cancer.
ation or omitting axillary nodal staging, especially
eters such as ductal carcinoma (HR 2.3; CI 1.3–4.4), in G3
patients with
(HR 2.0; CInegative
1.2–3.4) findings
negativeinsteroid
conventional
receptorsimaging.
(HR 10.1
based mostly on histological and biological features of malignancy because TNM classification is less useful in t
margins was performed all in of these patients. In one patient mastectomy was necessary because neoplastic c
t andoncogenesis,
east shortening thewetime
haveofgenerated
treatmentconditional
in majoritymouse
of patients
models for BRCA1- and BRCA2-associated hereditary b
or recurrences invariably remain sensitive to retreatment with these drugs. These results data suggest that (par
er taste
bjects and
with a smell changes
‘persistent’ usemay improveAI
of adjuvant the outcome ofwill
medication) cancer therapy, for
be evaluated reduce the cost
the first timeof care,
after and
one improve
year and a

arrays,
ding gene expression
psychosocial supportarrays and focused
and being their formutation analysis
the family (including
are explored. TP53).
Having anThe pathology
important roleof
asthe
BCN tumors
in thewt
idelines must provide information and support for the BCN how to organize a specialised nurse consultation
81.2% (p = 0.049) in control. During follow-up, the treatment failed in 15 patients (20.8%) in the study group atae
up, but breast
rimary not for cancer
distantbecame
metastasis. Further prospective
immunohistochemical 3+studies are necessary
in metastatic cancer to confirm
during these
follow up.results.
the newductal
nvasive features of the tumor.
carcinoma, c erb b2-positive
10 patients (13.2%) were patients should
invasive be treated
lobular withMedian
carcinoma. trastuzumab-based
DFS (25%) and therapy if
OS (16%
get a decision.
rogesteron receptor negativity (p = 0.003), axillary lymph node involvement (p = 0.0001), perinodal invasion (p
scintigraphy images. Sentinel node was identified at surgery in 24 patients.
-based therapy (P = 0.047). Also hematotoxicity grade 2–4 was noticed more often among 3R/3R homozygotes
studies aremedication
ncomitant warranted.will be presented.
01), location (pif =
demonstrate a simple intervention
0.01), and such as standardized
lymph-node-status written
(p = 0.03). The onlyinformation throughout the
statistically-significant first treatment
prognostic paramete y
grade
ysis theand progesterone-receptor,
most and b)were
notable prognostic factors The limited prognostic
nodal status valuesignificant,
(the most of various both
immunohistochemical paramet
by clinical assessment an
Selated
in SP decrease
pts was 38%of risk
andin23.8%
the whole population,
respectively (p =warrants further
0.009). The investigation.
overall 5-year and 10 year DFS was 45% and 32.1
CI 1.39–3.13) were unfavorable prognostic factors in the first five years after surgery and lost their prognostic
sions. One to
favorable beingsuffered
patient unfavorable.
a burnMore
wound then 3 involved
due axillary lymph
to heat conduction by anodes and LVIwire
localization are placed
time-independent
in the tumorunfav
befo
placement of a localization wire before the procedure should be avoided.
with the CT and to a mean of 92% (±5.9) with the NCT. In the controlateral breast the dose delivered to 5% of
fe lung and controlateral
H3 acetylation breast sparing,
was increased after TSA while maintaining
treatment. the of
Addition same
200PTVnM coverage
TSA increased sensitivity to docetaxel i
itivity
12% ofto docetaxel
pts; no patient butdeveloped
only in MCF-7 cells
febrile suggesting diarrhoea,
neutropenia; a cell line specific
mucositiseffect
and using this histonedid
nausea/vomiting deacetylation
not exceed
spital admission.
ze was described >2 cm in 53.2%, <2 cm in 46.8%. Lymph nodes were positive in 32.2% and negative in 67.8%
ecific histology needs training and diagnostic experience in order to minimize false further therapeutic interven
eLVEF
aggressive
declinepathological characteristics
<50%. At baseline compared
all available to non-basal
TnIs were subtype,
<0.06 ng/ml. confirming
During treatment the heterogeneity
22/37 pts (59%) of hadthe g
ele
dated
0 (40%)results will be said
oncologists presented including
they always pts with 10
(75–100%); CHF and LVEF
(40%) < 50%
said frequently (50–75%) and 5 (20%) said sometim
the Oncologists would calculate the outcomes for mortality benefit and
atients histopathological examination revealed a microscopic focus of viable tumor would discuss chemotherapy
cells at the marginwith their
of the tu
more, our results have led to the decision to perform a “hot retraction” to burn the needle tract in our ensuing i
 patients (43.1%) had postmenopausal status. 88 patients were classified as having early breast cancers (13 in
ing has significant
of either correlation
bupivacaine with staging
or ropivacaine alone.ofThe
disease.
mean Unfortunately, thereiniseach
number of patients no significance
study was 71of outcome among
(range 30–120)
ving LA pre-incision or pre-closure. Only one study has studied the effect of LA on long term pain. More
n section examination. All but 1 of these 4 SN-positive patients were ultimately proven to have invasive breast studies
itive histological examination; moreover, the 9% SN-positivity rate found in this study exceeds the 5% threshol
hipdirection.
CC between VEGF gene 936
Per patient and C/T polymorphism
in every direction, and coexistance
MM of D1–3 veryof invasive
well ductal
predicted thebreast carcinoma
eventual in a error
systematic samplo
ue
agetowas
strict
35patient
years inpositioning withand
the G+ group FCH38.5
and years
a tolerance
in the of
G- 5group.
mm in29lateral (Lat) and
pts received a cranial-caudal
taxane free ChT(CC)
(15directio
in G+,
 aging no statistical significance was found. On the other hand in patients with Estrogen receptor positivity (p =
of deaths (summary OR: 0.708, 95% CI: 0.482 to 1.041, P-value = 0.079), disease recurrences (summary OR: 0.
ceiving treatment.
ng 76 pts with ≥6 Until further
months evidence
F/U or from new trials
who discontinued will become
(8/29/08 available adjuvant bisphosphonates should
data-cut).
pecitabine +L
es were significantly better in BV+D treatment arms compared with PL+D except for week 9 with 15 mg/kg BV a
he BV+PAC
metry. arm compared with PAC alone.
periods, by 26%, 44% and 52% respectively in each time period as compared to the first (1991–1994), (1995–1
isease.
received were (A/B/C): 6 (1–25)/4 (1–15)/6 (1–18). Incidence of febrile neutropenia and neutropenic infections w
8.5 Gy) out of 327 with RTOG skin toxicity data available. 686 patients had 2-year photographic assessments, w
nes involved in lipid- and steroid metabolism seem to be differentially expressed between cases and controls. A
constitute
tropenia a neutropenic
(1), supplement to existing
infection diagnostic
(1), technology,
neutropenic but
colitis (1), noalso offer
toxic a breast
death. cancer
Efficacy wastest in areas
observed at were
each ma
DL

n and
ow PTENdifferentiation, mayassociated
expression, was delay or prevent SREs.
with poor We assessed
prognosis the efficacy and
after Trastuzumab safety
therapy. of denosumab,
Furthermore, the an invest
combined
currently analyzing a cohort of 50 patients who received neo-adjuvant Trastuzumab-based therapy to test whet
dicate with
rferes that ErbB
this combined therapy may
signal transduction, be of
while potential therapeutic
trastuzumab value in breast
is totally ineffective. cancer. an ErbB-dependent s
IMO induces
=level as novel
0.018) mechanism
and insomnia (P <of0.0005),
action. Altogether,
the majoritywe
of propose
symptoms IMO plus trastuzumab
maintaining as an effective
the improvement over therapeutic
the 6 cycless
ted pCR (EDC: 61/256, 23.8% vs. ED: 39/256, 15.2%; p = 0.036) despite the fact that significantly less patients
one site in 21%, two sites in 37% and more than three sites in 42% of pts. Distribution of metastases type is as
amily
lament protein and no cytokeratin 18, the epithelial counterpart in breast epithelial cells. Time-lapse videograp
atio 2.03; CI 1.04–3.94).
over several logs in response to chemotherapy and slow and long-lasting changes extending over several years
Gy. The median LV segmental dose in left-sided patients was 3 Gy. A reduction in S was observed immediately
consequences of the disease and related treatments need to be implemented and monitored and health care p
etween blood heterozygote and tumor was measured. If it was greater than the mean + standard deviation valu

pears necessary.
2 previous chemotherapies). Prior CAC treatment was adjuvant, anti-metastatic, or both in 14%, 46%, or 40% of
e
ypeonly independent
(differences predictive
of 16.6% and factor.
10.8% vs. control, respectively, see table). Similar trends were seen in subsets o
revention of CINV.
ode positive. High cytoplasmic Src and membrane Y419Src kinase expression levels were significantly associat
atients. Further investigations
s similar (6.4%, 21.6%, 31.8%, are
andneeded to determine while
54.1% respectively) underlying mechanisms
the proportion for this with
of patients observation.
pN0i+ and pN1mi w
as a different phenomenon
U/L (95% CI =37.72–44.30), respectively (p>0.05).
OE presented the polymorphism in 36% vs 17.2% who did not (OR 1.6, CI 95% 1.1–2.7, p = 0.021). We did not f
e to let known
groups: 42.0 forpharmagenomic
Hospira filgrastim of some drugs
and 41.9 forlike trastuzumab
Neupogen. in susceptible
The confidence persons.
interval for the difference in duration
197), in postmenopausal patients (7 trials, OR: 0.82, 95% CI 0.55–1.20 p = 0.298), and in patients receiving aro
or MNR diagnosis; brain was the first site of progression for 24 patients (52%). The median time to BM was 34.2
shigher
of patients
in thefor whom
study CNS imaging
population. screening
Patients and/or
with triple prophylactic
negative tumorsstrategies should
had a shorter be warranted
overall survival (3.0 years Vs
ange 0.5–2.7) for HER2 pos patients. The brain metastases were seen earlier among patients with HER2 over-ex
HER2 pos patients
g surgery developed
(BCS) were 57.6% and brain-metastases,
48.9% for AC and closeNACsurveillance (clinical and/or
groups, respectively imaging)
(p = 0.24). DFSseams
rates necessary
at 1, 5 andev1
tes at 10 years, new phase III trials testing NAC strategies should be done to definitely answer on its impact on
arkers of primary BC significantly differ between early vs. late BM subgroup. Therefore, HER2 over-expression, n
vinorelbine.
.ver 40 years (in Moscow – 0.2%).
collection
ipants wereinCaucasians.
order to give Ofan
theaccurate estimate
325 trials, only 40 of(12.3%)
screening testwere
trials and done
program sensitivity,
outside of Northstandardized detecti
America or Western
toderate/extensive
cancer worldwide,quantity
it is important
of DCISto inperform
the indexthese
tumortrials internationally
(p < 0.001, PPV =and 78%,toNPV
include racialAbsence
= 64%). information to hel
of washou
ch as partial
imary breast
endpoint, irradiation
with few nausea or MRI-guided high-intensity
episodes (FLIE nausea scores focused
afterultrasound.
the 1st CT course were 6.02 and 6.07 for P
of emesis could modify
he obtained dates about the perception and rate of such adverse events.
increase of TK activity and decrease of TP activity at a mammary gland cancer acco
t cancer.
 s. Thus, a tumor can be considered a hierarchy defined by a maturation process analogous to normal tissue hom
eton, with reduced cell-cell adhesion and E-cadherin expression observed in epithelial cells cultured in the prese
3iation of the
(97.4%) metastatic
showed cascade. Chest x-ray of 3 patients (2.6%) showed suspicious abnormality. Subsequent
no metastasis.
had lung metastasis.
ast Cancer Therefore
Coopertive for asymptomatic,
Group, DBCG, early, operable
371 women experienced breast cancer
pregnancy patients, routine
after treatment preoperative
of breast cancer (1). cI
osphamide ×4 allowed for node-negative disease), followed by radiotherapy if indicated. After central confirma
mia, coronary vasospasm and chest pain in 1 patient each). Conclusions: This is the first adjuvant trial specific
urrence who might benefit from additional treatment approaches.

ve86
In disease. Much remains
cases (96%), HER2 wasto be learned about
overexpressed bybiologic agents, in particular
immunohistochemistry. For new trials cases,
equivocal need toHER2
establish whethe
amplification
multiple metastases in 26% of patients, remaining had 2–7 lesions. First metastatic site was brain 38%, lung 19
o second BC diagnosis 86 months. In the SBBC group 88% of pts were postmenopausal, compared to 63% in th
tos atypical and complex
brain metastasis werepresentation patients
20.6, 19.5, and with bilateral
9.0 months, breast(p
respectively cancer require
= 0.012). compound
Overall and
survival individualized
from diagnosis to
eoadjuvant, eigthy patients received adjuvant chemotherapy. MBC was detected fifty four percents of the patie
–32 and loss of 16q12, 16q21 and 16q23. In addition to the aberrations found in CCLs, in situ and matching inva
hat lead towas
ollow-up the10.3
activation
years:of the ‘luminal’
distant pathway.
metastases occurred in 141 patients (116 as first event) and 103 (20) died of t
groups for whom tailored treatment strategies should be designed
ed PIs. The survival probabilities among the patient-groups and significantly
were found assessed based on their
different andvery different
various o
clinica

both NIS and RARA expression were detected in benign breast tissue (NIS: 1.65±0.25 log10 RQ; RARA: 1.01±0.1
SF prophylaxis was used in 69.9% of pts [of which 86.6% was primary prophylaxis (PP) and 13.4% secondary pr
than 7positive
eptor days ofand
FLGnegative
experienced an increase
cancers. in G3–4N.
Expression of the estrogen receptor α and CXCL12 does not correlate.
in 2 and lumbar pain in one patient. According to the medical history information, 7 patients were smokers, on
triple negative
on-study SRE was 806 days for ZA. Denosumab also significantly delayed the time to first and subsequent on-st

election
999) (IMS) and between
concordance characterization,
blood and in bone
manymarrow
cases followed
samplesby molecular
pre- studies on a purerespectively,
and post-chemotherapy, population ofwhen
cancer
cl
onat of DTCsedge
lateral in theofbone
2.46 marrow.
cm (0–5.2 cm) and at inferior edge of 2.47 cm (1–4.5 cm). Absolute volume reduction at
1) and worse than exemestane users on information processing speed (P = 0.02, Cohen's d = 0.36). Compared
lts underscorewith
y population the aneed to include
median age of potential cognitive
42.5 yrs (range effects
34–57) andofmedian
ET in long-term
tumour sizesafety studies.
60 mm (range 40–100). In th
e vasculature
val (odds ratiosuggests that capillary
(OR) = 1.043, permeability
n.s.), whereas is also
SR showed a higher
positiveinand
TNBC.
independent effect, with an OR of 0.502
ients 74 (82.6%) have had elevated urinal Dol excretion (>20.8 mkg/mmol) 2 weeks before chemotherapy and
evated urinary survival
on and overall Dol is one of the
were first or
similar, manifestations
even slightly of this disorder
longer, amongst which could
patients be prevented
receiving lower by breast
doses of Xcancer
versus
ting at a lower dose (<1,250 mg/m2), in order to reduce the incidence of AEs.
was negative and the technique will be repeated after three months. One with suspicion of papillary carcinoma
retion
ous for a long findings
examination time as the
werematerial arrives
either high fromorthe
school last ductgraduates,
university lobe in thisthis
technique
rate wasand the diagnosis
higher in subjectsiswith
moren
hanged from positive to negative in 1 patient (4%). PR status changed from positive to negative in 4 patients (1
vant
d G-CSFtreatment.
(41%) and A study
1175with a bigger
did not (46%). cohort might address
This difference this issue.
was highly We suggest
significant that ER/PR/HER2 status shou
(p < 0.0001).
gdirectly
2-sidedafter CHT. log-rank
stratified This could be(Cap:
test a possible explanation
80% power for the
to detect HR = often observed
0.75; T+Ant: 90%increase of to
power tumor markers
detect after
HR = 0.7).
verall treatment effect of combining B with capecitabine, taxanes, or anthracyclines in RIBBON-1 is seen across
ve analyses of PARP expression and clinical response will be presented.
sion of c-erb-B2 (p = 0.04). When comparing hormone levels with each other, a significant correlation between
fracture risk assessment. For example, the FRAX algorithm for PMO further refines fracture risk assessment us
determine who requires preventive therapy. Therapy options for CTIBL include calcium and vitamin D supplem
options
uent forpaclitaxel
after adjuvant treatment with breast
and capecitabine (12%)cancer patients.
than after CMF (7%) and CMX (7%). CTC 2 LVEF modification durin
erefore closed confirming that the sequence of AT and CMF is a feasible
respectively (p = 0.0001). Moreover, with regard to OS, a statistically and very difference,
significant active therapeutic option
regardless for w
of HER2
relatives or friends (32.5%) and women not diagnosed (72%). Most questions were medical (84.3%) or psycholo
stance in 97% of pts; prior taxanes in 94% of pts (39% taxane-resistant); prior anthracyclines in 76% of pts; and
marker data
antigens werewill be presented.
found to be expressed in 33% (16/49), 33% (16/49) and 22% (11/49) of patients, respectively. Im
to the expression of these C/T antigens before being able to definitely confirm this possibly original observation
 iodide transporter expression was much less pronounced. Similarly, SLC2A1 gene correlated with tumor grade;
.6]), to have a higher level of education (2.7, [1.1–6.5]), to have a body mass index ≤25 (5.0, [1.2–10.0], to hav
k factors
2.5, 95%CI and if they live
= [5–33]), withinthe
rural areas with
diagnosis few invasive
of non medical services available
breast cancer (9.1, [2.6–33]), and with the living place o
could help them to reduce diagnosis and treatment delay in the particular population of young breast cancer wo
ses originally
herapy regarded
price, to relative as ITC. of
usage AllSt-Gallen
micrometastases were cases with
and Adjuvant!Online and interpretation depending
to risk reduction on with
associated the definition
chemothea
patient's quality of life and rational use of resources are key factors in decision-making process, Mammaprint c
851 pg/ml (range: 121–3941) and 635 pg/ml (range: 12–4327) in cancer patients and normal volunteers respect
ys cancer
ance” screening.
genes, such as BRCA1 and BRCA2; “intermediate-penetrance” genes, such as ATM and CHEK2, in which
viously
E2 wassuspected
suppressedtoto
bevalues
related to carcinogenesis,
<40 and point
pg/mL in all patients. AftertoLH-RH
new disease mechanisms.
administration, While the
a statistically risks confer
significant im
American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and St. Gallen c
ata treatment
ine on adjuvant AIsdetermined
was with the release
as theoftime
the between
ATAC findings, NCCN
start and guidelines
stop were
of therapy, updated
allowing within
a 60 daysmonths. The A
gap between
ntinued
n of the any endocrine
optimal treatment
duration before
of anti her the completion
2 therapy of five years
in the neoadjuvant (see table). Multivariate analyses showed
setting.
ormal expressions of p53, ATM and BRCA1. In cases showing coexistent precursors with invasive component, MD

ose-dependent manner. During the process of cell death induced by HMPS, mitochondrial membrane potential w
andidate to treat the recurrent breast cancer by alone or combination with other conventional anticancer agen
ty was not statistical significant (p = 0.4).
tients
3f/3 d. treated with were
All patients hypofractionated
tested using RT could beand
spirometry explained by the tests
gas diffusion BED values and by the
on D0 (before RT),dosimetric
during RT data that
(on D7 anda
conclusions
ts an investigation
and negative of late
in 368 (51.8%) effects
pts. A safetyon a largerofnumber
analysis the firstof100
patients is necessary.
pts treated with X+I demonstrated that >7
t accumulation within ill-defined nodal structures. In 2 patients, SLN were identified only as areas of contrast ac
echnique
ed mayfatigued
as chronic also be (CF)
applicable to other
2–6 years aftersuperficial
diagnosis.malignancies
Non-fatigued survivors served as controls. Several gene se
h P53, ki67 overexpression, with low expression of ER and downregulation of bcl2 in histologically poor tumor di
mbrane is implicated in the apoptosis pathway and associated with high grade breast tumors, indicating oxidat
tween lower tumour grades 1 and 2 (62 and 55% respectively) and mammaglobin A expression, whilst a negati
nd trial duration, and effect of prior chemotherapy. Data on LET were not available, but data from the BIG 1–98
ve functioning,
riod of time after and more studies
diagnosis are pneeded.
(log rank = 0.016,ThelogBIG
rank1–98
p =trial will log
0.027, provide
rank information on LET vs TAM.
p = 0.013, respectively). There we
role for HER2 overexpression in predicting survival. The independent prognostic factor is inadequate
ut the 5 years ultimate local control rate after salvage treatment in patients with close or positive margin by inv anthracycl
eles
compared with negative
of FEC followed margin.
by 3 cycles Delayed hormone
of docetaxel therapy
(21). Before eachwas a prognostic
cycle factorreceived
of FEC, patients to increased
8 mglocal recurren
of dexameth
evels in either
isk patients who the impaired
should haveglucose tolerance
switched after 2 range (ie, 7.8–11.1
to 3 years mmol/L)
on tamoxifen hadornothe diabetic range
documented (ie,27%
switch. >11.1 mmo
of low r
omplex evidence base and highlights the need for clear guideline production. In addition responsibility for ensu
Ms were detected
(pts) ≥75 yr werevia less
imaging,
likelyrate of detection
to receive CT, andof the
malign or highofrisk
incidence DMlesion was almost
was higher half
than in of all Mpts
younger (45%), and
<75 yr s
(Ta
educes
hy recurrences,
age matched femaleregardless ofthe
controls), agelevels
(Crivellari
of twoetmiRNAs
al 2008). Early
were reductions
found in DM recurrence,
to be significantly higher as observed
in blood fromwb
cancer. In this, lies the expectation that circulating miRNAs will be clinically useful as a novel
conservation of tumor stroma. In the 3 series the number of mitosis was 1.4% and apoptosis was 3.6%. It was m minimally invasive
urvival, but patients with pN0i+ cancer had less favorable 5-year breast cancer-specific survival (95.2% vs. 98.4
o the needs of women from these communities. Women were concerned that educational materials did not refle
g to,range:
CE; culturally appropriate
38904–51.9 BCE services are important
(normal value considerations.
≤64 BCE)). Ultimately,
NTx determination the6 statutory
at 3 or month of and voluntary
therapy secto
with taxane

rapid
much intra-operative
more accurate assessment
to temporarytool
andtodefinitive
allow a single stage approach
pathological findings. to axillary node
Operative status.
time was We are now
shortened usingrouti
intr
rease over reference MOs). Around this time point, conditioned-MOs showed also the highest production of mem
s within an individual will be reported to formally compare event rates.

for 13 pts and ≥6 mo for 11 pts (range 1–17 mo). For the remaining 21 pts, 17 had stable disease (≥6 wks from
tological subtype and grade was revealed a significant difference in expression level between BC and PABC tum
ularity in PABC
ted using tumor
Kaplan Meiertissue may induce
analyses. activation
The three of specific
subgroups signal pathways,
were defined as follows:dramatic tumor with
(1) pts treated progression
<3 priorand
reg
ated a significant trt effect and no effect due to prior regimens or the interaction. OS cox model indicated a sign
 index breast falls. Partial-breast CTV was defined as tumour bed (clips/tissue distortion) +15 mm margin. WB c
er-breasted
and women
death. Insulin wasin measured
whom the on position
fastingisblood
likely obtained
to be detrimental. LAD doses
postoperatively, priorfrom PBI are overall
to systemic therapy, lower
using than
a2
193 (37.7%) received
en independent cancer. adjuvant chemotherapy and 197 (38.5%) received adjuvant hormone therapy. Short and l
n the last decade (35% vs 43% vs 24%, p < 0.001). The proportion of bone metastases decreased whereas live
ents,ofthey
tion appear
painful sooner, which
or symptomatic might be mainly
metastases. The use determined
of systemic bytherapy
more aggressive tumours following
cytotoxic chemotherapy initial trea
is effective in t
The
to use of checklists
Mesenchymal and allocation
Transition tables
(EMT) in both is a and
T47D pragmatic
SK-BR-3 approach,
cell lines.which recognizes
In both the SK-BR-3thatand
the T47D
ultimate cell goal
linesofth
er interactions
methylated ESR1 in serum of breast cancer patients was associated with ER-negative phenotype (p = 0.0179).
ul as markers
ancer for positivity
group CTC early detection of breast carcinoma.
was determined in 9.6% of These findingshowever
the patients, cast someonlydoubts
one ofon the utility
these had been for early ca
positive
nalysis of a multi-marker
ND (log-rank p < 0.0001;gene panel.
HR 3.17; 95%TheCI:newly introduced
1.72–5.83 surrogateanalysis),
at multivariate markers from
but notthefor
networks
patientsofwho
apoptosis,
underwi
theTopoIIa
ps presence of a single
negative micrometastatic
and MAPtau lymphoverexpression
positive. Bcl-2 node identifiedseems
duringto complete
be relatedserial sectioning
to response in of sentinel
the subgroup no
nly in the subgroup MAPtau positive, while HER-2 gene amplification is not related to response
erstanding of the metastatic cascade, apart from the potential to better understand tumor heterogeneity in gen to anthracyclines
medium follow up of 16 months. Seven pts are still receiving treatment. In 93 pts (56%) the dose was reduced
rgement (Arm B, 125 mg+D 75 mg/m2), and migraine (Arm B, 125 mg). The motesanib MTD has not been reac
%), and fatigue (gr 2/3: 31.0%). Most frequent grade 3–4 toxicities were neutropenia (81.6%), thrombocytopeni
of polo-kinase 1 inhibitors.
y. At a median follow-up of 36 months from the diagnosis, the incidence of CNS relapse was 3% (1.3% as first re
however presumable
non-anthracycline that, in some
CT according to thecases, improvements
physician's decision,in systemic
until control
disease and overall
progression, survival associated
unacceptable toxicity orwi
w
hs for Bev and 4.7±3.1 months for CT. Grade (G) 3–5 adverse
ts that were Topo IIA negative, 4 had Histological CR (29%). events (AEs) occurring at any G in >15% of pts (r
complete and partial remission were achieved in 71/217 and 130/217 patients respectively – stable disease in 1
ate remains
ation nearly
from initial untrodden
operation groundcancer
of breast in world literature.
to the detection of mediastinal LN or lung nodules) was similar betw
pies have been superior than targeted agents administrated alone.
combination
DMFS, DFS andwith
OS to
onchemotherapy.
multivariate analysis (p < 0.05). Radiation field to include supraclavicular area or not did n

markably
espectively.consistent results: the addition of trastuzumab significantly reduces recurrence by approximately 50%
ound 10%
analysis and a CB
showed of 40% should
no significant be considered
differences between asgroups
expected
overreasonable standard
time in any benchmarks
of the PSQIII for (PSQ
subscales futuretotal:
phasep
clinics, it could be appropriate for patients with long travel distances or mobility problems
patients, ranging from 19% in France to 56% in the Netherlands (p < 0.001). Independent factors for type of b

ors associated with increased risk of experiencing pain were young age (OR = 3.62; CI: 2.25–5.82, p < 0.0001)
hould include
decreased nerve-sparing
by TAM. axillary will
Final PK analysis dissection and attention
be presented to patients
at the meeting. with
Most other chronic
common adversepain complaints.
events for the com
otal of 259 cycles of tx with a median of 4 cycles/pt (range: 1–14). SU dose was reduced from 37.5 mg/d to 25 m
%) underwent neoadjuvant chemotherapybefore surgery. The regimens included cyclophosphamide/epirubicin/fl
etastasis size in SLN, number of negative and number of positive SLNs. Mean absolute error and mean area und
7the
pts;preoperative US examination
HER2/neu overexpression of the
(ICH axilla,
3+ or FISH+)which turned
in 13 out
pts. A as a powerful
minimum independent
of 3 cycles variable.
of CT was The valida
administered (me

werenumber
eutic analyzed. 31 cases
of HM (single(0.19%) had brain
vs multiple) metastases.
was associated Median
with CSS; ages of the
estrogen patients
and were 50receptors
progesterone years (range, 47.
on prim
apeutic TGFa level and the increase of VEGF levels between the first and the second sample. In multivariate an
ongoing.
eline CEA serum levels: (DF) 5.9±4.8 vs. (DR) 7.4±6.4 ng/mL (p = 0.099). Group 2: baseline CA 15–3: (DF) 27.3
t71.8%),
useful in
p=predicting relapse in elderly
0.0001. Significant patients
independent with BC factor for OS were BC subtypes (with relative risk (RR)
prognostic
resistant cell lines survived. The silencing of PSMB7 in the resistant cell lines decreased survival to 5.87%±10.2
sublethal damage during protracted irradiation was greatly reduced. The difference in dose prescription point (a
w doses, and the choice of dose depends critically on the actual value of RBE for late reaction. Therefore, the do
RT if they havesurgery.
st conserving a life expectancy in excess
A pCR in breast and of 5 years.
axillary The has
nodes rolebeen
of postmastectomy
observed in 17 RT in women
patients with
(39%). 1–3
Left involv
ventricu

750 QALYs. Mean costs and effects for nurse-led telephone f-up (f-up strategy 2) were €3933 and 0.766 QALYs,
dy drug (HR, 0.83; 95% CI, 0.71–0.97; P = 0.022) and time to first distant metastasis (HR, 0.81; 95% CI, 0.67–0.
e with breast cancer compared to a negative family history], large tumour size [RR 1.8 (95%CI 1.1–2.9) and 5.03
ancer or an impaired host defence mechanism. It may also imply that some CBCs are metastases from the prim

who respond
group to chemotherapy
B compared present
to only 51.62% a better
in group OS than
A, while non-responders.
complete However,
response occurred treatment
only in groupduration remains
B (1.61%). The r

rst 3 cycles. The control data are similar to those reported by Lyman. After randomization, 64.9% of controls ve

arly
20/42detection of breast
pts (47.6%); andTTP
median ovarian
from cancer. Inof
the start Croatian population
T was 9.6 of 4.5 million,
months (1.3–80+). an average
Median OS fromofthe
2,200 new
start of Tbrea
wa
erapy before entering trial. Adverse event information according to CTCAE V3.0 is presented in table. No local o

sk of acute skin radiation-induced reactions.

m start of the symptoms to diagnosis was 10 months. Mean size of lump was 5.5 cm. Distribution of malignant m
educational
involving an awareness programmes
initial loss of to acquaint
enzyme activity theby
followed significance
a decreaseof
inbreast
SphK1lumps in adolescent
gene expression. Wegirls.
have demonst

east cancer
creased affected
levels at the women in preservation
end of radiation therapyofand
ovarian
duringfunction and(At
follow-up fertility.
the end:Chemotherapy induced
123.57 ng/ml, amenorrhe
Follow-up: 90th d
e sensitive marker of lung inflammation than CRP. Regarding patients of the second group, the increased
eriod of diagnosis, T-classification, number of metastatic sites, co-morbidity, use of loco-regional radiotherapy SP-Das
anation for the improvement in overall survival, the effect of type of surgery and the impact of tumor free resec
ngs
tiveinsteroid
conventional
receptorsimaging.
(HR 10.1; CI 4.5–22.4), amplification HER2 (HR 7.4; CI 3.1–17.6) as independent significan
classification is less useful in this group of patients.
necessary because neoplastic cells in re-excison specimen. In 27 (20%) patients (selective) lymphadenectomy w
BRCA2-associated hereditary breast cancer based on combined inactivation of BRCA1/2 and p53 in epithelial tis
e results data suggest that (partial) BRCA1 activity is required for induction of platinum resistance. Indeed, it ha
the cost
first timeof care,
after and
one improve
year and a the quality
second timeofafter
life oftwo
these patients.
years. (3) Time to treatment and reasons for discontinuati

The pathology
important roleof
asthe
BCN tumors
in thewas
totalrigorously assessed
organisation and information
of a breast on histological
unit was translated type,asgrade,
in themes size, lymph
coordinating n
the en
cialised nurse consultation at each important phase in the total clinical pathway of a patient with breast
s (20.8%) in the study group and 26 patients (18.1%) in the control group. In first site of recurrence analysis, lo cancer
onfirm these
ng follow up.results.
trastuzumab-based
Median DFS (25%) and therapy if nocould
OS (16%) contraindications
not reach. In univariate analyses, we couldn't find any statistical signific
= 0.0001), perinodal invasion (p = 0.0001), lymphatic (p = 0.005), perineural (p = 0.0229) and c-erbB2 (p = 0.0

en among 3R/3R homozygotes (P = 0.076). When gastrointestinal toxicity has been considered, grade > 2 was

hroughout
significant the first treatment
prognostic year for
parameters may OSimprove
on LGMcompliance and hence
were menopausal patient
status (p < outcome
0.001), grade (p < 0.001), and p
immunohistochemical parameters commonly-used in practice.
both by clinical assessment and pathological analysis, p < 0.005), positive HER2 and negative ER/PR (p < 0.05)
10 year DFS was 45% and 32.1% respectively. The 5-year and 10-year DFS in 32 SN pts was 59.4 and 37.5% res
gery and lost their prognostic role thereafter. Positive ER (ER+ vs. ER) were a favorable prognostic factor only i
LVI are placed
n wire time-independent
in the tumorunfavorable prognostic factors
before the procedure, throughout
which healed the follow-up
completely period
after conservative treatment.
st the dose delivered to 5% of volume was 1.8 Gy (±0.3) with CT and 1.3 Gy (±0.3) with NCT. Ipsilateral lung re
e
eased sensitivity to docetaxel in MCF-7 resistant cells (P = 0.007) but, in contrast, increased resistance to docet
ing this histonedid
ausea/vomiting deacetylation
not exceed inhibitor. Treatment grade
gr.2; asymptomatic with both inhibitors,
2 LVEF declinehowever, increasedinresponse
was documented 2 pts, at to
thedocetax
4th an
n 32.2% and negative in 67.8%. Nuclear grade was 1 in 6.4%, 2 in 8% and 3 in 85.6%, respectively. Overall 6 ye
se further therapeutic interventions.
ming
tmentthe heterogeneity
22/37 pts (59%) of
hadthe group
elevations in TnI. 21 pts had minimal elevations (<0.31 ng/ml). 1 pt had elevated Tn
5%) and 5 (20%) said sometimes (25–50%) use Adjuvantonline. When asked if they discussed the percentage o
scuss chemotherapy
mor cells at the marginwith their
of the patients
tumor for12–3%
and in lesionbenefit
viable and
cellsrecommend
were found chemotherapy fortract.
lining the needle 4–5%Furthermore,
benefit. As th
he needle tract in our ensuing in vivo study.
 ng early breast cancers (13 in stage I/11.2%, 46 in stage IIA/39.66%, and 28 in stage IIB/24.14%) and 28 patien
hsignificance of outcome
study was 71 among Three
(range 30–120). both stages
studiedin pre-incision
this study. Therefore, we would
LA Vs pre-closure, 3 like to concluded
looked that Vs
at pre-closure vascular
placeboa
n long term pain. More studies are needed to assess the usefulness (and safety) of using LA to control
proven to have invasive breast cancer. All 4 patients underwent axillary lymph node dissection (ALND); in 1 pati postopera
study exceeds the 5% threshold for SNLB performance maintained in most studies and guidelines.
al
hebreast carcinoma
eventual in a error
systematic sample of the
over Croatian
wholewoman.
course, In addition,the
indicating there is no anyofdata
usefulness the about described
correction genetic
protocol. Usingp
and
d a cranial-caudal (CC)
taxane free ChT (15direction
in G+, 14and to the
in G-). use
One of a correction
woman protocol.
in each group Calculated
became CTV-PTV
pregnant. One ptmargins were6intro
died within mo
trogen receptor positivity (p = 0.0005) and Ki67 positivity (p = 0.037) Cyclin D1 and in Ki67 positive patients FR
e recurrences (summary OR: 0.843, 95% CI: 0.602 to 1.181, P-value = 0.321), and bone metastases (summary
juvant bisphosphonates should not be routinely recommended as agents that may potentially alter the course
for week 9 with 15 mg/kg BV and week 33 with 7.5 mg/kg BV (Table).

the first (1991–1994), (1995–1998: HR = 0.74, p = 0.002; 1999–2002: HR = 0.56, p < 0.001; 2003–2006: HR =
a and neutropenic infections were as follows (A/B/C): 2/0/6% and 0/0/12%, respectively. Incidence of grade 3 no
r photographic assessments, with mild and marked change in breast appearance in 18.8% and 1.7% after 50 G
between cases and controls. A 96 probe TaqMan based diagnostic tool BCtect® is developed partly based on t
st cancer
cacy wastest in areas
observed at were
each mammography screening
DL with a total of is insufficient.
1 complete response, 5 partial responses (PR) and 21 stabilization

afety
py. of denosumab,
Furthermore, the an investigative
combined fully
analysis of human
PTEN andmonoclonal antibodytwice
PIK3CA identified against RANKL,
as many for the at
patients treatment of risk
increased BM
mab-based therapy to test whether PI3K pathway activation status validates as a biomarker for response predict
stinduces
O cancer. an ErbB-dependent signal inhibition also in vitro, therefore we investigated if a functional/structural in
ab as an effective
mprovement over therapeutic
the 6 cycles.strategy in trastuzumab-resistant
There were breastanxiety
also trends towards lower cancers.
and indications of less service uti
that significantly less patients completed the scheduled 6 cycles (EDC: 75% vs. ED: 97%, p < 0.0001) mainly d
bution of metastases type is as follow: 16% of pts presented visceral metastases, 25% non-visceral and 59% mi
lial cells. Time-lapse videography reveals that these cells are very motile but can be restrained by inhibition of

s extending over several years in response to hormone therapy and trastuzumab. Stem cell like staining was se
n S was observed immediately and at 2 months post-RT (p = 0.0002) in left-sided patients, but not in right-side
d monitored and health care professional should systematically address in advance these issues when dealing
mean + standard deviation value then those tumor samples were chosen as departed from heterozygote to hom

or both in 14%, 46%, or 40% of pts, respectively. The overall CBR from PLD was 32.2% (95% CI, 26.7–37.8%), w
trends were seen in subsets of breast cancer patients receiving AC or non-AC chemotherapy, and in non-breas
vels were significantly associated with decreased disease specific survival (p = 0.03, p = 0.02). Lyn was not ass
or this with
atients observation.
pN0i+ and pN1mi was constant (12.1%, 14.1%, 19.0%, 14.2%) (Table 1).

1–2.7, p = 0.021). We did not find association between age, nodal status, clinical and pathologic response, nucl
rsons.
al for the difference in duration of severe neutropenia (DSN) in cycle 1 between Hospira filgrastim and Neupoge
), and in patients receiving aromatase inhibitors (6 trials, OR: 0.79, 95% CI 0.53–1.17 p = 0.242).
e median time to BM was 34.2 months from the diagnosis of metastatic disease and 29.6 months from the star
uld be warranted
overall survival (3.0 years Vs 4.4 years; p = 0.041) compared to other patients. These patients had a shorter ti
ong patients with HER2 over-expression than among HER2 negative patients, though not significant.
=r 0.24).
imaging)DFSseams
rates necessary
at 1, 5 andeven during
10 years effective
were systemic
91%, 73% treatment.
and 53% for the NAC group and 96%, 70% and 52% for t
nitely answer on its impact on quality of life and/or in a medico-economic perspective.
efore, HER2 over-expression, negative steroid receptor and triple negative status are potential markers only for

ensitivity,
de of Northstandardized detection
America or Western ratios and positive predictive value of recall for assessment. In addition, it is a
Europe.
nclude racialAbsence
PV = 64%). information to help kinetics
of washout provide at
insight intohigh
MRI had the potential
negative impact of race
predictive and
value forethnicity
extensiveonbreast
treatment out(
cancer
ourse were 6.02 and 6.07 for P and C, respectively) and very good compliance (81% patients complied with the
a mammary gland cancer according to a stage of cancer. This shift (simultaneously increasing of TK and decrea
 analogous to normal tissue homeostasis. Therefore heterogeneity arises as a consequence of the presence of b
helial cells cultured in the presence of tumour stromal cells. The proangiogenic factor VEGFA, and the invasion a
ious abnormality. Subsequent CT scan of thorax showed no pulmonary metastasis in these 3 patients.
patients,
eatment routine preoperative
of breast cancer (1). chest x-ray to detect
In a multivariate metastasis
analysis is not necessary.
that included age at diagnosis, stage of disease, and pr
ndicated. After central confirmation of immunohistochemistry status, patients are randomised to either 8 cycles
s the first adjuvant trial specifically targeting triple-negative patients and the first X trial to target a specific mol

trials cases,
vocal need toHER2
establish whether was
amplification these therapiesby
confirmed should be continued
FISH (range at PD.
8–20 HER2 copies). Estrogen (ER) and progestero
atic site was brain 38%, lung 19%, bones 12%, hepar 6%, multiple metastatic site 13%. Median time from treatm
pausal, compared to 63% in the MBBC group. A family history of breast cancer was more common in pts with M
everall
compound and
survival individualized
from diagnosis totreatment.
death were 52.9, 33.6, and 25.5 months, respectively (p = 0.026). However, Tim
fifty four percents of the patients at the follow-up period. Median disease free survival found 25.5 months. At p
CCLs, in situ and matching invasive components displayed additional genetic aberrations at 16 p13.3, 13q34, 2
st event) and 103 (20) died of their disease. Distance metastases as first event and breast cancer specific survi
based
tly on their
different andvery different
various outcome.
clinical Pts with
indications wereelevated
explorednumber
in theseofgroups.
lymph nodes and high
Each gene set ingenomic risk
our study have
was a
asse

0.25 log10 RQ; RARA: 1.01±0.13 log10 RQ). Analysis based on hormone receptor status, menopausal status, tum
s (PP) and 13.4% secondary prophylaxis (SP); 47.4% filgrastim (FLG) (88.6% PP) and 52.6% pegfilgrastim (PEG)
CXCL12 does not correlate.
n, 7 patients were smokers, one did alcohol abuse, 3 were overweight and 8 suffered from hypertension. Positiv
e to first and subsequent on-study SRE (multiple event analysis) compared with ZA (HR 0.77; 95% CI: 0.66, 0.89

on a purerespectively,
otherapy, population ofwhen
cancer cells specifically
classifying isolated
the results by the
as either CellPick
positive system (MMI).
or negative. The sentinel
The detection lymphmRNA
of CK-19 node
. Absolute volume reduction at V5 and V20 and MLD were 4.1%, 3.2% and 3.5% with 3-D planning, respectively
Cohen's d = 0.36). Compared with healthy controls, younger tamoxifen pts performed worse on ‘executive fun
afety
ze 60 mm studies.
(range 40–100). In the ER+/PR+/Her2- group, the median age was 49 yrs (range 26–70) and median
ent effect, with an OR of 0.502 (95%-CI: 0.307 – 0.819; p = 0.006). This positive effect was corroborated by the
eeks before chemotherapy and 85 (94.6%) during and 2 weeks after chemotherapy. ML of cultured dermal fibro
be prevented
ceiving lower by breast
doses of Xcancer
versuspatients
full doseselection
X in all ofand
theDPC regulation.
studies examined. In addition, reduced X doses were ass
uspicion of papillary carcinoma had an MRI which was negative and after 3 months the repeat of ductal lavage w
eique
wasand the diagnosis
higher in subjectsiswith
more safe. examination findings (23.7%; p < 0.001). Among the subjects in whom a m
normal
tive to negative in 4 patients (16%) and from negative to positive in one patient (4%). One patient (4%) change
<st 0.0001).
that ER/PR/HER2 status should routinely be checked in both core biopsy sample and also resection specimen
crease
0% of to
power tumor markers
detect after CHT
HR = 0.7).
nes in RIBBON-1 is seen across the prespecified clinically relevant subgroups. These results are consistent with

significant correlation between estradiol and progesterone (p < 0.0001), an inverse one between estradiol and F
es fracture risk assessment using BMD and clinical risk factors to determine the 10-year probabilities of hip and
alcium and vitamin D supplementation, lifestyle advice, and bisphosphonate therapy based on degree of fractu
. CTC 2 LVEF modification during chemotherapy was documented in one patient in each of the study arms. A ba
active therapeutic
difference, option
regardless for women
of HER2 status,with
has early
been breast cancer.
observed between pts with elevated and lower ECD levels (log-
re medical (84.3%) or psychological (17.7%) issues. 76.3% of users were satisfied or very satisfied with the res
nthracyclines in 76% of pts; and 48% of pts refractory or resistant to lapatinib. Mean duration of study treatmen
9) of patients, respectively. Immunohistochemical data concerning these C/T antigen expressions were correlat
is possibly original observation.
 e correlated with tumor grade; no such relationship was noted for SLC5A5. The groups of patients with high exp
ex ≤25 (5.0, [1.2–10.0], to have a better prognosis (low grade tumours) (4.6, [2.0–10.9], and not to have a fam
33]), and with the living place of the women (OR = 2.41 [1.3–4.6] for women living in towns <200,000 inhabitan
tion of young breast cancer women
n depending
tion on with
associated the definition applied. Seven false negative cases, including three micrometastases and four IT
chemotherapy.
making process, Mammaprint can be considered to be an efficient tool. As more costly systemic therapies are lik
and normal volunteers respectively (p = 0.013). CXCL9 concentration was significantly higher in patients with E
h as ATM and CHEK2, in which mutations confer 2–3 fold risks; and “low-penetrance” loci (such as FGFR2), in wh
hanisms. While the
on, a statistically risks conferred
significant by the susceptibility
improvement was observedalleles are low, the
in lymphocyte combined
number effects a
(p < 0.005), are sufficiently
decrease larg
in T-reg
etwork (NCCN), and St. Gallen consensus. Several regional guidelines were also reviewed: National Institute for
updated
owing within
a 60 daysmonths. The ASCO
gap between technology
refills. The switchassessment, St. Gallen
from tamoxifen to an consensus, and NICE(anastrozole,
aromatase inhibitor guidelines were upd
exeme
Multivariate analyses showed that discontinuers were less likely to be aged 50–69 years (versus 70 years; HR =
rs with invasive component, MDM4 expression was identical in both lesions. On multivariate analysis that includ

chondrial membrane potential was disturbed and caspase-3 and PARP cleavage were observed. Moreover, HMPS
conventional anticancer agents.

d by the
efore RT),dosimetric
during RT data that
(on D7 andare still and
D21) under analysis
after and could
completion of RTdiffer
at 3, in
6, the two
9, 12 treatment
months. Highgroups.
resolution CT scans
essary.
with X+I demonstrated that >75% of pts received the full dose and cycles of chemotherapy. During the entire r
ed only as areas of contrast accumulation. In 9 patients, the procedure failed. Contrast enhanced ultrasound co
ed as controls. Several gene sets involved in plasma- and B cell pathways differed between the CF and the non
in histologically poor tumor differentiation and presence of lymph node metastasis.
reast tumors, indicating oxidative mechanism at the mitochondrial level in the tumor cells.
n A expression, whilst a negative correlation with grade 3 tumours, with mammaglobin protein expression decre
e, but data from the BIG 1–98 trial on the impact of TAM vs LET on cognition will be presented at ASCO 2009.
rmation on LET vs TAM.
0.013, respectively). There were no significant correlations with HER2 overexpression and 5-year survival in th
factor
close or positive margin by invasivedose
is inadequate anthracyclines in the adjuvant
carcinoma was lowersetting.Table
than that of1. Prognostic
patient factors inmargin
with negative stage II(92.3%
breast vs.
ca
ctorreceived
nts to increased
8 mglocal recurrence-free(po).
of dexamethasone survival. Becausewho
The patients of the low incidence
received docetaxelof local
had 8recurrence, the large-scal
mg of dexamethasone (p
diabetic range
cumented (ie,27%
switch. >11.1 mmol/L).
of low Increasing number
risk post-menopausal of patients
women developed
were switched glucose intolerance
unnecessarily to an AI.as cycles prog
addition responsibility for ensuring switching needs to be clearly allocated within the multidisciplinary team at a
lmost
than inhalf of all Mpts
younger (45%), and
<75 yr since in
(Table). Thesitu tumors
2.5-yr andwere
5-yr detected
cumulative theDM
most
(95%as CI)
M (75%)
for ptsand
<75M yr
arevsfound therespe
≥75 yr, mos
DM recurrence,
nificantly higher as observed
in blood fromwith initial
breast adjuvant
cancer LET compared
patients (Thurlimann to B et al. N(p
controls Engl J Med. 2005;353:2747–57;
< 0.001). Increased systemic miRMau
uld as a novel minimally invasive tool to aid in the early diagnosis and monitoring of breast cancer.
apoptosis was 3.6%. It was marked a plural toxic damage of cells and signs of destruction of stroma. In the 4
pecific survival (95.2% vs. 98.4%; P = 0.035), and they were more frequently diagnosed with distant metastase
ucational materials did not reflect their cultural needs and portrayed breast cancer as a ‘White women's disease
e6 statutory
month of and voluntary
therapy sectors,decreased
with taxanes and patients, must
in all collaborate
patients exceptto improve
one, the4BME
but only cancer
patients experience.
achieved NTx normal

e node status.
time was We are now
shortened usingroutinely acting US
intraoperative on the
but basis of statistically
without the TIC result.
singnificance. There were no intraoperativ
the highest production of membrane-bound uPR, and secretion of MMP9 and CXCL8/IL8, CXCL5 chemokine. Of

ad stable disease (≥6 wks from start of therapy to PD) and 4 had PD. PFS (time from 1st dose to date of PD or d
evel between BC and PABC tumor tissues with receptor cores number 1.78±0.62 and 0.36±0.20 per vascular en
amatic
1) tumor with
pts treated progression
<3 priorand further (2)
regimens; angiogenesis
pts treatedinwith
pregnancy
≥3 prior– regimens,
associatedwhere
BC patients.
a regimen was defined as a
. OS cox model indicated a significant interaction, however trt and number of regimens were not significant. Pts
tortion) +15 mm margin. WB clinical target volume (CTV) was defined using radio-opaque wire marking clinicall
rom PBI are overall
to systemic therapy,lower than
using from WBIimmunometric
a 2-epitope but prone positioning is again likely
chemiluminescent to be (Beckman-Coulter).
method detrimental in women with di
Distant br
t hormone therapy. Short and long-term prognostic effects of insulin are provided in the table below. Adverse e
stases decreased whereas liver and CNS metastases occurred more often. Skin and lymph node metastases sh
cechemotherapy
tumours following initial treatment.
is effective Potential
in the treatment of improvements in treatment
all biologic subtypes of cancer,
of breast M0-patients who
but is developed
more resourcemeta
inten
gnizes thatand
e SK-BR-3 the T47D
ultimate
cell goal
linesof every
there health
was care system
significant is to offer
upregulation optimal care
in expression of to
theallmesenchymal
patients. Themarker
use of proce
Vime
ative phenotype (p = 0.0179). Of the available cases, 60 pts (56%) were Luminal A, 10 pts (9.3%) Luminal B, 13
oubts
one ofon the utility
these had beenfor early cancer
positive diagnosis
before of highly
operation. sensitive
In three techniques
patients to identify
with multimarker hypermethylation
expression of spe
early metastas
om thefor
ut not networks
patientsofwho
apoptosis, invasion,
underwent SLNBangiogenesis
(log-rank p =and stem cell phenotype should improve early detection o
0.36).
serial
ed sectioning
to response in of
thesentinel node(s).
subgroup MAPtau positive (p 0.006). Other prognostic factors (age, c-erbB2, p53 and Ki67
dndtotumor
response to anthracyclines
heterogeneity in general. or to TopoIIa expression. These results should be considered in a larger cohort o
s (56%) the dose was reduced or interrupted at least once. The median dose of X was 3500 mg per day (range
tesanib MTD has not been reached; the target dose is 125 mg QD. 28 (85%) pts had motesanib-related adverse
enia (81.6%), thrombocytopenia (19.7%) and anemia (15.5%). Most frequent non-hematologic toxicities were fa

elapse was 3% (1.3% as first recurrence). The median time to death from the diagnosis of CNS metastases was
dion,
overall survival associated
unacceptable toxicity orwith trastuzumab-based
withdrawal. The primarytherapy lead
endpoint wastosafety
an “unmasking” of CNS
(CTCAE v3.0); relapseendpoints
secondary that would
i
ring at any G in >15% of pts (related or unrelated to Bev) are shown below. The incidences of ≥G3 predefined
spectively – stable disease in 16/217 patients. Surgery was possible in 201/217 (92%) patients – BCS in 126/217
lung nodules) was similar between two groups (7.8 months (A) vs 9.5 months (B), p = 0.386). Between two grou

upraclavicular area or not did not seem to be any relationship with LRFFS, DMFS, DFS and OS. In pN0 and pN1 p

currence by approximately 50% and improves overall survival by 30% irrespective of tumour size, nodal status,
rd benchmarks
e PSQIII for (PSQ
subscales futuretotal:
phase II trials.
p= 0.713, TC: p = 0.300, IA: p = 0.304, AC: p = 0.517) (power >0.80 and a = 0.0
problems
dependent factors for type of breast surgery were country, age, tumour size and calendar year of surgery. Radio

62; CI: 2.25–5.82, p < 0.0001) and adjuvant radiotherapy (p < 0.05), but not chemotherapy (p = 0.95). Axillary
er chronic
mon adversepain complaints.
events for the combination were: fatigue grade (gr) 1/2 (76%), diarrhoea gr 1/2 (60%), pain gr 1/2
educed from 37.5 mg/d to 25 mg/d in 19/53 pts (36%). Most (70%) pts received SU + T as 1st-line tx. ORR was
cyclophosphamide/epirubicin/fluorouracil, paclitaxel/cisplatin, vinorelbine/fluorouracil/leucovorin, capecitabine,
solute error and mean area under the ROC curve equals to 0.016 and 0.77 for the first, 0.023 and 0.75 for the s
dependent
les variable.
of CT was The validation
administered (medianresults for3–6).
4, range all three nomograms
Treatment seem promising.
compliance was good and no dose reduction was

ents were 50receptors

rogesterone years (range, 47.2–56.7).
on primary tumour5 of the associated
were 31 patientswith
initially presented
improved DFS.with brain metastases
Furthermore, positive (16 percen
Herceptin
ond sample. In multivariate analysis, ER positivity (OR = 0.233, p = 0.028) and the increase of VEGF levels betw
2: baseline CA 15–3: (DF) 27.3±13.2 vs. (DR) 20.4±6.5 U/L (p = 0.023); baseline serum CEA levels: (DF) 6.6±5.
btypes (with relative risk (RR) luminal B 4.7, Her2 3.6 and triple negative 12.08 referent to luminal A, p = 0.000
reased survival to 5.87%±10.2%, which had a statistical significance of p = 0.0346. We downloaded 1079 micr
nce in dose prescription point (applicator surface for single-dose IORT, 1 cm distance for APBI) influenced the iso
ate reaction. Therefore, the dose-effect relationship for late reaction should be tested in a phase II trial.
y RT
17 in women
patients with
(39%). 1–3
Left involved nodes
ventricular or fraction
ejection node negative
(LVEF) with otherevaluated
has been risk factors
atisbaseline,
uncertain and12–13
after underweeks,
investig
a

were €3933 and 0.766 QALYs, and for hospital f-up with EGP (f-up strategy 3) €3281 and 0.746 QALYs. Hence,
asis (HR, 0.81; 95% CI, 0.67–0.98; P = 0.028). Discontinuation rates were 29.5% (n = 1434) for tamoxifen patie
 R 1.8 (95%CI 1.1–2.9) and 5.03 (95%CI 2.9–8.8) for tumours 2–5 cm and ≥5 cm compared to tumours ≤2 cm, r
are metastases from the primary tumour.

der, treatment
only in groupduration remains
B (1.61%). controversial.
The remainder of theShould we had
patients continue treatment
stationary until
disease disease
after progression
the regimens: or should
33.87% of g

mization, 64.9% of controls versus 17.5% of G-CSF intervention patients had a second neutropenic event (p < 0

, an average
edian OS fromofthe
2,200 new
start of Tbreast cancer
was 29.6 and 400
months ovarian cancer
(3.7–99.6+). cases pts
Twenty-one annually have been
were HER3+ withreported
a cut-offover the la
of 50%. H
s presented in table. No local or distant recurrences developed.

cm. Distribution of malignant masses was as follows: 1 Ductal carcinoma in situ (DCIS), 3 Carcinomas (1 inflamm
s expression.
in adolescent
Wegirls.
have demonstrated that both pharmacological and siRNA-mediated SphK1 inhibition leads to a

motherapy
123.57 induced
ng/ml, amenorrhea
Follow-up: (CIA)
90th day: has ng/ml,
113.86 many objective
140th day:(osteoporosis, cardiovascular,
116.22 ng/ml), urogenital
whereas patients of theatrophy, co
third group
ond group, the increased
of loco-regional SP-Dand
radiotherapy serum
useexpression
of systemicattherapy,
the endsurgery
of radiotherapy
appearedand during
to be follow-up may
an independent be sugges
prognostic f
the impact of tumor free resection margins are investigated.
17.6) as independent significant predictors for DFS. Nodal index (HR 1.5; CI 1.0–2.1) and palpation of the tumor

(selective) lymphadenectomy was performed following positive SNB. In one patient both positive SNB and posit
RCA1/2 and p53 in epithelial tissues [2,3]. The mammary tumors that arise in our BRCA1 mouse model show str
tinum resistance. Indeed, it has been reported that BRCA-associated hereditary ovarian cancers may become re
t and reasons for discontinuation of AI will be analysed. Specialized questionnaires will be used to evaluate med

gical type,asgrade,
themes size, lymph
coordinating node metastasis
the entire and ER
care and acting as was available player
an important for all cases. This study is the team.
in the multidisciplinary largest ever d
of a patient with breast cancer. The guidelines will be flexibel and acceptabel for implementation
t site of recurrence analysis, loco-regional recurrences developed in 11 patients (15.3%) of the former in all and
breast u
8 pa

dn't find any statistical significant between DFS and all parameters. Only there was statistical significant betwe
= 0.0229) and c-erbB2 (p = 0.0056) positivity were found to be the prognostic factors affecting adversely the di

en considered, grade > 2 was observed exclusively in GSTP1 Ile/Ile or Ile/Val carriers in 5-FU treated subgroup

utcome
001), grade (p < 0.001), and progesterone-receptor status (p < 0.001), and for PFS was tumor size (p < 0.001)
and negative ER/PR (p < 0.05). In the analyzed cohort of patients below age of 35 years, older patients showed
SN pts was 59.4 and 37.5% respectively. The 5-year and 10-year DFS in 21 SP pts was 23.8% (p = 0.095). Amon
vorable prognostic factor only in the first year after surgery, from 1–5 years they had no prognostic role, after 5
ponservative
period treatment.
.3) with NCT. Ipsilateral lung received a mean dose of 7.8 Gy (±1.6) and a V20 at 14% (±2.8) with CT; with NCT
, increased resistance to docetaxel in MDA-MB-231 cells. Concurrent treatment with decitabine and TSA enhanc
increasedinresponse
umented 2 pts, at to
thedocetaxel in both
4th and 6th docetaxel-resistant
cycle; cellsyndrome
asthenia, hand&foot lines. These
andresults suggestwere
constipation that transient
combination
and
5.6%, respectively. Overall 6 year survival rate was 95.1%, 6 year disease free survival rate was 85%.

31 ng/ml). 1 pt had elevated TnI above normal range (>0.31 ng/ml) with AC#4. MUGA 1 wk later was unchange
hey discussed the percentage of benefit with patients, 7 (28%) said always; 9 (36%) said frequently; 7 (28%) sa
therapy
the fortract.
needle 4–5%Furthermore,
benefit. As this tool
in 2 is designed
cases to lesion
the target be used in completely
was conjunctiondestroyed,
with patients
butand to improve
viable DCIS waspatien
found
tage IIB/24.14%) and 28 patients were classified as having locally advanced breast cancers. The majority of cas
ke to concluded
oked that Vs
at pre-closure vascular
placeboand perineural
and 2 studiedinvolvement
pre-incision might be poor
Vs placebo. Noprognostic
differencefactor in thisinour
was found data.
pain scores an
of using LA to control postoperative pain in breast surgery as well as
de dissection (ALND); in 1 patient further axillary metastases were found. to identify the optimal drug and method of
s and guidelines.
data
the about described
correction genetic
protocol. Usingpolymorphism
the formula ofamong Croatian
Van Herk et al.,feemale
marginspopulation.
should be 6Wemm enrolled twoLat
in AP and groups
and 7ofmm
fee
ed CTV-PTV
gnant. One ptmargins were6introduced
died within in our
months after EOCcentre,
due toallowing a better
progression. sparing
6 women of the with
started organs at risk.
regular menstruation w
and in Ki67 positive patients FRP1 (p = 0.024) expression percentages were significantly high. β-catenin expres
d bone metastases (summary OR: 0.925, 95% CI: 0.768 to 1.114, P-value = 0.413). Conversely, adjuvant treatm
ay potentially alter the course of disease in breast cancer adjuvant setting.

6, p < 0.001; 2003–2006: HR = 0.48, p < 0.001). The effect of metastatic diagnosis time period remains almost
ctively. Incidence of grade 3 non-haematological toxicities (≥5%) were: 9% of diarrhoea in arm A, 0% in arm B,
e in 18.8% and 1.7% after 50 Gy, 24.1% and 9.1% after 30 Gy, and 20.0% and 4.0% after 28.5 Gy. Risk ratios fo
is developed partly based on these results and will be launched in Europe in 2009.
ponses (PR) and 21 stabilizations (including 6 unconfirmed PR).

RANKL,
many for the at
patients treatment of risk
increased BM in
forpatients with compared
progression solid tumors (excluding
to PTEN alone.breast and prostate) or multiple myelom
biomarker for response prediction in the neo-adjuvant setting.
ated if a functional/structural interaction between TLR9 and ErbB receptors may occur. We demonstrated for the
d indications of less service utilization in the home care group. No difference between the two groups was seen
ED: 97%, p < 0.0001) mainly due to capecitabine-induced side effects.
, 25% non-visceral and 59% mixed. Celiptium was administered the most frequently in combination with etopos
be restrained by inhibition of the FAK system. Furthermore, a partial differentiation seems to be induced by FA

b. Stem cell like staining was seen in a minor fraction of cells (1%) in about 10% of patients. An increase in cell
d patients, but not in right-sided patients. Within the left-sided patient group, S and SR were reduced post-RT fo
nce these issues when dealing with young patients.
rted from heterozygote to homozygote regions. Subsequently, for every SNP the frequencies of disparity of ind

32.2% (95% CI, 26.7–37.8%), with no difference between pts who were considered anthracycline resistant (defin
emotherapy, and in non-breast cancer patients receiving non-AC-based regimens. Overall, the incidences of ad
03, p = 0.02). Lyn was not associated with survival at any cellular location. High membrane Lck expression was

and pathologic response, nuclear grade and the polymorphism. In the HER2 subgroup we found a higher preva
Hospira filgrastim and Neupogen (primary endpoint) was within the predefined range and demonstrated equiva
1.17 p = 0.242).
and 29.6 months from the start of trastuzumab therapy. In patients developing BM median OS was significantly
These patients had a shorter time to development of brain metastasis after diagnosis, though not statistically s
ugh not significant.
p and 96%, 70% and 52% for the AC group, respectively (p = 0.85). OS rates at 1, 5 and 10 years were 96%, 8
ective.
s are potential markers only for early but not for late BM relapse. These results contribute to the opinion that in

assessment. In addition, it is anticipated that these data will allow us to provide a tentative prediction of the lik
and
e forethnicity
extensiveonbreast
treatment outcomes.
cancer (p = 0.036, NPV = 89%, PPV = 50%).
1% patients complied with the protocol). Adverse events related to nausea occurred in 51% vs. 47% of the pati
sly increasing of TK and decreasing of TP) indicates about more intensively proceeding processes of a proliferat
nsequence of the presence of biological distinct classes of cells with differing functional abilities and behavior w
actor VEGFA, and the invasion associated gene MMP3, were also upregulated in the tumour stromal cell populat
s in these 3 patients.
nosis, stage of disease, and pregnancy history prior to diagnosis, women who had a full-term pregnancy subseq
randomised to either 8 cycles of X (1000 mg/m2 bid, d1–14 q21 d) or observation, stratified by centre, prior ta
t X trial to target a specific molecular subtype. Accrual of the planned 868 patients is anticipated during 2009, w

). Estrogen (ER) and progesterone receptors (PgR) were expressed in respectively 44/90 cases (49%) and 22/79
e 13%. Median time from treatment dissemination to brain relapse was 1.2 years (range 0.02–9.2). Median time
as more common in pts with MBBC (19%) than in pts with SBBC (7%). Initial metastases were more frequent in
ively (p = 0.026). However, Time from brain metastasis to death was not significantly different (p = 0.276).
urvival found 25.5 months. At presentation of MBC, % 55 had visceral metastasis and %11 had multipl metastat
errations at 16 p13.3, 13q34, 20q13.33, 11q13.1-q14.1, 17q25.3, 19 p13.3, 7 p22.2, 8q24.3, 9q34.3, 14q32.33,
nd breast cancer specific survival according to LN group (PN) and genomic profile (MP) show the high prognosti
sgene
and high
set ingenomic risk
our study have
was a very for
assessed poor prognosis
risk and
prediction might need using
performance to be PIs
considered for univariate
both in the stronger treatment com
setting and

status, menopausal status, tumour grade or stage revealed no significant differences in NIS or RARA expression
and 52.6% pegfilgrastim (PEG) (84.8% PP)]. In pts with G-CSF, prophylaxis the incidences of G3–4N and FN were

ered from hypertension. Positive medical history for familiar or hereditary breast cancer had 3 (17.6%) patients
ZA (HR 0.77; 95% CI: 0.66, 0.89; P = 0.001). Rates of adverse events (AEs; 96% denosumab, 97% ZA), infectiou

.MMI). The sentinel

The detection lymphmRNA-positive
of CK-19 nodes were cut in half,
CTCs andone half
DTCs was disaggregated
before chemotherapyandwasused for IMSwith
associated withdecreased
an anti-EpC
ov
with 3-D planning, respectively.
ormed worse on ‘executive functioning’ (P = 0.01, Cohen's d = 0.54), while older tamoxifen pts performed wors
yrs (range 26–70) and median tumour size 50 mm (range 25–150). Median kep values were significantly higher
ffect was corroborated by the analysis of subscales for Achieve satisfaction/well-being (OR = 0.918; 95%-CI: 0.8
py. ML of cultured dermal fibroblasts from these patients revealed lowered incorporation of radiolabel into full-le
tion, reduced X doses were associated with a lower incidence of treatment-related AEs, specifically hand-foot sy
s the repeat of ductal lavage was negative. Patients with atypia are under close supervision (physical examinat
mong the subjects in whom a mass had been detected, the rate of the subjects followed-up at the city center w
(4%). One patient (4%) changed from HER2 negative to HER2 positive after NC.
le and also resection specimen.

ese results are consistent with the findings of E2100 and AVADO and suggest that B with standard chemotherap

se one between estradiol and FSH (p = 0.04) and a direct one between LH and prolactin (p = 0.001) were found
10-year probabilities of hip and major osteoporotic fractures. In the breast cancer setting, recently published co
rapy based on degree of fracture risk. Individualized fracture risk assessment will allow more proactive manage
n each of the study arms. A bank of paraffin embedded biopsies and tumor blocks successfully collected more t
ated and lower ECD levels (log-rank test p = 0.003).
d or very satisfied with the response time; 70.3% were satisfied or very satisfied with amount of information; 71
ean duration of study treatment was 24 wks in the 5–10 mg/d and 31 wks in the 30 mg/w cohorts. G3–4 neutrop
igen expressions were correlated with the following MBC clinicopathological features: patient's age at diagnosis
groups of patients with high expression of glucose or iodide transporter (over 75th percentile) did not show any
0–10.9], and not to have a family history of breast or ovarian cancer (2.6, [1.1–6.3]. Age, maternal language, m
ng in towns <200,000 inhabitants, and OR = 0.68 [0.28–1.62] for women living in rural areas when compared w

e micrometastases and four ITC, were detected among the originally 400 SNB negative cases. No association b
costly systemic therapies are likely to become standard in the future, the economic advantages of Mammaprint
cantly higher in patients with ER-negative breast cancer (mean: 999 pg/ml) as compared to normal volunteers (
nce” loci (such as FGFR2), in which common polymorphisms confer more moderate risks, typically <1.5 fold. The
pned effects a
< 0.005), are sufficiently
decrease largenumber
in T-reg to be important in risk
(p < 0.005) andprediction,
VEGF (p < targeted screening
0.005) with respectand prevention.
to baseline values. After
eviewed: National Institute for Health and Clinical Excellence (NICE; UK), Danish Breast Cancer Cooperative Gro
e, inhibitor
and NICE(anastrozole,
guidelines were updated several
exemestane yearswas
or letrozole) later, but upfrontCox
determined. AIsregression
were not recommended over tamoxifen
was used to identify independ
69 years (versus 70 years; HR = 0.74; 95%CI: 0.60–0.91) and were more likely to have 2 or more concomitant d
multivariate analysis that included NPI, MDM4-overexpression was an independent prognostic marker for patient

were observed. Moreover, HMPS decreased cell number of LTED MCF-7 cells (Long term estradiol deprived cell) e

reatment
onths. Highgroups.
resolution CT scans were performed at 6, 9, 12 months after completion of RT. Respiratory symptom
motherapy. During the entire recruitment period, no safety-related amendment to the study protocol was requi
ontrast enhanced ultrasound correctly identified SLN in 61 of 70 patients (87%). Eleven patients were found to h
ed between the CF and the non-fatigued, suggesting that a dysregulation in these pathways is associated with C
sis.
mor cells.
globin protein expression decreasing as tumour grade increased. No correlation was found between presence/a
be presented at ASCO 2009.
ession and 5-year survival in this population (log rank p = 0.51). In multivariate analysis, inadequate anthracycl
tic factors inmargin
th negative stage II(92.3%
breast vs.
carcinomas compared
98.4%). There werewith 5-year survival
no statistical differences in LRFS between patients with clos
ocal 8recurrence,
had the large-scale
mg of dexamethasone (po)studies are 12
24 hours, needed
hourstoandobtain conclusive
immediately outcome.
before docetaxel. For each cycle of chem
cose intolerance
cessarily to an AI.as cycles progressed; 6 had blood glucose levels in the impaired tolerance range and 8 had lev
the multidisciplinary team at a local level.
75%)
for ptsand
<75M yr
arevsfound therespectively,
≥75 yr, most easily via
were MMG,
4.0%it's shown even
(3.2–4.8) in 35–49
and 8.7% year old
(8.5–10.9) women
versus how
9.0% importantand
(6.5–11.5) the14
M
J Med. 2005;353:2747–57;
0.001). Mauriaclevels
Increased systemic miRNA L et al.
in Ann Oncol.
breast 2007;18:859–67]
cancer may
patients are also translate
reflected in to the observed
breast tumours. survival
We also
of breast cancer.
destruction of stroma. In the 4 series mitosis decreased to 0.2% and apoptosis was 2.8%. It was marked the nec
agnosed with distant metastases from breast cancer (8.1% vs. 1.9%) during the first 5 years of follow-up (P = 0.
er as a ‘White women's disease’. They reported difficulties obtaining coloured prostheses or lymphoedema slee
BME cancer
patients experience.
achieved NTx normalization.

ce. There were no intraoperative or postoperative complications due to detection method used.
CL8/IL8, CXCL5 chemokine. Of note, these modifications were absent in MOs incubated with TCS obtained from

rom 1st dose to date of PD or death), was ≥6 mo in 27 (64%), ≥9 mo in 18 (43%) and ≥10 mo in 11 (26%) pts (
and 0.36±0.20 per vascular endothelium length unit in BC and PABC patients, respectively (p < 0.002). Over e
C patients.
ere a regimen was defined as any prior therapy in any setting (neo-adjuvant, adjuvant or metastatic); and (3) p
imens were not significant. Pts who received only 1 prior metastatic trastuzumab regimen had a 46% reduction
 o-opaque wire marking clinically palpable breast tissue. Heart & LAD were outlined. Tangential-field PBI & WBI p
de (Beckman-Coulter).
detrimental in women with disease-free
Distant breast volumes
and≤1000
overallcm3.
survival were analysed using Cox multivariate models adj
d in the table below. Adverse effects were present in short-term, but not long-term, analyses. Short-term effects
and lymph node metastases showed best prognosis until 10 years follow up. Time to and survival after metastas
-patients
ncer, who
but is developed
more resourcemetastases
intensive toseem to be
provide. nullified
The by aofworse
provision pattern
endocrine of metastases,
therapy with the shift
requires relatively to liv
few speci
to
theallmesenchymal
patients. Themarker
use of process
Vimentin metrics
(rangecan facilitating
158–276 fold), the
the development
anti-apoptoticoftranscription
multidisciplinary,
factorintegrated,
Snail (rangefisca
4–
A, 10 pts (9.3%) Luminal B, 13 pts (12%) Basal like and 9 pts (8.4%) HER2+. We observed that methylated ERS
entify hypermethylation
rker expression of specific
early metastasis was gene promoters
clinically in DNA
confirmed extracted
later. from serum.
Progressive diseaseAlthough numerous
in metastatic breastissues
cancerre
ould improve early detection of metastasis, monitoring of therapy response and efficacy and selection of tailore
rs (age, c-erbB2, p53 and Ki67) are not related with response either to anthracyclines and taxanes (p > 0.01), in
considered in a larger cohort of patients, also to identify the role of other factors in the subgroup of responders
X was 3500 mg per day (range 1594 to 4500 mg). The main reason for dose reduction or discontinuation was PD
had motesanib-related adverse events (AEs). The most common (highest gr) AEs were: diarrhea, Arm A/B 60%/6
-hematologic toxicities were fatigue (gr 2/3: 31.0%), alopecia (26.7%), anorexia (14.1%), and nausea (12.7%), m

gnosis of CNS metastases was 25 months. Among the HER-2+ pts, there was a significant association between
king” of CNS
E v3.0); relapseendpoints
secondary that would otherwise
included TTPhave
and remained
OS. clinically silent prior to a patient's death.
incidences of ≥G3 predefined Bev-related AEs of special interest were: DVT in 0.3% (all G3); thrombosis in <0.1
92%) patients – BCS in 126/217 (58%) patients, MRM in 75/217 (35%). Pathological CR was noted in 65/217 (30
, p = 0.386). Between two groups, initial T stage (p = 0.145) and N stage (p = 0.749) was not different. Hormon

, DFS and OS. In pN0 and pN1 patients, 5-year DFS was 86.6% and 68.8% in SCNRT+ group, compared with 80.

e of tumour size, nodal status, schedule of administration, and type of chemotherapy. Nevertheless, there rema
517) (power >0.80 and a = 0.05).
calendar year of surgery. Radiotherapy after breast conserving surgery (BCS) was given in 93% of patients, bein

motherapy (p = 0.95). Axillary lymph node dissection increased risk of pain (OR = 1.75; CI: 1.41–2.17, p < 0.00
hoea gr 1/2 (60%), pain gr 1/2 (60%), rash gr 1 (40%) and nausea gr 1/2 (32%). To date, best response observe
SU + T as 1st-line tx. ORR was 24% and clinical benefit rate (CBR) was 39%. 2 (4%) pts achieved a CR, 10 (20%
racil/leucovorin, capecitabine, docetaxel/capecitabine/cisplatin, and docetaxel/epirubicin/cyclophosphamide. Ei
e first, 0.023 and 0.75 for the second and 0.014 and 0.79 for the third nomogram.
ing.
od and no dose reduction was required; 12 cycles were delayed by one week because of hematological toxicity

th brain metastases
urthermore, positive (16 percent).
Herceptine 42 breast
receptor cancer
(HerR) patients tumour
on primary withoutwas
metastases
associatedwere randomly
with selected
worse CSS as con
(p < 0.0102
he increase of VEGF levels between the first and the second sample (OR = 5.13, p = 0.027) were the only 2 fac
serum CEA levels: (DF) 6.6±5.2 vs. (DR) 3.7±2.5 ng/mL (p = 0.015).
eferent to luminal A, p = 0.0001), and the number of positive nodes (N1–3 RR = 6.6 and N > 4 8.3 referent to N
46. We downloaded 1079 microarray samples with available clinical follow-up from GEO. In these, 442 patients
nce for APBI) influenced the isoeffective doses for different applicator sizes. The predicted risk of local recurren
ested in a phase II trial.
sbaseline,
uncertain and12–13
after underweeks,
investigation
and at in the
the BIG
end of2–04 MRC/EORTC
therapy. SUPREMO
Mean LVEF% trial
(range) was(8).61.8% (52%-77%), 61.1% (50

3281 and 0.746 QALYs. Hence, in the incremental cost-effectiveness analysis, nurse-led telephone f-up with EGP
(n = 1434) for tamoxifen patients and 18.9% (n = 926) for exemestane patients, and 754 tamoxifen patients sw
compared to tumours ≤2 cm, respectively], axillary lymph node involvement [RR 2.5 (95%CI 1.2–4.9) for >10 p

disease
fter progression
the regimens: or should
33.87% we stop
of group it once
A and a positive
48.39% of groupresponse or stabilization
B. The odds of the disease
ratio for developing has response
a partial been achie
a

econd neutropenic event (p < 0.01). A subgroup analysis showed a major benefit for pegfilgrastim compared wi

have been
HER3+ withreported
a cut-offover the last
of 50%. HER3 ten years and 800was
overexpression women die of breastcorrelated
not significantly cancer each year
with response to T, TTP, inci

DCIS), 3 Carcinomas (1 inflammatary, 2 ductal) and 2 cases of malignant cystosarcoma phyllodes. There was 1
ted SphK1 inhibition leads to a four-fold decrease in the docetaxel IC50 dose.

ascular,
reas urogenital
patients of the atrophy, cognitive
third group etc.)highest
expressed and subjective (hot flushes,
levels, above normalsleep disturbances,
range, change
at all time points. of mood etc
Considering CR
during follow-up may be suggestive of radiation-induced lung inflammation. However, CRP does not appear
be an independent prognostic factor for overall survival (HR 0.62; 95% CI 0.51–0.76). Results of the medical cha to re

2.1) and palpation of the tumor (HR 2.0; CI 0.95–4.1) appeared to have effect on DFS either but on the limit stat

ent both positive SNB and positive margins necessitated mastectomy; whereas in another patient after selective
r BRCA1 mouse model show strong similarity to BRCA1-associated breast cancer with respect to high tumor gra
ovarian cancers may become resistant to carboplatin by acquiring genetic reversion mutations in BRCA1/2, resu
es will be used to evaluate medication adherence and the patient's feelings and beliefs on the disease and ther

This study is the team.

multidisciplinary largest ever done and reveals the molecular taxonomy of breast cancer is more complex than
implementation in
(15.3%) of the former all and
breast units in (5.6%)
8 patients Belgium.
of the latter, in contrast, distant metastasis developed in 5 patients

as statistical significant between OS and both of lymph node and C-erb-B2 (p = 0.029 and p = 0.031). In multiv
ctors affecting adversely the disease free survival in univariate analysis. Axillary lymph node involvement (p = 0

riers in 5-FU treated subgroup (P = 0.020). Nausea and vomiting grade 2–3 were also associated with GSTP1 Ile

FS was tumor size (p < 0.001).

5 years, older patients showed poorer prognosis compared to very young women: patients aged 34–35 showed
s was 23.8% (p = 0.095). Among pts with p53 positive or negative no statistically significant differences were o
had no prognostic role, after 5 years they became borderline unfavorable prognostic factor (HR 1.50 95% CI 0.9

t 14% (±2.8) with CT; with NCT mean lung dose was 6.8 Gy (±1.8) and V20 was 12% (±3.3). In the 2 left sided
with decitabine and TSA enhanced response to docetaxel in MCF-7 docetaxel-resistant cells (IC50 resistant cells:
ults suggestwere
onstipation that transient
combination
and of methylation
quickly and The
reversible. histone deacetylation
overall inhibitors
response rate may
(RR) was offer
88% better
(95% CI: therapeutic
22–54) with
urvival rate was 85%.

MUGA 1 wk later was unchanged (LVEF 75%) but she died from sepsis during subsequent treatment without evi
%) said frequently; 7 (28%) said sometimes; 1 (4%) said rarely (0–25%) and 1 (4%) did not answer. Majority 12
patients
yed, butand to improve
viable DCIS waspatient communication
found just outside the and transparency,
ablated area. it was surprising to see that majority rarely (
 st cancers. The majority of cases (n = 105) were invasive ductal carcinoma. None of them were graded as well
tic factor
nce in thisinour
was found data.
pain scores and analgesic requirements between pre-incision and pre-closure LA. Four studies
he optimal drug and method of administration

6We
mmenrolled twoLat
in AP and groups
and 7ofmm
feemale
in CCpatients:
direction.122 subjects with invasive breast carcinoma (mean age 54.1±4, r
he with
ed organs at risk.
regular menstruation within 5–8 months after the last application of chemotherapy, 1 in G+ and 5 in G-.
ificantly high. β-catenin expression was increased only in p53 posivite patients (p = 0.039). Disease free and ov
3). Conversely, adjuvant treatment with bisphosphonates was not associated with any statistical significant diff

sis time period remains almost unchanged in the presence of the following significant prognostic factors: perfor
arrhoea in arm A, 0% in arm B, 8% of fatigue and 19% of hand-foot syndrome in arm C (no grade 4 toxicity). Dis
0% after 28.5 Gy. Risk ratios for mild and marked change for 30 Gy vs. 50 Gy were 1.39 (95% CI 0.98–1.97) and
9.

d prostate) or multiple myeloma (MM) in a phase 3 study. A total of 1776 eligible adult patients who were naïve

occur. We demonstrated for the first time that TLR9 is also expressed under the plasmamembrane of KPL4 cells,
ween the two groups was seen for hand-and-foot syndrome, quality of life and depression.

ntly in combination with etoposide/mitomycin in 70% of pts. The majority of pts (71%) received elliptinium-base
ion seems to be induced by FAK inhibition as indicated by the expression of cytokeratins.

of patients. An increase in cell numbers and in the fraction of HER2/neu amplified cells was under all treatment
nd SR were reduced post-RT for the apical LV segments (p < 0.0001 and p = 0.011), in contrast to the mid and

frequencies of disparity of individuals were calculated and visualized for each chromosome with the A allele ab

d anthracycline resistant (defined based on the study records) and those who were not (31.9 v 31.6%, respectiv
s. Overall, the incidences of adverse events were generally similar in the APR (61.9%) and control groups (66.5%
membrane Lck expression was significantly associated with improved survival (p = 0.03).

group we found a higher prevalence of cardiac toxicity (45% vs. 21% p = 0.05), in patients with genotype Ile/Ile
ange and demonstrated equivalence of the two agents (DSN = 1.85 days and 1.47 days for each drug respectiv

M median OS was significantly lower than in those without brain lesions (40.2 months versus 65 months, p = 0.
nosis, though not statistically significant (2.3 years Vs 3.9 years; p = 0.107). Patients with triple negative breast

1, 5 and 10 years were 96%, 82% and 64% for the NAC group and 97%, 72% and 62% for the AC group, respec

ontribute to the opinion that initial poor prognostic characteristics have limited value in late relapse prediction

a tentative prediction of the likely future effect of the screening on breast cancer mortality. In addition, we will

rred in 51% vs. 47% of the patients treated with P and C, respectively (p = 0.48). FLIE and NCI-CTC vomiting sco
eeding processes of a proliferation at tumour pathology.
ctional abilities and behavior within the hierarchy. As opposed to the stochastic model the hierarchy model pred
he tumour stromal cell population. In contrast, the level of FAP detected in tumour stromal cells was lower than

d a full-term pregnancy subsequent to breast cancer treatment were found to have a reduced risk of dying (rela
n, stratified by centre, prior taxane (yes vs no), involved nodes (0 vs 1–3 vs ≥4) and phenotype (basal vs triple
ts is anticipated during 2009, with first safety and efficacy results in 2010 and 2011, respectively. The trial is sp

y 44/90 cases (49%) and 22/79 cases (28%), and 19 pts (21%) had a pN+, pN0i+ or pNmi+ status. Elston-Ellis g
(range 0.02–9.2). Median time to BM was longer in ER+ patients 3.4 yeas vs ER- patients 2.3. (p < 0.00001). M
astases were more frequent in SBBC group, 36%, compared to 12.5% in MBBC. Only 4% of SBBC was manifeste
antly different (p = 0.276).
and %11 had multipl metastatic region. Brain metastasis developed on fourteen MBC patients during the follow
2.2, 8q24.3, 9q34.3, 14q32.33, 5 p15.33 and 10q25.3 and losses on 10q22, 8 p, 11q24–25, 15q11.2, 17 p11.2, 9
e (MP) show the high prognostic value of genomic profiling in this patient population.
ered for univariate
h in the stronger treatment combinations.
setting and compared with clinical information added by Adjuvant! Online. The results showe

nces in NIS or RARA expression. However, when analysed on the basis of epithelial subtype there was a trend t
cidences of G3–4N and FN were 12.1% and 5.6%, respectively. Pts treated with PP had a lower incidence of G3–

cancer had 3 (17.6%) patients. All tumours were ductal invasive carcinomas, nine of which (53%) exhibited mo
denosumab, 97% ZA), infectious AEs (46% denosumab, 49% ZA), serious AEs (44% denosumab, 46% ZA), and in

dsused for IMSwith

associated withdecreased
an anti-EpCam antibody,
overall survival and
(p =the other
0.024 andhalf
p= for0.015,
immunohistochemical (IHC) identification
respectively), whereas, wit
their simultaneo

tamoxifen pts performed worse on ‘verbal memory’ (P = 0.003, Cohen's d = 0.58) and ‘information processing
alues were significantly higher in TNBC (0.70 vs 0.56, p < 0.05). Significantly lower median values for ve were a
being (OR = 0.918; 95%-CI: 0.867 – 0.972) and Change behaviour to reach goal (OR = 0.936; 95%-CI: 0.942 – 0
poration of radiolabel into full-length dolichol-linked allele oligosaccharides and glycoproteins. sGPT activity was
d AEs, specifically hand-foot syndrome, diarrhoea, and stomatitis.
supervision (physical examination every three months).
ollowed-up at the city center was 65%, whereas it was 35% for those in the other group.

t B with standard chemotherapies provides benefit to HER2-negative MBC pts with differing clinical characterist

rolactin (p = 0.001) were found.

r setting, recently published consensus recommendations suggest evaluating clinical risk factors, such as age, a
allow more proactive management of bone health in patients with breast cancer
ks successfully collected more than 95% of the specimens.

with amount of information; 71.5% were satisfied or very satisfied with information content; 70.7% got the ans
30 mg/w cohorts. G3–4 neutropenia occurred in 3 (50%), 8 (47%) and 4 (40%) pts in the 5 mg/d, 10 mg/d and 30
ures: patient's age at diagnosis, type of operation, tumor size, axillary lymph node metastasis, adjuvant therapy
 h percentile) did not show any major overlap; thus it seems that these genes are up-regulated in distinct tumor
3]. Age, maternal language, marital status, children, type of symptom and tumour size were unrelated to patien
rural areas when compared with those living in towns ≥200,000 inhabitants). Socio-demographic characteristic

egative cases. No association between the ITC finding and the preoperative biopsy method of the primary tumo
mic advantages of Mammaprint might become even more apparent.
ompared to normal volunteers (p = 0.003), a data consistent with gene expression profile. Meanwhile, Fibronect
te risks, typically <1.5 fold. The high-penetrance loci are central in genetic counselling, but most genetic variat
ening and
espect prevention.
to baseline values. After a median follow-up of 100 months, 10-years overall progression-free survival an
Breast Cancer Cooperative Group (DBCG), and German Gynecological Oncology Working Group (AGO).
nrecommended over tamoxifen.
was used to identify With
independent the release of
determinants of data indicating an
discontinuation of emerging survival
any endocrine benefit(tamoxifen
treatment with upfront le
and
have 2 or more concomitant diseases (versus no comorbidity; HR = 1.54; 95% CI: 1.06–2.26). Conclusions:
t prognostic marker for patients survival outcomes [HR, 0.4; p < 0.0001]. In high risk patients who had received

g term estradiol deprived cell) effectively.

on of RT. Respiratory symptoms were recorded. The percentance of incidence of radiation-induced pneumonitis
to the study protocol was required. 305 SAEs were reported, the majority due to gastrointestinal (45), skin (38)
Eleven patients were found to have LN metastasis. In all metastatic cases, SLN were correctly identified and loca
e pathways is associated with CF and that a B cell mediated inflammatory process might underlie fatigue. The c

was found between presence/absence of nodal metastases, PR status, Her-2 status or tumour size.

nalysis, inadequate anthracyclines dose (p = 0.028) was independent factor of poor outcome (Table 1).
RFS between patients with close or positive margin by DCIS and those with negative margin. Other pathologic fa
e.
cetaxel. For each cycle of chemotherapy non-fasting glucose was measured before the treatment cycle began,
d tolerance range and 8 had levels within the diabetic range following the 5th cycle.

d women
versus how
9.0% importantand
(6.5–11.5) the14.8%
MMG is in diagnosing
(11.3–18.3). breast
Of the 344ca
ptsatwith
an earlier stagedied during follow-up.
DM, 75.6%
slate
ed in to the observed
breast tumours. survival
We also advantage (Mouridsen
report significant H et al. between
associations Cancer Res. 2009;69[suppl]:66s.
circulating Abstract
miRNAs and the 13) with
clinicopatholo
as 2.8%. It was marked the necrosis of cells and destruction of tumor stroma. Results of the 5 series were most
irst 5 years of follow-up (P = 0.001). Several traditional prognostic factors, such as histological grade, steroid ho
ostheses or lymphoedema sleeves, and accessing suitable hair loss services. ‘Finding a connection’ with women

method used.
ubated with TCS obtained from starving MDA-MB231 cells.

) and ≥10 mo in 11 (26%) pts (range 0.5–17.9 mo).

spectively (p < 0.002). Over expression of KDR in PABC tumor tissues in comparison to BC ones was confirmed
uvant or metastatic); and (3) pts treated with only 1 prior metastatic trastuzumab regimen, regardless of other
b regimen had a 46% reduction in the risk of progression with L+C and a 37% reduction in the risk of death
ed. Tangential-field PBI & WBI plans were generated for each position (total: 88 plans). Mean normal tissue dose
ng Cox multivariate models adjusted for age, T stage, N stage, hormone receptors, grade, adjuvant chemothera
m, analyses. Short-term effects were present in both hormone receptor positive and negative BC but were grea
e to and survival after metastases was worse for patients with ER or PR negative tumours.
metastases, with the shift
py requires relatively to liver andresources,
few specialized CZS but optimally requires knowledge of hormone receptor status to
ltidisciplinary,
scription factorintegrated,
Snail (rangefiscally responsible,
4–7 fold) continuously
and N-Cadherin (rangeimproving,
9–32 fold).and flexible
Inclusion of approaches
an antibodyto
tothe global
VEGF en
in the
observed that methylated ERS1 was preferably associated with phenotype Basal Like and worse interval progr
m.
seAlthough numerous
in metastatic breastissues
cancerremain to be
patients wasresolved, the quantitative
characterized by elevatedmeasurement
marker levelsofofcirculating methylated
CXCR4 (86%), survivinDN
(
efficacy and selection of tailored therapy regimes.
lines and taxanes (p > 0.01), in particular HER-2 gene amplification did not alter neither the response to anthra
in the subgroup of responders which are TopoIIa negative and MAPtau positive and the mechanism of resistanc
ction or discontinuation was PD (71%). 69 SAEs were reported, the majority (33/69) due to underlying disease,
were: diarrhea, Arm A/B 60%/61% (gr 3, 0%/13%); fatigue, 30%/26% (gr 3, 10%/4%); hypertension, 20%/22% (
(14.1%), and nausea (12.7%), mostly grade 1–2. An unconfirmed partial response was observed in a melanoma

gnificant association between trastuzumab and subsequent CNS metastases (P = 0.02). However, in multivaria
a patient's death.
3% (all G3); thrombosis in <0.1% (G3); GI perforation in 0.2% (<0.1% G3, <0.1% G4, 0.1% G5); CHF in 0.1% (G
cal CR was noted in 65/217 (30%) patients. No patients had more than RTOG Grade 2 skin toxicity.
749) was not different. Hormone receptor positivity was more prevalent in group A (72.2% vs 40.9%, p = 0.048

RT+ group, compared with 80.8% and 100% in SCNRT- group, respectively (p = 0.9794, p = 0.0713).

rapy. Nevertheless, there remain many unanswered questions regarding optimal adjuvant trastuzumab, such a

s given in 93% of patients, being 100% in France and Belgium, while up to 13–14% of patients from Japan, the U

= 1.75; CI: 1.41–2.17, p < 0.0001) compared with sentinel lymph node dissection. Mastectomy increased the ris
To date, best response observed was stable disease in 6/25 pts (24%). Ten pts progressed and 6 pts discontinue
%) pts achieved a CR, 10 (20%) pts had PRs and 21 (41%) had SD (5 unconfirmed PRs). The majority of respons
pirubicin/cyclophosphamide. Eight of them (89%) experienced disease progression. The response in one patient
.
cause of hematological toxicity (WHO grade 3/4 neutropenia in 14% of cases, 2 case of febrile neutropenia) and

were
ed randomly
with selected
worse CSS as control group. P values less than ≤0.05 was considered statistically significant. Diffe
(p < 0.0102).
p = 0.027) were the only 2 factors significatively associated with a pCR, allowing us to develop an index able to

6.6 and N > 4 8.3 referent to N0 category, p = 0.004), respectively. Significant independent prognostic factor fo
om GEO. In these, 442 patients had a PSMB7 expression higher than the average (2800). The comparison of the
predicted risk of local recurrence was lower after isoeffective hypofractionation compared with single-dose IORT

8).
s 61.8% (52%-77%), 61.1% (50%-78%) and 61% (53%-77%) respectively. No clinically relevant cardiac events

se-led telephone f-up with EGP dominated all other f-up strategies. Uncertainty analysis showed that the proba
and 754 tamoxifen patients switched early to exemestane. No between-group differences were observed for ti
 2.5 (95%CI 1.2–4.9) for >10 positive versus negative lymph nodes], and a decreased risk with treatment with t

n of the disease
developing has response
a partial been achieved? Different
after the strategies of
triple association maintenance
regimen chemotherapy
compared have
to the double been used
association in was
one rand

for pegfilgrastim compared with filgrastim in respect of the primary endpoint: 85.1% achieved 85% or greater

each
ed year
with response to T, TTP, incidence of CNS metastases; OS from start of T was shorter in HER3+ tumors comp

arcoma phyllodes. There was 1 case of mediastinal Nonhodgkins lymphoma with secondary metastasis to breas

urbances, change
all time points. of mood etc.)
Considering CRP,consequences. In patients
serum levels were within with breast
normal cancer
range at allwho
timewish to avoid
points a CIA and
for patients to pr
of the fir
ever, CRP does not appear to reflect these effects since no corresponding
76). Results of the medical chart review are expected before September 2009. increase was detected. Concluding SP

DFS either but on the limit statistical significance (p > 0.05). The significant independent predictors of OS on mu

another patient after selective lymphadenectomy, mastectomy was necessary because of margins' infiltration
with respect to high tumor grade, expression of basal cell markers and high degree of genomic instability due t
ion mutations in BRCA1/2, resulting in re-expression of BRCA1/2 and re-activation of homology-directed DSB rep
beliefs on the disease and therapy (EORTC-INPATSAT-32, OPTIMA-X, GHQ-12, FACT-ES, compliance questionnair

st cancer is more complex than gleaned until now. A copy-number based classification of breast cancer shows th
astasis developed in 5 patients (6.9%) and 22 patients (15.3%), respectively. Therefore, in survival analysis, th

0.029 and p = 0.031). In multivariate analyses axillary lenf node presence and C-erb-B2 overexpression were a
ymph node involvement (p = 0.0023) and progesteron receptor negativity (p = 0.022) were found to be associ

also associated with GSTP1 Ile allele (P = 0.058). Response rate (complete or partial) in the group was 42%. Th

n: patients aged 34–35 showed significantly worse 5-yr survival (41.9%), compared to younger patients (78.4%,
y significant differences were observed in terms of 5-year and 10-year DFS and OS. A multivariate analysis in SP
ostic factor (HR 1.50 95% CI 0.98–2.30). Positive axillary lymph nodes (4–9 lymph nodes: HR 2.55; 95% CI 1.91–

12% (±3.3). In the 2 left sided treated breast, heart received a V33 at similar volume for both treatments.
stant cells (IC50 resistant cells: 18.1±1.9 vs. IC50 resistant-treated cells: 5.5±5.0; P = 0.016). Furthermore, doc
swas
may offer
88% better
(95% CI: therapeutic
22–54) withpotential than
7 complete using
(20%, 4 single
in the inhibitors
liver, 3 in to overcome
lymph drug
nodes), andresistance
22 partial (65%) respons

sequent treatment without evidence of CHF. Of 22 pts with elevated TnI, 4 had LVEF decline >10% and 9 had L
%) did not answer. Majority 12 (48%) of the responders rarely, and none of them always, gave copies of the res
ng to see that majority rarely (48%) or only sometimes (32%) gave copies of the results to their patients
e of them were graded as well differentiated. Eleven of them had vascular involvement. Treatment regimens w
nd pre-closure LA. Four studies showed a reduction in pain with LA which was usually early (<6 hours post op) w

arcinoma (mean age 54.1±4, range 36–81 years) and 156 healthy control subjects (mean age 57.4±6, range 32
motherapy, 1 in G+ and 5 in G-. 9 serious adverse events occurred, which were mainly chemotherapy related (3
p = 0.039). Disease free and overall survival rates were not found to be correlated with β-eta catenin, Cycln D1
h any statistical significant difference for type of recurrences: distant metastases (OR = 0.896, 95% CI 0.674–1.

cant prognostic factors: performance status, hormonal receptor status, previous adjuvant treatment, visceral m
arm C (no grade 4 toxicity). Disease control rate (CR+PR+ SD ≥3 months) in the intent-to-treat population acco
re 1.39 (95% CI 0.98–1.97) and 5.55 (1.94–15.84), p < 0.001; and for 28.5 Gy vs. 50 Gy were 1.09 (0.75–1.58) a

e adult patients who were naïve to intravenous bisphosphonates were randomized 1:1 in a double-blind, double-

lasmamembrane of KPL4 cells, partially co-localizing with EGFR. Moreover, TLR9 coimmunoprecipitates with bo
pression.

71%) received elliptinium-based chemotherapy as second or third metastatic line. Median number of administe

d cells was under all treatment conditions unequivocally significantly correlated to highly increased risk of relap
11), in contrast to the mid and basal segments. The decrease in S remained significant 2 months post-RT (p < 0

hromosome with the A allele above and B allele frequencies below the X axis. SNPs with equal propensity to lose

re not (31.9 v 31.6%, respectively, p = 1). There also was no difference in CBR from PLD between pts who rece
1.9%) and control groups (66.5%).
p = 0.03).

n patients with genotype Ile/Ile, Ile/Val, Val/Val cardiac toxicity was 11/53 (21%), 4/10 (40%) and 1/1 respective
7 days for each drug respectively). Incidence of severe neutropenia in cycle 1 was similar for Hospira filgrastim

onths versus 65 months, p = 0.004). Median post-BM-OS was 23.5 months. Statistical analysis showed that neith
ents with triple negative breast cancer had shorter survival after the development of brain metastasis, compare

d 62% for the AC group, respectively (p = 0.2). With univariate analysis prognostic factors for OS were OR, SBR

alue in late relapse prediction

r mortality. In addition, we will assess the feasibility, resource needs, and likely effects of incorporating routine

FLIE and NCI-CTC vomiting scores were similar between the 2 arms (6.91 vs. 6.88, p = 0.47, and 20% vs. 21%,
model the hierarchy model predicts that tumor-initiating cells can be identified prospectively and purified from t
ur stromal cells was lower than that detected in normal stromal cells.

ve a reduced risk of dying (relative risk: 0.73; 95% confidence interval: 0.54–0.99) compared with other women
and phenotype (basal vs triple-negative). The primary endpoint is 5-year disease-free survival. Secondary endp
011, respectively. The trial is sponsored by CIBOMA/GEICAM.

or pNmi+ status. Elston-Ellis grade was III in 34% (30/89 cases) without any significant difference between T1a
patients 2.3. (p < 0.00001). Median time to BM was longer in HER2- patients 3.3 years vs HER2+ 2 years (p <
nly 4% of SBBC was manifested as inflammatory breast cancer (IBC), while in MBBC group 12.5% of first and 33

MBC patients during the follow-up. Overall survival for patients with MBC found 36.7 months. Twenty patients w
1q24–25, 15q11.2, 17 p11.2, 9 p11.2 and Xq. Amplification of cyclin D1 was detected by CISH in ILCs and their

vant! Online. The results showed that the overall predictive information added by multiple gene sets was signifi

ial subtype there was a trend towards higher levels of NIS expression in more invasive epithelial subtypes, with
P had a lower incidence of G3–4N (7.8%) than pts with SP (40.9%, p < 0.001), irrespective of whether they rece

e of which (53%) exhibited moderate differentiation grade II and the rest, 8 (47%) low differentiation, grade III.
% denosumab, 46% ZA), and infectious serious AEs (7% denosumab, 8% ZA) were similar for both treatment ar

hemical (IHC) identification

ely), whereas, with andetection
their simultaneous anti-cytokeratin antibodywith
was associated applied to ten sections
an increased of each
incidence node. The IMS deat
of disease-related met

8) and ‘information processing speed’ (P = 0.03, Cohen's d = 0.44).

er median values for ve were also observed in TNBC (0.33 vs 0.39, p = 0.001) and MTT was shorter (44.27 vs 4
(OR = 0.936; 95%-CI: 0.942 – 0.987), and also reproducible when diagnoses were replaced by their respective t
lycoproteins. sGPT activity was reduced to approximately 85.4–98.4% of normal levels.

group.

th differing clinical characteristics and disease history.

nical risk factors, such as age, aromatase inhibitor use, family fracture history, corticosteroid or alcohol use, and
r

ion content; 70.7% got the answer they expected and 46.2% achieved a positive impact on their quality of life.
s in the 5 mg/d, 10 mg/d and 30 mg/w cohorts, respectively with 2 cases of febrile neutropenia. G3 stomatitis oc
de metastasis, adjuvant therapy, ER, PR, HER-2 expression, and patient's survival. No significant correlation betw
 up-regulated in distinct tumor subtypes.
ur size were unrelated to patient delay.
cio-demographic characteristics of women, family history of breast or ovarian cancer, symptoms presentation,

y method of the primary tumour was detected, p = 0.859. Conclusions: No signs

n profile. Meanwhile, Fibronectin 1 mean concentration was 190 μg/ml (range) for cancer patients and 125 μg/m
elling, but most genetic variation is explained by lower risk loci. While most if not all the important high-penetr
all progression-free survival and overall survival rate were 83% with no difference between ER+ and ER- patien
Working Group (AGO).
survival benefit(tamoxifen
rine treatment with upfront letrozole
and/or for 5 years,
aromatase guidelines
inhibitor are being
use) during revisited,
five years and further updates are expec
of follow-up.
I: 1.06–2.26). Conclusions: Only half of the breast cancer patients starting tamoxifen continued five years of
risk patients who had received systemic adjuvant therapy, MDM4-overexpression predicted better response to

radiation-induced pneumonitis for the two treatment groups, is directly derived from the data of the table: i) G
gastrointestinal (45), skin (38) and cardiac (43) disorders.
ere correctly identified and localised with guide-wires pre-operatively.
s might underlie fatigue. The chronic fatigued also had a higher level of leucocytes, lymphocytes and neutrophi

us or tumour size.

oor outcome (Table 1).

ive margin. Other pathologic factors such as T stage (p = 0.34), N stage (p = 0.95), presence of DCIS compone
re the treatment cycle began, immediately after the pre-chemotherapy Dexamethasone was administered but b
le.

ed during follow-up.
9[suppl]:66s. Abstract
miRNAs and the 13) with wellvariables
clinicopathologic characterized adverse
ER and events.
HER2/neu receptor status, and nodal status.
sults of the 5 series were most interesting. Mitosis was 0, i.e. process of cell fissions practically stopped. Apopto
as histological grade, steroid hormone receptor status, and the cell proliferation rate were more strongly associa
ding a connection’ with women who had experienced cancer was important. Peer support was strongly desired,

ison to BC ones was confirmed by RT PCR Automatic extraction of DAB-positive cores along vascular endotheliu
b regimen, regardless of other regimens received in neo-adjuvant or adjuvant settings. Cox regression with trea
duction in the risk of death Conclusion: Results from these exploratory analyses suggest there
 ans). Mean normal tissue doses (NTDmean) for heart/LAD, & maximum LAD (LADmax) doses were compared fo
s, grade, adjuvant chemotherapy and hormone therapy.
and negative BC but were greater in hormone receptor negative BC [HR death Quartile 4 vs. Quartile 1 = 6.35, 9
tumours.
e of hormone receptor status to assure treatment of patients most likely to benefit. HER2-targeted therapy is ve
ble
of approaches
an antibodyto tothe global
VEGF enhancement
in the of breast
MSC- conditioned cancer
media treatment.
significantly reduced the change in Vimentin expression
l Like and worse interval progression free and survival global though p > 0.05. We observed that hypermethyla
velsofofcirculating
nt methylated
CXCR4 (86%), survivinDNA is aand
(58%) promising
CD276 tool for cancer risk assessment.
(50%).

neither the response to anthracyclines (p 0.86) nor TopoIIa expression (p 0.4).

and the mechanism of resistance in non-responders which are TopoIIa positive and MAPtau negative.
69) due to underlying disease, including three fatal SAEs (myocardial infarction, cerebral bleeding and liver failu
4%); hypertension, 20%/22% (gr 3, 10%/4%); and nausea, 10%/26% (no gr 3). No related AE ≥gr 4 was reporte
e was observed in a melanoma patient. The five strata were closed after 12 eligible patients had been entered w

= 0.02). However, in multivariate analysis, HER-2 status regardless of trastuzumab therapy was found to be the

G4, 0.1% G5); CHF in 0.1% (G3); impaired healing in 0.2% (0.1% G3, 0.1% G4); cerebral haemorrhage in <0.1
de 2 skin toxicity.
A (72.2% vs 40.9%, p = 0.048) and triple-negativity was more prevalent in group B (16.7% vs 40%, p = 0.113)

0.9794, p = 0.0713).

adjuvant trastuzumab, such as: i) the relationship between trastuzumab efficacy and markers of HER2 assessm

% of patients from Japan, the UK/Ireland and the USA did not receive radiotherapy in this setting. An axillary lym

n. Mastectomy increased the risk of moderate to severe pain (OR = 1.37; CI 1.00–1.87; p < 0.05) compared to b
ogressed and 6 pts discontinued early.
d PRs). The majority of responses (11/12 pts) occurred in pts who were tx-naïve or had received only adjuvant t
n. The response in one patient was not evaluable. Twelve MCB patients (30.8%) developed metastatic disease

ase of febrile neutropenia) and G-CSF support was given in 3 pts. Grade 1 cardiotoxicity occurred in 2 pts at the

ed statistically significant. Differences between dichotomous variables were tested with Chi-square test or Fishe
us to develop an index able to predict the probability of pCR.

ndependent prognostic factor for DFS were BC subtypes (with relative risk (RR) luminal B 4.8, Her2 3.9 and tripl
(2800). The comparison of the survival of the two groups consisting of patients having high and low PSMB7 exp
ompared with single-dose IORT. The reduction was larger with α/β = 10 Gy than with α/β = 4 Gy for tumour cel

nically relevant cardiac events were observed. One patient in arm A experienced a drop of 24 percentage points

analysis showed that the probability of this dominance ranged between 62& and 70% for different QALY thresho
ifferences were observed for time to contralateral breast cancer or OS, and no unexpected safety issues were r
ased risk with treatment with tamoxifen [RR 0.25 (95%CI 0.16–0.40)].

herapy
he have
double been used
association in was
one randomized clinical
1.25:1. We trials significant
observed to answer this question.
toxicities A good
for triple inclusion regimen
association criteria for mainte
when com

5.1% achieved 85% or greater RDI compared with 70.7% of patients who received filgrastim.

shorter in HER3+ tumors compared to HER3 tumors (28.2 vs 42.7 months; p = 0.152). These data confirm the n

secondary metastasis to breast. The most common clinical presentation was palpable mass (n = 5) followed by

ho
mewish to avoid
points a CIA and
for patients to preserve
of the their fertility
first and second groupovarian protection
compared by GnRH
to healthy agonists,
controls cryopreservation
(114.2–3832.6 of op
ng/ml) wherea
e was detected. Concluding SP-D seems to be indicative of lung inflammation in breast cancer patients under r

pendent predictors of OS on multivariate analysis were ductal carcinoma (HR 4.1; CI 1.6–10.6), G3 (HR 3.2; CI 1

ecause of margins' infiltration by comedo type carcinoma. Altogether breast and axillary lymph node preservat
ree of genomic instability due to loss of homology-directed double-strand break (DSB) repair [3]. This model ma
n of homology-directed DSB repair [6,7]. In the mouse mammary tumors BRCA1 is inactivated by a large deletio
CT-ES, compliance questionnaire, and EM feedback questionnaire in Group B patients).

ation of breast cancer shows there are new subtypes that have been previously missed. Copy number vs gene
erefore, in survival analysis, there were no differences in the distant metastasis free survival (78.1% versus 79.

erb-B2 overexpression were a strong negative prognostic factor on disease free survival and overall survival (p
0.022) were found to be associated with systemic metastases rather than local recurrence as the first recurrenc

rtial) in the group was 42%. There was slight preponderance of TYMS 3R/3R homozygotes and heterozygotes am

ed to younger patients (78.4%, p = 0.004). In Cox regression modelling, age at diagnosis increased the relapse
S. A multivariate analysis in SP pts showed an Hazard Ratio (HR) of 2.6 (CI 1.2 to 5.5; p = 0.012). When SP was
nodes: HR 2.55; 95% CI 1.91–3.40; ≥10 lymph nodes: HR 4.65; 95% CI 3.29–6.58) and LVI (HR 1.58; 95% CI 1.2

ume for both treatments.

0; P = 0.016). Furthermore, docetaxel sensitivity was also increased in MDA-MB-231 cells (IC50 resistant cells: 4
drug
), andresistance
22 partial (65%) responses; 3 pts had stable disease >6 months and 2 pts progressed, for an overall dise

VEF decline >10% and 9 had LVEF decline 5 ≤10%. Only 3 of 15 pts (20%) with TnI <0.06 ng/ml had LVEF decli
always, gave copies of the results to their patients with 5 (20%) saying frequently and 8 (32%) saying sometim
results to their patients
ement. Treatment regimens were as follows; 99 patients underwent surgery followed by adjuvant chemotherap
ally early (<6 hours post op) while one study also found a significant reduction in pain at 3 months. Two studie

ts (mean age 57.4±6, range 32–75 years) without any history of malignancy in which the clinical evaluation inc
ainly chemotherapy related (3 febrile neutropenias, 2 neutropenias, 2 nauseas, 1 infection of port-catheter and
 d with β-eta catenin, Cycln D1, FRP1 ve FRP2 expression percentages. β-catenin localization and disease free a
(OR = 0.896, 95% CI 0.674–1.192, p = 0.453), visceral recurrences (OR = 1.051, 95% CI 0.686–1.609, p = 0.82

adjuvant treatment, visceral metastasis at entry and number of metastatic sites. When exploring the effect of n
intent-to-treat population according to the investigator and after an independent review was (A/B/C): 73%, 48%
50 Gy were 1.09 (0.75–1.58) and 2.33 (0.73–7.42), p = 0.22. Any clinically-assessed moderate/marked adverse

d 1:1 in a double-blind, double-dummy design to receive subcutaneous denosumab 120 mg or intravenous zole

coimmunoprecipitates with both ErbB2 and EGFR and IMO reduces such interaction, particularly with EGFR. Fin

e. Median number of administered cycles was 3 (range 1–10). The rate of response was of 26% [7% (22 pts) com

o highly increased risk of relapse.

ificant 2 months post-RT (p < 0.001), whereas SR went back to baseline values. We also observed that segmen

Ps with equal propensity to lose both alleles resulted a symmetric plot, while SNPs where one of the allele was p

rom PLD between pts who received prior CAC adjuvant only (33.3%), anti-metastatic only (34.4%) or both (29.4

4/10 (40%) and 1/1 respectively, being a trend (p = 0.09).

as similar for Hospira filgrastim (77.6%) and Neupogen (68.2%). In cycle 1, mean time to ANC recovery was 7.8

tical analysis showed that neither tumor grade nor ER-negative status or adjuvant anthracycline- and/or taxane
nt of brain metastasis, compared to patients with receptor positive cancer (2.4 months Vs 6.2 months; p = 0.008

c factors for OS were OR, SBR and post operative staging AJCC. With multivariate analysis, OR and SBR remaine

ffects of incorporating routine blood marker studies into the Yugra screening program.

88, p = 0.47, and 20% vs. 21%, p = 0.73, for P and C, respectively). Grade II-III nausea occurred in 17.6% and 1
 ospectively and purified from the bulk of non-tumorigenic population based on intrinsic characteristics. The fact

9) compared with other women with breast cancer. The effect was not significantly modified by age at diagnosis
-free survival. Secondary endpoints include overall survival and safety. An optional pharmacogenetic substudy

nificant difference between T1a and T1b; 29% of tumours showed lymphovascular invasion (LVI). In one case of
years vs HER2+ 2 years (p < 0.00001). Higher node ratio was also significant risk factor for faster BM (p < 0.0
BBC group 12.5% of first and 33% of second malignancy was diagnosed cancer mastitis. Negative nodal status a

36.7 months. Twenty patients with MBC are currently alive.

ected by CISH in ILCs and their matching LN and FEA lesions.

y multiple gene sets was significant and the model incorporated gene-set predictors outperformed Adjuvant! On

vasive epithelial subtypes, with the Luminal B group having significantly lower expression than the Her2 group (
espective of whether they received FLG or PEG. The incidence of G3–4N with FLG or PEG was similar (9.4% vs 1

%) low differentiation, grade III. Moreover, based on immunohistochemical analysis, 8 cases (47%) were triple ne
e similar for both treatment arms. Osteonecrosis of the jaw occurred infrequently (20 [2.0%] denosumab, 14 [1

ons of each
idence node. The IMS death
of disease-related method showed
and by far
decreased the highest
overall sensitivity,
survival but The
(p = 0.016). there was onlyofaeither
detection minimal overlap
CTCs and/oi

d MTT was shorter (44.27 vs 47.69, p = 0.007). There was no correlation between age and any kinetic paramet
e replaced by their respective tumour stages in the analysis for a finer resolution of the cancer diseases.

rticosteroid or alcohol use, and smoking, with or without BMD to determine whom to treat.

impact on their quality of life. Some important suggestions received were more detailed answers, some kind of
e neutropenia. G3 stomatitis occurred in 1 pt (17%), in the 5 mg/d cohort, 3 pts (18%) in the 10 mg/d, and 3 pts
. No significant correlation between the above-stated clinicopathologic parameters and the antigen expression
ncer, symptoms presentation, and specialty of first consulted physician were unrelated to provider delay.

Conclusions: No signs of benign epithelial displacement was detected in the examined ITC cases. Furth

r cancer patients and 125 μg/ml (range) for normal volunteers (p < 0.001). AUC for breast cancer diagnosis we
t all the important high-penetrance loci have been identified, identification of lower penetrance loci through ge
e between ER+ and ER- patients.

and further updates are expected. In the 2009 St. Gallen consensus vote, the majority (70%) favored upfront us
llow-up.
moxifen continued five years of endocrine treatment. Identification of patients at risk of discontinuation will assi
n predicted better response to both hormone- [HR, 2.7; p < 0.0001] and chemo-therapies [HR, 6.7; p = 0.008].

from the data of the table: i) Group-A: 12.5% (6-month follow up) and 25% (9-month follow up), and ii) Group-B

es, lymphocytes and neutrophils compared with the non-fatigued, thus further indicating that an activation of th

5), presence of DCIS component (p = 0.29), presence of infiltrative tumor border (p = 0.15), presence of endoly
hasone was administered but before chemotherapy and, immediately after chemotherapy and 10 days after ea

nd nodal status.
ons practically stopped. Apoptosis was 8.1% against the expressed destructive changes of stroma and almost to
ate were more strongly associated with outcome than the pN0i status.
support was strongly desired, both for emotional support and practical ‘tips’. Knowledge and use of cancer cha

ores along vascular endothelium scatter plots showed more homogenous expression pattern in PABC tumors th
tings. Cox regression with treatment (trt), prior regimens, and an interaction was performed.
oratory analyses suggest there may be benefit in using L+C in pts treated with fewer prior regimens and with o
Dmax) doses were compared for prone vs supine positions (paired t-test) and by individual patient (IP).Reviewin

uartile 4 vs. Quartile 1 = 6.35, 95% CI 1.1 vs. 36.8] than in hormone receptor positive BC [HR death Quartile 4 v

it. HER2-targeted therapy is very effective in tumors that overexpress the HER2/neu oncogene, but cost largely
change in Vimentin expression in both cell lines. MSC secreted TGFb-1 was also shown to play a role in upregul
We observed that hypermethylation of ERS1 and 14–3-3σ combined differentiated between breast cancer patien

nd MAPtau negative.
erebral bleeding and liver failure). The median TTP was 32.2 weeks (95% CI 29.58, 34.81). The best ORR was C
o related AE ≥gr 4 was reported. 2 deaths occurred on study (Arm B; 50 and 125 mg, n = 1 each); neither was
ble patients had been entered without responding.

b therapy was found to be the only independent predictive factor for CNS metastases (either as first or as subs

cerebral haemorrhage in <0.1% (G5), pulmonary embolism in 0.4% (0.1% G3, 0.2% G4, <0.1% G5); hypertensi

p B (16.7% vs 40%, p = 0.113). The mean size of the largest lesion was bigger in group B than in group A (20.8

y and markers of HER2 assessment (HER2 protein expression, gene copy number, and chromosome 17 polysom

py in this setting. An axillary lymph node dissection (ALND) was performed in 82% of patients, ranging from 75%

–1.87; p < 0.05) compared to breast-conserving surgery. Pain complaints from other parts of the body were ass

or had received only adjuvant therapy (for this group: ORR = 32%; CBR = 44%). Median PFS was 26 wks (95% C
developed metastatic disease as initial presentation or during follow-up after primary treatment. Among them,

toxicity occurred in 2 pts at the 4th cycle and in 3 additional pts at the completion of adjuvant CT; other non ha

ed with Chi-square test or Fisher's exact test. Conclusion: It has been observed that high Ca 15–3, C-e

minal B 4.8, Her2 3.9 and triple negative 7.7 referent to luminal A, p = 0.0001), the number of positive nodes >
aving high and low PSMB7 expression resulted in high significance (p = 0.006).
with α/β = 4 Gy for tumour cells but the size of the sphere of equivalence (within which local control is the sam

a drop of 24 percentage points from baseline at the end of therapy, still remaining above the limit of normal.

70% for different QALY threshold values. Furthermore, sensitivity analyses with a range of cost prices for hospit
nexpected safety issues were reported. Patients ≥70 years old and those with N1 tumors had significant better
 od inclusion regimen
association criteria for maintenance
when comparedchemotherapy would be34%
with standard regime: patients with3HER-2
of grade (-) tumors,
neutropenia negative
versus 15% andhormone
15%

d filgrastim.

152). These data confirm the notion that HER2/HER3 heterodimer is the major oncogenic unit in HER2+ MBC.

pable mass (n = 5) followed by progressive increase in breast size (n = 2). Tumour staging in the study group w

sgonists, cryopreservation
(114.2–3832.6 of operative
ng/ml) whereas sampled
increased levelsovarian
(4946.2tissue or were
ng/ml) obtained fertilized
observed onlyor non-fertilized
prior eggs
to radiation after f
therapy
breast cancer patients under radiation therapy, serving as a specific noninvasive serological marker.

; CI 1.6–10.6), G3 (HR 3.2; CI 1.6–6.4), negative steroid receptors (HR 9.4; CI 3.1–28.5) and amplification HER2 (

axillary lymph node preservation was possible in 108 (78%) of patients. Fifteen patients (11%) had fibrosis of t
DSB) repair [3]. This model may therefore be helpful in predicting chemotherapeutic responses of human BRCA
s inactivated by a large deletion in the Brca1 gene that cannot be reversed by any secondary mutation. To mod
ents).

missed. Copy number vs gene expression correlation has highlighted both copy-number dependent as well as c
ree survival (78.1% versus 79.1%, p = 0.847), but 5-year loco-regional recurrence free survival was statistically

survival and overall survival (p = 0.04, p = 0.03 for DFS and p = 0.03, p = 0.007 for OS). E-cadherin and bcl-2 f
ecurrence as the first recurrence pattern. Progesteron receptor positivity predicts systemic metastases to bone

ozygotes and heterozygotes among responders versus nonresponders (P = 0.077). In treated with 5-FU in turn,

agnosis increased the relapse risk by 7.6% per each year (p = 0.07), within the moderately narrow age frame a
5.5; p = 0.012). When SP was associated with several prognostic variables (age, ER, PR, G2/3, Ki 67, stage T4 d
8) and LVI (HR 1.58; 95% CI 1.21–2.06) were time-independent risk factors throughout the follow-up.

31 cells (IC50 resistant cells: 43.3±8.6 vs. IC50 resistant-treated cells: 22.4±2.6; P = 0.016).
progressed, for an overall disease control of 94%. Median PFS was 12 months, median overall survival has not

TnI <0.06 ng/ml had LVEF decline >5%. Elevations in TnI occurred only during chemotherapy and no pt had a Tn
ly and 8 (32%) saying sometimes. All (100%) the oncologists calculated outcome for mortality and 9 (36%) calc
owed by adjuvant chemotherapy, 17 patients received neo-adjuvant therapy, and 51 patients received postoper
n pain at 3 months. Two studies showed no difference between placebo and LA. There was no difference in post

which the clinical evaluation including mammography and breast ultrasound did not reveal any breast pathology
1 infection of port-catheter and 1 psychogenic hyperventilation).
localization and disease free and overall survival relation was also assessed 64 patients and existence of cytop
, 95% CI 0.686–1.609, p = 0.820) and local relapses (OR = 1.056, 95% CI 0.750–1.487, p = 0.756).

When exploring the effect of new treatment introduction, taking into account the same significant prognostic f
t review was (A/B/C): 73%, 48%, 79% and 71%, 37% and 69%, respectively. Lower disease control rate in Arm B
sed moderate/marked adverse effects in the breast were increased for 30 Gy compared with 50 Gy (hazard rat

ab 120 mg or intravenous zoledronic acid (ZA) 4 mg or adjusted for creatinine clearance every 4 weeks. Patient

ion, particularly with EGFR. Finally, on human endothelial cells, the combination IMO plus trastuzumab produces

se was of 26% [7% (22 pts) complete remission (CR), 19% (57 pts) partial remission]; 23% (71 pts) presented st

We also observed that segments exposed to more than 3 Gy, showed a decrease in S immediately and at 2 mon

s where one of the allele was preferentially lost, resulted in an asymmetric plot. Based on an arbitrary threshold

atic only (34.4%) or both (29.4%; p = .71), nor there were differences for CBR regarding the cumulative dose of

time to ANC recovery was 7.8 days for both groups. Incidence of febrile neutropenia (FN) over cycles 1–3 was 2

nt anthracycline- and/or taxane-based chemotherapy were significantly correlated with the risk of developing BM
onths Vs 6.2 months; p = 0.0086).

e analysis, OR and SBR remained significant. Timing of chemotherapy did not impact on OS. If NAC, the patholog

ausea occurred in 17.6% and 15.7% of patients receiving P and C (p = 0.62).

 trinsic characteristics. The fact that most epithelial cancers are composed of cells that retain at least some leve

ly modified by age at diagnosis, tumour size, nodal status, or pregnancy history before diagnosis of breast canc
nal pharmacogenetic substudy is exploring polymorphisms of thymidylate synthase and methylenetetrahydrofo

r invasion (LVI). In one case of pN0 IDC, initial work up revealed a single bone metastatic deposit while hepatic
sk factor for faster BM (p < 0.00001). A median time to BM shortened with T stage and was 4.4, 3.1, 2.3 and 1.5
astitis. Negative nodal status at diagnosis was similar in groups, 33% of SBBC and 28% of MBBC. In a group of S

ors outperformed Adjuvant! Online model.

pression than the Her2 group (p < 0.05).

G or PEG was similar (9.4% vs 12.1%, p = 0.35), but in FLG pts, a higher incidence of G3–4N was observed when

s, 8 cases (47%) were triple negative ER(-) PR(-) HER-2(-), 7 (41%) were ER(+) PR(+) HER-2(-) and 2 (12%) ER(+
y (20 [2.0%] denosumab, 14 [1.4%] ZA; P = 0.39). AEs potentially associated with renal toxicity occurred in 4.9%

e was onlyofaeither
detection minimal overlap
CTCs inDTCs
and/or results
wasbetween the two methods.
an independent factor (p Verification of the cells
= 0.040) associated withidentified
decreasedwith IMS a
surviva

n age and any kinetic parameters. When stratified according to tumour size and nodal status, kep was higher in
of the cancer diseases.

m to treat.

detailed answers, some kind of follow-up and the possibility to organize “patient forums” or “group therapies”.
18%) in the 10 mg/d, and 3 pts (30%) in the 30 mg/w. G3 asthenia/fatigue was observed in 2 pts (33%) in the 5
rs and the antigen expression was identified. The only exception was the patients' survival data which indicate
 elated to provider delay.

n the examined ITC cases. Furthermore, ITC were not detected more frequently in patients with more invasive p

for breast cancer diagnosis were 0.78 and 0.62 for Fibronectin 1 and CXCL9 respectively. A combined score incl
wer penetrance loci through genome-wide association studies is still in its infancy, and more further loci should

ajority (70%) favored upfront use of AIs. Conclusions: Of the 3 classes of adjuvant therapy investigated in this
risk of discontinuation will assist in the development of interventions to improve adherence.
herapies [HR, 6.7; p = 0.008].

nth follow up), and ii) Group-B: 66.7% (6-month follow-up) and 25% (9-month follow-up).

dicating that an activation of the immune system plays a role in the biology of CF in BC survivors.

(p = 0.15), presence of endolymphatic tumor emboli (p = 0.12) had no significance for LRFS. Also the time inte
motherapy and 10 days after each cycle.

hanges of stroma and almost total cell destruction.

owledge and use of cancer charities varied. Services provided by the statutory and voluntary sectors were often

sion pattern in PABC tumors than in sporadic BC ones.

s performed.
ewer prior regimens and with only one prior trastuzumab regimen.
 ndividual patient (IP).Reviewing IP data for WBI, prone positioning improved heart/LAD doses in 13/22 cases (m

itive BC [HR death Quartile 4 vs. Quartile 1 = 3.03 (1.18–7.75)]. Smoothed HR curves over time show an increa

neu oncogene, but cost largely prevents the use of this treatment in LMCs.
shown to play a role in upregulation of N-Cadherin expression in the SK-BR-3 cell line.
between breast cancer patients and healthy controls (p = 0.0001) with a sensitivity of 81% (95% CI: 72–88%) a

8, 34.81). The best ORR was CR in 7.9%, PR in 17.6%, SD in 37% and PD in 27.9%. 3.6% of pts withdrew conse
mg, n = 1 each); neither was considered to be motesanib-related. Motesanib PK parameters were generally wi

tases (either as first or as subsequent recurrences; P < 0.001).

2% G4, <0.1% G5); hypertension in 3.0% (3.0% G3, <0.1% G4). Median TTP is 9.5 months (95% CI: 9.1–10.0). O

group B than in group A (20.8 mm vs 14.4 mm, p = 0.024). There was no difference in the number of lesions b

, and chromosome 17 polysomy), topoisomerase II co-amplification, c-MYC and PTEN; ii) the selection of patient

% of patients, ranging from 75% in the USA to 99% in the UK/Ireland. In multivariate logistic regression analysis,

her parts of the body were associated with increased risk of pain in the surgical area (p < 0.0001). 10% of pain

Median PFS was 26 wks (95% CI, 19.4–31.9). Most AEs were G1/2; G3 non-hematologic AEs (occurring in ≥10% p
mary treatment. Among them, 10 patients received chemotherapy. Only 2 patients (20%) had partial response,

n of adjuvant CT; other non haematological toxicities were within grade 1–2. All 52 pts underwent surgery witho

bserved that high Ca 15–3, C-erb-B2 positivity and estrogen receptor negativity are risk factors for brain metas

the number of positive nodes >4 (RR 2.01 referent to N0 category, p = 0.049) and tumor size (T2 RR 2.28 refer

which local control is the same as for external beam RT) was larger than 10 mm in all cases.

ng above the limit of normal.

a range of cost prices for hospital visits (€50–200) and telephone f-up (€10–50) showed that cost-effectiveness r
tumors had significant better DFS on exemestane compared to those on tamoxifen.
 2 (-) tumors,
tropenia negative
versus 15% andhormone receptor tumors
15% peripheral or hormone
neuropathy refractory patients. In HER-2 (+) patients the use o
versus 3%.

ncogenic unit in HER2+ MBC.

ur staging in the study group was as follows: Stage IIA: n = 1, stage IIIB: n = 2 and stage IV: n = 2. Patients with

ed or
only non-fertilized
prior eggs
to radiation after for
therapy stimulation andof
the patients puncture
the thirdorgroup.
embryos after in vitro
No disease fertilization
progression was are technically
observed pos
accordin
serological marker.

28.5) and amplification HER2 (HR 4.1; CI 1.2–15.2). Neither regimen of irradiation (p = 0.5) nor period of treatm

patients (11%) had fibrosis of the treated breast quadrant. In patients after breast conservation who reached 1
utic responses of human BRCA1-associated and BRCA1-like tumors. Indeed, preclinical intervention studies with
ny secondary mutation. To model chemotherapy resistance by genetic reversion, we have generated novel BRC

number dependent as well as copy-number independent chromosomal loci. New breast cancer oncogenes and t
e free survival was statistically significant between two groups (93.3% versus 79.1%, p = 0.0026).

for OS). E-cadherin and bcl-2 failed to have an effect on disease free survival and overall survival in our study.
systemic metastases to bone and soft tissue rather than visceral organ involvement and patients who have cra

7). In treated with 5-FU in turn, 2R allele was found to be prevalent among good responders (P = 0.051).

moderately narrow age frame assessed in our study. The effect of age group (34–35 vs younger) was significant
, ER, PR, G2/3, Ki 67, stage T4 d and HER2) the HR ranged between 2.3 and 2.6, whereas when SP was associat
ghout the follow-up.

P = 0.016).
median overall survival has not been reached.

emotherapy and no pt had a TnI > 0.06 ng/ml during TL or at 18 mth F/up. At baseline 29/37 pts (78%) had nor
e for mortality and 9 (36%) calculated for both mortality and relapse. When asked as to at what percentage of m
d 51 patients received postoperative radiation. During a median follow-up time of 4 years, 8 patients experience
There was no difference in post-operative complications. No study documented at mortality

not reveal any breast pathology. Genomic DNA was isolated from peripheral venous blood, while single nucleotid
patients and existence of cytoplasmic localization of β-catenin was not found to affect survival rates.
1.487, p = 0.756).

e same significant prognostic factors, the effect of time period disappears and the same effect magnitude is exp
er disease control rate in Arm B could be due to higher prevalence of patients with visceral disease in this arm.
mpared with 50 Gy (hazard ratio, HR 2.12, 95% CI 1.34–3.36, p = 0.001), but similar for 28.5 Gy (HR 1.02, 95%

earance every 4 weeks. Patients were stratified by tumor type (non-small cell lung cancer, MM, or other), amon

MO plus trastuzumab produces a cooperative antiangiogenic effect related to a complete suppression of endoth

on]; 23% (71 pts) presented stable disease, 45% (139 pts) progression disease and 6% (17 pts) non-evaluable

in S immediately and at 2 months post-RT (p = 0.0003), in contrast to segments receiving less than 3 Gy. Furth

Based on an arbitrary threshold, only the asymmetric SNPs were highlighted. Finally, genes involved in the asym

garding the cumulative dose of the prior CAC. There was a trend towards a higher CBR in pts who received PLD

enia (FN) over cycles 1–3 was 2.4% for both treatments, and incidence of hospitalisation due to FN was similarly

d with the risk of developing BM. In the multivariate analysis only younger age at diagnosis (<50 versus >50) w

pact on OS. If NAC, the pathological complete response rate was 13% with OS rates at 1, 5 and 10 years: 100%,
s that retain at least some level of differentiation suggests that the cancer stem cell generates a linage restrict

before diagnosis of breast cancer. Furthermore, neither spontaneous abortions nor induced abortions subseque
se and methylenetetrahydrofolate reductase in relation to efficacy and tolerability of X.

etastatic deposit while hepatic metastases were discovered 2 years later. All patients were treated by surgery; r
e and was 4.4, 3.1, 2.3 and 1.5 years for T1-T4 respectively and also shortened with N stage and was 3.7, 3.1, 1
d 28% of MBBC. In a group of SBBC, 21 of 40 (52.5%) tumors were found to be ductal and 14 (35%) were lobula

e of G3–4N was observed when treatment duration was <7 days/cycle (13.6% vs 3.7% for ≥7 days, p = 0.018).

R(+) HER-2(-) and 2 (12%) ER(+) PR(-) HER-2(-). The stage of the disease in 7 cases (41%) was IIA, in 3 cases (1
h renal toxicity occurred in 4.9% of the denosumab arm and in 8.5% of the ZA arm. Overall survival (HR 0.95; 9

f the cells
ociated withidentified
decreasedwith IMS as tumour cells was obtained by simultaneous binding of non-magnetic fluorescen
survival.

nodal status, kep was higher in TNBC but the differences did not reach statistical significance. Values for ve we

forums” or “group therapies”.

bserved in 2 pts (33%) in the 5 mg/d, 3 pts (18%) pts in the 10 mg/d, and 2 pts (20%) in the 30 mg/w cohorts. T
s' survival data which indicate a possible association between the expression of these C/T antigens and decreas
n patients with more invasive preoperative biopsy methods.

ectively. A combined score including Fibronectin 1 and CXCL9 dosages presented a sensitivity of 53% and a 98%
, and more further loci should be identifiable through genome scans and resequencing. Generally, genetic loci c

ant therapy investigated in this study, the inclusion of adjuvant trastuzumab into guidelines has generally been
adherence.

F in BC survivors.

nce for LRFS. Also the time interval between surgery and radiotherapy (p = 0.22) as well as the sequence betw

nd voluntary sectors were often not seen as relevant to, or representative of, women from these communities.
rt/LAD doses in 13/22 cases (mean improvement in LAD NTDmean = 8.1 Gy) but worsened doses in 9/22 cases

rves over time show an increased risk of distant recurrence and death for the first 5 years after diagnosis, with

vity of 81% (95% CI: 72–88%) and specificity of 88% (95% CI: 78–94%). In addition observed lower methylated

%. 3.6% of pts withdrew consent and in 6.1%, study therapy was discontinued at the investigator's decision.
parameters were generally within the range described for single-agent motesanib treatment. PK profiles of P a

.5 months (95% CI: 9.1–10.0). OS data are still immature (78% of pts alive at data cut-off). C

ence in the number of lesions between two groups (2.17 (A) vs 2.76 (B), p = 0.361). PET was performed in 29 pa

TEN; ii) the selection of patients for non-anthracycline based chemotherapy; iii) the decision to administer trast

ate logistic regression analysis, country, type and year of breast surgery were independent factors associated w

area (p < 0.0001). 10% of pain patients had contacted a physician with the last 3 months for pain complaints in

ologic AEs (occurring in ≥10% pts) were asthenia (13%) and hypertension (11%). G3/4 neutropenia occurred in
ts (20%) had partial response, all the other 8 patients (80%) had progressive disease. All of the patients with m

52 pts underwent surgery without delay; breast conserving surgery was performed in 24/29 candidate pts; 5 pts

are risk factors for brain metastasis in our study. We could not detect any association with more commonly kno

d tumor size (T2 RR 2.28 referent to T1 category, p = 0.004).

in all cases.

howed that cost-effectiveness results were robust.

fen.
 In HER-2 (+) patients the use of trastuzumab until progression appears to be clinically justified, as well as the u

d stage IV: n = 2. Patients with malignant cystosarcoma had localized disease. Treatment was with a combinati

fertilization
ression was are technically
observed possible.
according However
to clinical there are
evaluation notumor
and evidence-based recommendations
marker measurements for preservation
(CEA and CA 15–3).

n (p = 0.5) nor period of treatment (p = 0.4) were significant predictors of DFS. However the risk of death for pa

st conservation who reached 1 year follow-up, the BCCT.core® general aesthetic score was excellent in 52%, go
linical intervention studies with conventional and targeted chemotherapeutics showed a selective sensitivity of
we have generated novel BRCA1-deficient mouse mammary tumor models mimicking defined human BRCA1 fo

breast cancer oncogenes and tumor suppressor genes have been identified. The genomic landscape of breast c
.1%, p = 0.0026).

d overall survival in our study. In addition, p53 mutation positivity was observed in seven patients (9.2%), there
ment and patients who have cranial and leptomeningeal involvement during the first recurrence have a tendenc

esponders (P = 0.051).

–35 vs younger) was significant also in multivariate analysis, in the context of nodal and hormone receptor statu
whereas when SP was associated with p53 the HR was 3.27 (CI 1.5 to 7.2).

seline 29/37 pts (78%) had normal CRP (<0.8 mg/dl). Elevations in CRP (>0.8 mg/dl) occurred in 29/37 (78%) pt
d as to at what percentage of mortality benefit they would discuss and recommend chemotherapy, the answer v
 4 years, 8 patients experienced relapse, of which 2 were local relapses and 6 were distant relapses (brain and
t mortality

us blood, while single nucleotide polymorphism 936 C/T genotyping in the VEGF receptor was performed using
ffect survival rates.

e same effect magnitude is explained directly by the introduction of taxanes or trastuzumab (taxanes at 1st lin
h visceral disease in this arm. Due to short follow-up, the progression-free survival and overall survival have no
ilar for 28.5 Gy (HR 1.02, 95% CI 0.60–1.73, p = 0.94). To date, 2 local tumour relapses have been recorded.

g cancer, MM, or other), among other variables. All patients were strongly recommended to take daily supplem

complete suppression of endothelial ErbB-related signaling.

nd 6% (17 pts) non-evaluable (treatment refusal or toxicity). Concerning the correlation of response to ER, we r

receiving less than 3 Gy. Furthermore, significant correlations were found between the decrease in S post-RT a

ally, genes involved in the asymmetric region were obtained. Results: Table shows SNP numbers, unc

r CBR in pts who received PLD >12 months versus ≤12 months since the end of their prior CAC (34.2 v 26.3%,

lisation due to FN was similarly low at 2.1% in each group. Incidence of treatment-related adverse events (TRAE

diagnosis (<50 versus >50) was significantly associated with increased risk of BM (p < 0.005).

es at 1, 5 and 10 years: 100%, 83%, 83%, respectively.

cell generates a linage restricted progeny with a finite life span which nevertheless constitute the majority of th

or induced abortions subsequent to breast cancer treatment seem to influence the prognosis. Overall, the fertil

ents were treated by surgery; radiotherapy, chemotherapy and TZM were delivered in 75%, 54% and 45% of pt
with N stage and was 3.7, 3.1, 1.5 and 1 for N0-N3. Patients with brain metastases as a first site had a shorter ti
uctal and 14 (35%) were lobular carcinoma. In a group of MBBC frequency of ductal and lobular carcinoma was

3.7% for ≥7 days, p = 0.018). In pts receiving FLG, achievement of FDOS was less frequent with SP vs PP (54.2%

ses (41%) was IIA, in 3 cases (18%) IIIA, in 3 (18%) IIIB, in 2 (12%) IV, in 1 (5.5%) IIB and in 1 case (5.5%) was st
m. Overall survival (HR 0.95; 95% CI: 0.81, 1.11; P = 0.50) and time to cancer progression (HR 0.99; 95% CI: 0.8

ng of non-magnetic fluorescent beads coated with antibodies recognizing known breast cancer markers (Muc1,

significance. Values for ve were significantly lower in T3/4 TNBC (0.33 vs 0.41, p = 0.009) and for node negativ

20%) in the 30 mg/w cohorts. Thirty pts were evaluable for efficacy. In the 5–10 mg/d cohorts (N = 21), we obse
these C/T antigens and decreased overall survival: MAGE-A1 P = 0.07960, MAGE-A3/4 P = 0.01088, NY-ESO-1 P
d a sensitivity of 53% and a 98% specificity. Similar performances were observed for ER-negative tumors.
encing. Generally, genetic loci combine multiplicatively, consistent with multiple independent pathways.

guidelines has generally been the most rapid, and the inclusion of adjuvant taxanes into guidelines has been th

) as well as the sequence between radiotherapy and chemotherapy (p = 0.41) had no significance for LRFS. How

men from these communities. As a result, women were often dissatisfied with services used.
worsened doses in 9/22 cases (mean increase in LAD NTDmean = 9.8 Gy). A supine LAD NTDmean of ≥12 Gy c

st 5 years after diagnosis, with no excess risk after 5 years. Conclusions: Adverse prognostic effects of h

on observed lower methylated ERS1 and 14–3-3σ value after surgery, respect pretreatment levels, but without a

the investigator's decision.

ib treatment. PK profiles of P and D showed high interpatient variability; AUC was higher in some pts after mote

a cut-off). Conclusions: In this large study, safety and efficacy of Bev combined with taxane-

1). PET was performed in 29 patients (67%). Metastatic lesions had significantly higher maximal SUV than that o

he decision to administer trastuzumab in a sequential or concurrent manner with chemotherapy; iv) the minima

dependent factors associated with ALND.

months for pain complaints in the surgical area. Risk of sensory disturbances was associated with young age (O

G3/4 neutropenia occurred in 6 pts (12%). In total, 3 non-hematologic G4 AEs occurred (6%; all considered rela
ease. All of the patients with metastatic diseases died of their diseases (3 year survival = 0%). The median surv

ed in 24/29 candidate pts; 5 pts preferred total mastectomy. The clinical overall response rate (ORR) was 86% (

ation with more commonly known risk factors such as being triple negative, menopausal status, T stage and nod
nically justified, as well as the use of endocrine therapy in hormone receptor (+) tumors following chemotherapy

reatment was with a combination of surgery, chemotherapy and radiotherapy. At 34 months follow up in 3 patie

mmendations
ements for preservation
(CEA and CA 15–3). of fertility or ovarian function in breast cancer patients. Except the cryopreservat

However the risk of death for patients treated between 1999–2002 was nearly three times more then for patient

score was excellent in 52%, good in 42%, and fair in 6% of patients. There was neither poor aesthetic outcome
howed a selective sensitivity of BRCA1-deficient mouse mammary tumors towards agents that directly or indirec
icking defined human BRCA1 founder mutations (185-delAG and 5382-insC).

genomic landscape of breast cancer is therefore extremely complex and this has both biological and clinical im

in seven patients (9.2%), there was not any effect on prognostic parameters (p = 0.419 for DFS and p = 0.218
irst recurrence have a tendency to have progesteron receptor negative tumors (p = 0.028). In multivariate anal

dal and hormone receptor status, with hazard ratio of 1.93 (p = 0.016).

/dl) occurred in 29/37 (78%) pts during chemotherapy but only in 8/37 (22%) pts during TL or at 18 mth F/Up.
nd chemotherapy, the answer varied from 0 to 10%, but majority (60%) said they would discuss chemotherapy
ere distant relapses (brain and lung metastasis). At the end of the study, 106 of 116 are not metastasis till the c

receptor was performed using PCR-RFLP methode. We have not detected any 936 T/T genotype of VEGF gene b
rastuzumab (taxanes at 1st line: yes vs. no: HR = 0.73, p = 0.004; trastuzumab at 1st line: yes vs. no: HR = 0.6
al and overall survival have not been reached.
lapses have been recorded.

mended to take daily supplemental calcium (≥500 mg) and vitamin D (≥400 IU). This study is sponsored by Am

relation of response to ER, we registered CR in 10% (15 pts) of positive ER pts, and in 6% (4 pts) of negative ER

een the decrease in S post-RT and the side of irradiation, the BMI, the mean LV segmental dose and the volume

Table shows SNP numbers, uncontaminated (after filtering) and asymmetric SNPs involved in horizontal disparit

their prior CAC (34.2 v 26.3%, respectively, p = .21) and in taxane naïve pts (39.4 vs. 27.7; p = .089). A signific

t-related adverse events (TRAEs) was similar (24.6% for Hospira filgrastim, 23.2% for Neupogen). Consistent wi

M (p < 0.005).
ess constitute the majority of the tumor. It follows that the bulk of the tumor would die out without being replen

he prognosis. Overall, the fertility rate is reduced to one third, and the incidence of induced abortion is significa

red in 75%, 54% and 45% of pts respectively. With a 27 months median follow-up, 2 invasive recurrences have
s as a first site had a shorter time to BM than patients with other primary sites (2.0 vs 3.4 years).
ctal and lobular carcinoma was the same, 15 of 35 (43%). Same HP results in both breasts were found in 79% of

ss frequent with SP vs PP (54.2% vs 73.7%, p = 0.045), whereas no difference was observed for pts receiving PE

IIB and in 1 case (5.5%) was stage I. The patients were treated accordingly with anthracyclines and taxanes ba
ogression (HR 0.99; 95% CI: 0.89, 1.11; P = 0.90) were balanced between treatment arms.

breast cancer markers (Muc1, erbB2, EGFR, B7-H3). Surprisingly, such validated tumour cell positive samples w

p = 0.009) and for node negative BC (0.33 vs 0.41, p = 0.004). In node positive BC rBF was significantly higher i

mg/d cohorts (N = 21), we observed 2 CRs, 7 PRs, 11 SDs and 1 PD, for an overall response rate (ORR) of 43%. I
A3/4 P = 0.01088, NY-ESO-1 P = 0.11742.
for ER-negative tumors.
ndependent pathways.

nes into guidelines has been the slowest. Clinicians have traditionally relied on guidelines to assist them in trea

d no significance for LRFS. However, The sequence of hormone therapy was revealed to be important; initiation

rvices used.
ine LAD NTDmean of ≥12 Gy correlated with a benefit from prone treatment on LAD NTDmean (p < 0.001) & LA

Adverse prognostic effects of hyperinsulinemia are seen in hormone receptor positive and negative BC in the fir

treatment levels, but without an overall statistically significant difference. With a median follow up of 6 years, w

s higher in some pts after motesanib coadministration. Efficacy at data cutoff in pts with measurable disease at

of Bev combined with taxane-based therapy was similar to E2100 and AVADO results. Bev has minimal impact

higher maximal SUV than that of benign lesions (6.42 vs 3.41, p = 0.021). mSUV more than 6.0 could define the

h chemotherapy; iv) the minimal effective duration of trastuzumab and v) the treatment of small (<1 cm) node-

as associated with young age (OR = 5.14; CI: 3.13–8.48, p < 0.001) and axillary lymph node dissection (OR = 4.

ccurred (6%; all considered related to tx): LVEF decline, pulmonary embolism and pancreatitis. One G5 AE occur
urvival = 0%). The median survival after metastasis was only 11.3 months (range: 2.73–34.9 months).

esponse rate (ORR) was 86% (95% CI: 77–94), with 21 (40%) complete responses (CR); the sonographical OOR

opausal status, T stage and nodal status. High index of suspicion should be maintained during follow up breast
tumors following chemotherapy. Over the last 20 years, ten randomized clinical trials have been published com

34 months follow up in 3 patients (2: cystosarcoma phyllodes and 1: DCIS) all were alive. Subgroup analysis in

ents. Except the cryopreservation of embryos all other procedures are experimental. It is also undefined who is

ee times more then for patients treated between 1995–1998 (HR 2.9; CI 1.1–7.4).

neither poor aesthetic outcome. In one patient pulmonary metastases were detected prior to local recurrence in
s agents that directly or indirectly cause DSBs, such as platinum drugs [4] or PARP inhibitors [5]. Treatment of t

both biological and clinical implications.

= 0.419 for DFS and p = 0.218 for OS).

p = 0.028). In multivariate analysis, c-erbB2 positivity (p = 0.0001), axillary lymph node involvement (p = 0.006

during TL or at 18 mth F/Up.

y would discuss chemotherapy at 2–3% and recommend chemotherapy at 4–5%. When asked as to at what perc
116 are not metastasis till the censored date (31 March 2009). The 5 years disease free overall survival (DFS) is

6 T/T genotype of VEGF gene but significant association of breast cancer risk was shown in the group of woman
at 1st line: yes vs. no: HR = 0.64, p < 0.001).

. This study is sponsored by Amgen Inc. (ClinicalTrials.gov NCT00330759). Treatment groups were generally ba

nd in 6% (4 pts) of negative ER pts. A total of 45% of pts with CR received Celiptium as second line metastatic. T

egmental dose and the volume of the LV receiving 30 Gy.

s involved in horizontal disparity.

4 vs. 27.7; p = .089). A significant association of PLD efficacy was detected for ECOG performance status (CBR

% for Neupogen). Consistent with previous studies of filgrastim, the most common TRAE was bone pain.
 d die out without being replenished from the cancer stem cells. Other than that little is known about the functio

of induced abortion is significantly increased among women treated for breast cancer.

p, 2 invasive recurrences have occurred. Those 2 pts had initial IDC classified as pN0, ER-, PgR- and LVI-. In one
2.0 vs 3.4 years).
h breasts were found in 79% of SBBC and 50% of MBBC. 73% of SBBC were hormone receptor positive, while in

s observed for pts receiving PEG SP vs PP (70.3% vs 81.1%, p = 0.13). In total, 5.6% of pts with G-CSF were hos

anthracyclines and taxanes based chemotherapy, radiotherapy and hormonal therapy (tamoxifen – aromatase i
ent arms.

tumour cell positive samples were equally distributed between the IHC positive and negative groups. The resu

C rBF was significantly higher in TNBC (5.87 vs 1.96, p = 0.046) and MTT shorter (43.69 vs 47.28, p = 0.008). B

l response rate (ORR) of 43%. In the 30 mg/w cohort (N = 9) we observed 3 PRs, 5 SDs and 1 PD. Most of the pt
uidelines to assist them in treatment decision-making. In the current era of rapid advances in oncology, the gui

ealed to be important; initiation of hormone therapy after completion of radiotherapy resulted in lower 5 years L
LAD NTDmean (p < 0.001) & LADmax (p = 0.02). In the context of PBI, prone positioning improved cardiac dose

sitive and negative BC in the first 4 years after diagnosis but are not present beyond 4–5 years post-diagnosis. I

a median follow up of 6 years, we found that patients with a significant decrease of sera methylated levels of bo

pts with measurable disease at baseline is shown (Table).

esults. Bev has minimal impact on the safety profile of CT. Hypertension >G3 was reported in 0.1% of pts (4% G

more than 6.0 could define the lesion to be metastasis with the sensitivity of 50% and the specificity of 92% by

atment of small (<1 cm) node-negative HER-2 positive tumours. Longer follow-up from the adjuvant trastuzuma

ymph node dissection (OR = 4.97; CI: 3.92–6.29, p < 0.0001)

d pancreatitis. One G5 AE occurred (cardiogenic shock). LVEF decline was observed in 17/53 pts (32%) and all G
e: 2.73–34.9 months).

s (CR); the sonographical OOR was 96% (95% CI: 87–98) with 7 CRs (13%). A pCR (ypT0) with negative axillary

tained during follow up breast cancer of patients.

rials have been published comparing short vs. long duration treatment in MBC patients. Seven of these studies

ere alive. Subgroup analysis in rest showed that 12 month survival for stage 4 patients was zero, stage IIIB was

ntal. It is also undefined who is going to carry the costs. Moreover, there are recent data that the reappearance

cted prior to local recurrence in the breast.

RP inhibitors [5]. Treatment of tumor-bearing mice with the clinical PARP inhibitor olaparib (AZD2281) inhibited t

h node involvement (p = 0.006), age under 35 (p = 0.008), progesterone receptor negativity (p = 0.082), perin

When asked as to at what percentage of relapse benefit they would discuss and recommend chemotherapy, the
se free overall survival (DFS) is 76.68% (95%CI: 57.17 to 88.16). Hazard ratio for locally advanced to early breas

s shown in the group of woman with breast invasive ductal carcinoma compared to healthy group. Carriers of th
ment groups were generally balanced for baseline characteristics, except for gender, age category, and visceral

um as second line metastatic. The median treatment free interval was 1 month [0–81] and the median progress

COG performance status (CBR 41%, 34%, and 14% in ECOG PS 0, 1, and 2, respectively; p = .006). This was ref

n TRAE was bone pain.

ittle is known about the function of differentiated cancer cells.

pN0, ER-, PgR- and LVI-. In one pure micropapillary case, in situ local recurrence occured 5 years later.

one receptor positive, while in MBBC hormone receptor negative tumors were more common, 55%. In SBBC gro

.6% of pts with G-CSF were hospitalized due to FN for a mean (SD) of 6.6 (3.5) days. There were no differences

erapy (tamoxifen – aromatase inhibitors).

and negative groups. The results suggest important methodological problems inherent to both IMS and IHC det

(43.69 vs 47.28, p = 0.008). Baseline ve was the best predictor of triple negativity (sensitivity 81%, specificity

5 SDs and 1 PD. Most of the pts benefited from treatment, independently of taxane resistance (ORR = 56% in p
d advances in oncology, the guideline process needs to be modified to help integrate emerging evidence in a tim

rapy resulted in lower 5 years LRFS (80.0% vs. 93.1%, p < 0.01).
itioning improved cardiac doses in only 6/22 cases (mean LADmax improvement = 19.0 Gy) but worsened dose

ond 4–5 years post-diagnosis. Interventions targeting insulin should focus on the first 4–5 years post-diagnosis

of sera methylated levels of both genes after surgery had better time to progression an overall survival respect

s reported in 0.1% of pts (4% G3) and only 1 pt (<0.1%) had Bev-related cerebral haemorrhage. No new Bev-re

% and the specificity of 92% by ROC curve.

p from the adjuvant trastuzumab trials suggests that trastuzumab-induced cardiac toxicity may be time-limited

ed in 17/53 pts (32%) and all G1/2 cases (13 pts) were resolved with either no action or a temporary dose delay

R (ypT0) with negative axillary lymph nodes was confirmed in 10 pts (19%) and additional 4 pts had in situ lesio
atients. Seven of these studies did not use new agents such as taxanes or pegilated liposomal adriamycin (PLA)

atients was zero, stage IIIB was 51% and for stage IIA was 81.7%.

ent data that the reappearance of ovarian hormones may stimulate occult tumor cells in hormone sensitive brea

olaparib (AZD2281) inhibited tumor growth without signs of toxicity, resulting in strongly increased survival. H

or negativity (p = 0.082), perinodal invasion (p = 0.025) were found to be the independent adverse prognostic

recommend chemotherapy, the answer varied from 0 to 20%, but majority (66.6%) said they would recommend
locally advanced to early breast is 2.45 (95%CI: 0.58 to 10.38). The 5-year survival rate was 63.77% (95%CI: 20

to healthy group. Carriers of the 936 C/T genotype were more frequent among woman with invasive ductal carc
der, age category, and visceral metastases (lung). Denosumab delayed the time to first on-study SRE (patholog

0–81] and the median progression free survival was 3 months [0–87]. The median survival after administration

ctively; p = .006). This was reflected by a significantly longer progression-free and overall survival times for pts
occured 5 years later.

ore common, 55%. In SBBC group 28% of pts without initial metastasis had a disease progression with a median

ays. There were no differences in FN hospitalization between pts receiving PP vs SP, or FLG vs PEG prophylaxis.

herent to both IMS and IHC detection approaches. To further investigate this, we used qRT-PCR and arrayCGH o

ty (sensitivity 81%, specificity 76%, area under ROC curve 0.80).

ne resistance (ORR = 56% in pts resistant to H and prior taxanes in the 5–10 mg/d cohorts).
rate emerging evidence in a timely manner.
= 19.0 Gy) but worsened doses in 16/22 cases (mean LADmax increase = 19.7 Gy). For both WBI & PBI, breast

first 4–5 years post-diagnosis

sion an overall survival respect patients without this observation.

l haemorrhage. No new Bev-related safety signals were observed

c toxicity may be time-limited and reversible with discontinuation of trastuzumab and the introduction of cardia

tion or a temporary dose delay. PK data confirmed no significant drug–drug interactions.

dditional 4 pts had in situ lesions only in breast tissue (ypDCIS), with an overall pCR rate of 25%. There was no
ted liposomal adriamycin (PLA). Overall, these trials have shown a consistent benefit in terms of better time to p

cells in hormone sensitive breast cancer. Therefore it seems necessary to inform breast cancer patients about t

strongly increased survival. However, long-term treatment with olaparib resulted in the development of drug r

dependent adverse prognostic factors.

%) said they would recommend chemotherapy at 10–20%.

val rate was 63.77% (95%CI: 20.07 to 88.16) for locally advanced and 80.77% (95%CI: 58.40 to 91.87) for early

oman with invasive ductal carcinoma (46 of 122 examinies, 37.7%) than among control group (7 of 156 examin
to first on-study SRE (pathologic fracture, radiation therapy or surgery to bone, or spinal cord compression) and

n survival after administration of elliptinium-based chemotherapy was of 6 months [0–119].

nd overall survival times for pts with ECOG 0 and 1 vs. 2 (both p < 0.001). In multivariate analyses and oligovar
ease progression with a median DFI 28 months. In MBBC progression was detected in 37.5% pts with a median

SP, or FLG vs PEG prophylaxis.

used qRT-PCR and arrayCGH on the IMS selected cells followed by specific isolation of 5–20 bead-confirmed tum

/d cohorts).
Gy). For both WBI & PBI, breast volume >1000 cm3 correlated with a benefit from prone treatment (p = 0.003).

b and the introduction of cardiac medications. However, longer follow-up is required to further confirm this hypo

CR rate of 25%. There was no case of progressive disease. Among clinical and tumour characteristics evaluated
efit in terms of better time to progression (TTP) for the maintenance arm, but only one has shown an improvem

breast cancer patients about the possible negative effects of preservation of ovarian function.

d in the development of drug resistance, caused by up-regulation of P-glycoprotein drug efflux pumps. Indeed,
5%CI: 58.40 to 91.87) for early breast cancer. The patients with vascular/perineural involvement had increased

control group (7 of 156 examinies, 4.5%). The difference was statisticaly significant (p < 0.0001). This study fou
r spinal cord compression) and was noninferior to ZA (hazard ratio [HR]: 0.84; 95% CI: 0.71–0.98; P = 0.0007).

hs [0–119].

tivariate analyses and oligovariate adjustment models, results were maintained for ECOG performance status (p
ed in 37.5% pts with a median DFI 41 months.

on of 5–20 bead-confirmed tumour cells. qRT-PCR targeting mammaglobin, AGR2, TFF1, and SBEM mRNA were
m prone treatment (p = 0.003).

red to further confirm this hypothesis. Future studies with promising novel anti-HER2 agents, such as the ongoin

mour characteristics evaluated as potential predictors of pCR, ER status and HER2/neu overexpression resulted
ly one has shown an improvement in OS and, in one data on this parameter are still pending. In conclusion, ma

arian function.

in drug efflux pumps. Indeed, acquired resistance could be effectively reversed by co-administration of olaparib
ral involvement had increased risk of relapse (p = 0.005). Cell type grading between locally advance and early

ant (p < 0.0001). This study found significant evidence that examined gene polymorphism is a key factor associ
% CI: 0.71–0.98; P = 0.0007). The median time to first on-study SRE was 20.6 months for denosumab and 16.3

or ECOG performance status (p = .03 regarding CBR), but not for taxane pre-treatment and anthracycline-free
2, TFF1, and SBEM mRNA were positive with at least one marker in 50% of 60 IMS EpCam positive samples stud
ER2 agents, such as the ongoing ALTTO trial with lapatinib, will use cutting edge technologies to prospectively

R2/neu overexpression resulted significantly correlated with pCR in univariate analysis (p = 0.04 and 0.02, respe
still pending. In conclusion, maintenance chemotherapy may be a reasonable approach to obtain better TTP but

by co-administration of olaparib and the P-glycoprotein inhibitor tariquidar.

een locally advance and early cancer was significantly different (P < 0.005).

morphism is a key factor associated with susceptibility to invasive ductal carcinoma of the breast in a sample of
onths for denosumab and 16.3 months for ZA. Although numerically greater, the delay in time to first on-study

atment and anthracycline-free interval, while they remained unchanged for the other parameters.
S EpCam positive samples studied, but was negative in cells isolated from bone marrow. ArrayCGH showed amp
technologies to prospectively identify biomarkers for rational tailing of anti-HER-2 targeted therapy.

alysis (p = 0.04 and 0.02, respectively); in multivariate analysis triple-negativity and ER-negativity showed an in
proach to obtain better TTP but a modest benefit in OS according to a recent meta-analysis. Further trials with c
ma of the breast in a sample of Croatian women.
delay in time to first on-study SRE with denosumab was not superior to ZA based upon the statistical testing st

ther parameters.
marrow. ArrayCGH showed amplification or deletions in many but not all lymph node samples. Surprisingly, one
2 targeted therapy.

and ER-negativity showed an independent relationship with pCR.

a-analysis. Further trials with current agents/regimens are required in order to obtain evaluable-relevant clinica
d upon the statistical testing strategy (adjusted P = 0.06). Time to first-and-subsequent SRE was also numerical
ode samples. Surprisingly, one IMS EpCam positive sample that was negative for all other markers, and also by
btain evaluable-relevant clinical new data to help us in decision making to justify a change in clinical practice. A
equent SRE was also numerically greater but not statistically superior for denosumab compared with ZA (HR: 0.9
all other markers, and also by IHC, showed distinct amplifications and deletions proving the malignant nature o
a change in clinical practice. Any clinical trial should have quality of life as a secondary end-point since added
mab compared with ZA (HR: 0.90; 95% CI: 0.77–1.04; P = 0.14). Adverse events (96% denosumab, 96% ZA) and
proving the malignant nature of the cells. Together the results suggest the existence of heterogenic micrometas
ondary end-point since added extra toxicity is a major concern in any form of maintenance treatment
96% denosumab, 96% ZA) and serious AEs (63% denosumab, 66% ZA) were consistent with what has previous
nce of heterogenic micrometastatic tumor cell populations with a complex gene and protein expression pattern
intenance treatment
sistent with what has previously been reported for these two agents. Overall survival was balanced between th
and protein expression pattern, including differences between cells obtained from different. The data raises que
vival was balanced between the groups (HR: 0.95; 95% CI: 0.83–1.08; P = 0.43). Osteonecrosis of the jaw was s
m different. The data raises questions on the accuracy of the methods used for identification of micrometastatic
Osteonecrosis of the jaw was seen in 10 patients (1.1%) on denosumab and 11 patients (1.3%) on ZA (P = 1.0).
entification of micrometastatic tumour cells, and also suggest the presence of tumour cells in the two tissue typ
atients (1.3%) on ZA (P = 1.0). In conclusion, denosumab was noninferior to ZA in delaying the time to first on-
mour cells in the two tissue types without the capacity to give rise to relapse.
n delaying the time to first on-study SRE in patients with advanced solid tumors and MM. This study continues a
and MM. This study continues as an open-label study with denosumab.